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Introduction
1.1 Myxoid tumours of soft tissue
1.1.1. Classification and grading of soft tissue tumours
Uniform annotation of bone-, and soft tissue tumours is performed on the basis of the
international consensus guidelines of the World Health Organization (12). Hereby, soft
tissue tumours are classified according to their cell type of differentiation, e.g. adipocytic,
fibroblastic, pericytic or vascular. This concept is only partial true for bone tumours
which main entities are basically classified according to the dominant pattern of
extracellular matrix (ECM) formation on microscopy, i.e. cartilage or osteoid. In this
respect myxoid tumours of soft tissue are not a well-defined group as such in the WHO
classification and rather a historically based "hybrid" concept of soft tissue tumours
named after the predominant microscopy of their ECM. On the basis of their biological
potential, soft tissue tumours are divided into the following four categories: (1) benign,
(2) intermediate (locally aggressive), (3) intermediate (rarely metastasizing) or (4)
malignant. In case of malignancy, a histological grade should be provided aiming at
predicting the level of aggressiveness of the tumour (23). The world wide standard
grading occurs according to the (modified) criteria of the Fédération Nationale des
Centres de Lutte Contre le Cancer (25).
1.1.2. Definition of myxoid tumours of soft tissue
Myxoid tumours of soft tissue are mesenchymal tumours characterized by the presence
of abundant so-called "myxoid" extracellular matrix (ECM) at microscopy (24). The
term "myxoid" was first used by Rudolf Virchow to describe tumours that histologically
resembled the structure of the umbilical cord, referring to the substance of Wharton's
jelly (figure 1) (69). Myxoid/mucoid appearance of the ECM on light microscopy can
be a feature of a variety of both epithelial and mesenchymal tumours (75). In myxoid
tumours of soft tissue this myxoid ECM is intrinsic to the entity though often not
directional for diagnosis: this group comprises a broad spectrum of tumours with
overlapping histology but different clinical behavior ranging from truly benign to frankly
malignant warranting adequate recognition of the entities (24, 75).
1.1.3. Challenges in differential diagnosis
The differential diagnosis of myxoid tumours of soft tissue can be very challenging
especially in biopsies because of significant histological overlap between the different
entities at the light microscopical level (75). As for all (soft tissue) tumours, integration
of microscopy with microscopy including immunohistochemistry as well as extensive
additional clinical and radiological data is essential to render the correct diagnosis.
Moreover, during the recent years, many sarcomas have been shown to harbour tumour-
specific genetic alterations which do not only give insight into their biology; they also
provide helpful tools in differential diagnosis and treatment (table 1) (13, 23).
Myxofibrosarcoma and intramuscular myxoma are relatively common soft tissue
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tumours, usually occurring in the extremities of adult or older patients. Accurate dia-
gnosis and grading is crucial for the decision on adjuvant therapy. According to the
2010 ESMO guidelines adjuvant radiation therapy is a standard for soft tissue tumours
of high-grade deep seated tumours regardless of diameter (< or > 5 cm). Radiation
therapy is added in selected cases of low-grade, superficial, >5 cm, and low-grade,
deep, <5 cm soft tissue tumours. In the case of low-grade, deep, >5 cm soft tissue
sarcoma, radiation therapy is recommended to be discussed in a multidisciplinary
fashion. Radiation therapy is also recommendatory following marginal or R1-R2
Figure 1: Characteristic macroscopy and histomorphology of the myxoid ECM.
Rudolph Virchow introduced the term myxoma for those tumours morphologically resembling Wharton's
jelly of the umbilical cord (a), which contains large amounts of GAGs as detected by Alcian Blue (b).
High-power image of Wharton's jelly showing abundant myxoid ECM containing fibrillary collagens,
interspersed between myofibroblast-like stroma cells (c). Intramuscular myxoma characteristically
has a gelatinous appearance on cut surface (d) and is well circumscribed towards its peripheral tissue
(e). On higher magnification, it shows the same abundant myxoid ECM as the umbilical cord (c) and
no significant atypia of the sparse tumour cells (f). Histological criteria are still a hallmark of dia-
gnosis, showing characteristic lobulated, hypocellular morphology of grade I myxofibrosarcoma at low
magnification (g).Curvilinear blood vessels are quite specific for grade I myxofibrosarcoma (but are
not diagnostic), whereas tumour cells show vesicular, slightly atypical nuclei compared to intramuscular
myxoma (h). Another hallmark of myxofibrosarcoma is areas with abrupt transition of grade (i) which
was already mentioned by Mentzel et al. (41).
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excisions, if these cannot be rescued through re-excision (11), Compartmental resection
of an intracompartmental tumour, does not require adjuvant radiation therapy. Adjuvant
chemotherapy is not standard treatment in adult-type soft tissue sarcomas, although it
is proposed by some as an option in high-risk patients with tumours of intermediate- or
high grade, deep-seated and >5 cm) (51). Some histological types are more
chemosensitive and the histotype may therefore be considered in the decision-making
(11). Accurate diagnosis is thus essential warranting the need of additional diagnostical
tools with high specificity, both for assessment of prognosis as well as for tailoring
therapy and metastatic disease.
Table 1: Clinicopathological and (cyto) genetic characteristics of myxoid tumours of soft
tissue
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1.2 Molecular genetics and cytogenetics of myxoid tumours of soft tissue
Based on molecular genetics and cytogenetics, sarcomas can be divided in two major
groups: (a) sarcomas with relatively "simple" karyotypes showing specific genetic
alterations (such as balanced translocations) with the formation of tumour specific
fusion genes (table 2), or specific genetic mutations (often in proto-oncogenes), and
(b) sarcomas with non specific gene alterations and very complex karyotypes with
structural and numerical aberrations (49). Overlap exists between groups (a) and (b)
with sometimes additional/secondary complex karyotypic aberrations superimposed
upon initial specific driver mutations (e.g. gastrointestinal stromal tumours (GIST))
(58).
1.2.1. Activating and inactivating mutations
Activating mutations in proto-oncogenes have been described in many epithelial and
mesenchymal tumours (6). These mutations often act as driver mutations (22). Usually
they affect directly or indirectly the de-phosphorylation (often GTPase) region of a
protein involved in cell signaling (4). In a normal acting cell, phosphorylation of the
Table 2: Molecular genetics and cytogenetics of myxoid tumours of soft tissue
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protein leads to the temporarily activation of cell signaling, which stops at de-
phosphorylation. The responsible phosphorylase which can be an intrinsic part of the
protein, thereby acts as an "on-off" switch in cell signaling and transduces extracellular
signals via ligand-receptor binding to a downstream target (31, 54). Activating mutations
occur mostly in the binding pocket of the phosphorylase and thereby block de-
phosphorylation of the protein (figure 2). This results in constitutive cell signaling and
continuous stimulation of pathways involved in cell growth. Activating mutations in
sarcomas are exemplatory (e.g. KIT and PDGFR in GIST) and are also found in
mesenchymal tumours-related syndromes (9, 18, 68). Somatic and germline mutations
in GNAS1 gene have been described in fibrous dysplasia, both in isolated lesions as
well patients suffering Mazabraud syndrome (mono/polyostotic fibrous dysplasia and
Figure 2: Activating mutations in GNAS1 lead to constitutive activation of protein
kinase A
G-proteins transmiss signals from activated seven transmembrane spanning receptors to intracellular
effectors, e.g. adenylate cyclase. Activation of adenylate cyclase converts ATP to cAMP which
subsequently activates protein kinase A and cAMP responsive genes. In the inactive state, the G-
protein is a αβγ heterotrimer with the α subunit bound to guanosine triphosphate (GTP). Binding of
GTP leads to a conformational change of the α-subunit which then dissociates from the complexed βγ
dimer and increased affinity for the receptor and the intracellular effector. Hydrolysis of GTP to guanosine
diphosphate by the intrinsic GTPase of the G-protein leads to the re-formation of the heterotrimeric
complex and subsequent ending of the activation signal. Activating mutations in codon 201 or codon
227 reduce the α subunit's GTPase activity. Hereby it prevents hydrolysis of the GTP bound to the α
subunit and causes consecutive activation of adenylate cyclase and downstream cell signaling.Adapted
from: Lania AG et al (36).
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intramuscular myxoma) and McCune-Albright syndrome (cafe-au-lait spots, precocious
puberty and fibrous dysplasia) (71). This leads to downstream activation of cFos which
acts as a transcription factor (10). Activating mutations in codon 12/13 of KRAS also
lead to downstream activation of c-Fos. KRAS-activating mutations have been described
in both mouse and human sarcomas. Kirsch et al. showed that KRAS and TP53
mutations were sufficient to initiate high-grade sarcomas with myofibroblastic features
in mice (33). P53 is a major cellular gatekeeper for cell growth and division (37).
Inactivating TP53 mutations are relatively common in sarcomas with nonspecific genetic
aberrations compared with sarcomas with reciprocal specific translocations (8). This
was sustained by previously published data that p53 immunohistochemical staining
was predominantly found in myxofibrosarcoma of grade II and III harboring non-
specific cytogenetic aberrations compared to grade I tumours which have less aberrant,
sometimes normal karyotypes (47, 74). Another important gene involved in cell cycle
regulation is P16, Inactivation of P16 (either by promoter hypermethylation, inactivating
mutations or deletions) has been extensively described in many sarcomas (43, 45, 61).
Significant reduction in p16 expression has been found in the (more aggressive and
therefore grade determining) round cell component of myxoid liposarcoma and is partly
due to promotor hypermethylation and mutation (48). Also in myxofibrosarcoma,
reduced p16 expression correlates with worse prognosis (47), suggesting that p16
might play an important role in tumourprogression in these tumours.
1.2.2. Balanced translocations
Balanced translocations have been described in both benign and malignant tumours,
especially in hematological malignancies and sarcomas, and are increasingly recognized
in epithelial tumours (5, 42, 44, 52, 67). Though the involved genes are often (but not
always!) tumour specific, their fusion partners are mostly restricted to a certain group
of genes. For example, EWSR1 (the Ewing sarcoma breakpoint region 1, a.k.a. EWS)
is not only translocated in Ewing sarcoma (17, 59), but also in desmoplastic small
round cell tumour (35), clear cell sarcoma (20) angiomatoid fibrous histiocytoma (3,
60), extraskeletal myxoid chondrosarcoma (66), and a small subset of myxoid
liposarcoma (50). Interestingly, one and the same gene can be translocated in both
epithelial and mesenchymal tumours, such as the Xp11.2 gene, coding for tfe3 which
is translocated in both peadiatric renal cell carcinoma and alveolar soft part sarcoma
(30, 72). Balanced translocations can drive tumourigenesis by different mechanisms.
First, the transcribed fusion protein can act as a kinase or transcription factor and
thereby activate transcription of genes and proteins involved in cell cycle, growth,
angiogenesis etc (42). Hereby, they do not only play a role in tumour proliferation but
sporadically also in driving tumour morphology such as FUS/DDIT3 in myxoid
liposarcoma (56, 57). Secondly, balanced translocations can cause a promoter swap in
which one gene involved in the translocation is placed under the transcriptional control
of the promoter of an other (highly transcribed) gene. For example, in (myxoid)
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dermatofibrosarcoma protuberans, the COL1A1-PDGFB fusion leads to PDGF
overexpression, increased autocrine stimulation and subsequent cell proliferation (46,
64).
1.2.3. Gene specific amplification.
Next to non-specific randomly occurring gene amplifications, some sarcomas are
characterized by gene specific amplifications, such as of CDK4 and MDM2. These
amplifications are (not exclusively) present in the majority of well- and dedifferentiated
liposarcoma and believed to play a role in their genesis (15, 29). Detection of these
amplifications by FISH or their transcribed proteins by immunohistochemistry can be
used in their differential diagnosis (29).
1.2.4. Non-specific karyotypic aberrations
The more frequent occurring sarcomas show non-specific numerical and structural
cytogenetic changes which are the reflection of genetic instability (13). These complex
karyotypic aberrations increase upon tumour progression suggesting a multistep tumour
progression model and are often associated with functional and/or structural loss of
genes involved in guarding the genome, such as TP53 or RB (40, 62). Superimposed,
often non-specific karyotypic aberrations such as observed in myxofibrosarcoma and
osteosarcoma can also be seen in translocation-driven sarcomas (16, 43, 47).
1.2.5. Hereditary syndromes involving the occurrence of mesenchymal tumours
During the recent years, an increased number of (Mendelian) inherited sarcoma-related
syndromes has been reported. Subsequent molecular-genetic knowledge of genes
predisposing to these syndromes, provide not only insight into their genetic pathways;
they also serve as a solid basis for genetic counseling. Some of these relatively fre-
quent syndromes are associated with mesenchymal and epithelial neoplasms, both benign
and malignant. A not exhaustive list is summarized in table 3 and includes more general
cancer syndromes such as Li Fraumeni-, and Retinoblastoma syndrome, caused by
mutations in tumour suppressor genes involved in cell cycle check point regulation
(such as TP53 and RB). Interestingly, hereditary syndromes including (intramuscular)
myxomas involve activation of the G-protein-prkar alpha1 axis. This activation is
either caused by (1) activating mutations in GNAS1 gene coding for (the alpha subunit
of) the G-protein, such as in Mazabraud syndrome and McCune-Albright syndrome,
or (2) activating mutations in the PRKAR gene, coding for the downstream protein
kinase A receptor, such as in Carney complex. Interestingly, mutations in the GNAS1
gene are also involved in mesenchymal tumour-related syndromes without myxomas
such as in Albright hereditary osteodystrophy. Interestingly, this latter syndrome is
caused by inhibiting (and not activating) mutations in the GNAS1 gene (55).
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1.3 Analytical tools for extracellular matrix analysis
The classification of soft tissue tumours by microscopical features (i.e. on the basis of
their normal cellular counterpart) corresponded wonderfully well with the increasing
differential biological/molecular genetic data of these different tumour types. In this
respect, the more historically originated concept of naming tumours after their (myxoid)
ECM, turned out to be not so adequate. This might partially be explained by the
restrictive discriminative power of examination of the ECM by microscopy alone, as
the constituents which can be identified by (immuno) histochemistry are often not
tumour specific (such as collagens, GAGs). Though Rudolf Virchow already mentioned
that the ECM might influence the biology of (cancer) cells, study of ECM molecules
was rather restricted. Indeed 150 years after the introduction of the term "myxoid" as
an ubiquitous microscopical feature, knowledge of the exact constituents and possible
function of this so-called myxoid ECM are still very limited. However, during the last
decade, recognition of the importance of the ECM and its interactions with-tumour
cells in their development and maintenance, has led to a more profound study of the
ECM and its (low-abundant) molecules.
1.3.1. Alcian Blue staining
Discovered in 1950, Alcian Blue (AB) is a phthalocyanine cationic dye containing
copper ions and non-covalently binding negatively charged macromolecules. It was
John Scott who used this staining to distinguish different glycosacominoglycans in
tissue sections by varying the electrolyte concentration. By adding gradual increasing
concentrations of Mg2+ which competes with AB for binding to mucopolysaccharides
and glycosaminoglycans, AB selectively identifies neutral, sulphated and phosphated
mucopolysaccharides (63). Kindblom et al showed that the myxoid ECM of various
Table 3: Molecular genetics of syndromes involving myxoid tumours of soft
tissue
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(non) neoplastic lesions contained various amounts of the different GAGs (36). It has
become clear during the years that myxoid changes of the extracellular matrix can be
found in reactive and neoplastic (benign and malignant) lesions of both epithelial and
mesenchymal origin (75). Thereby myxoid ECM is not specific for any tumour type at
all (neither from mesenchymal nor epithelial origin), and nowadays AB staining of the
ECM is not of much use in discriminating sarcomas anymore.
1.3.2. Immunohistochemistry
Immunohistochemistry is a crucial adjunct technique in routine diagnostics as well as
in research. Though more expensive, the epitopes recognized by immunohistochemistry
are usually much more specific than histochemical stainings (although over time this
specificity always tends to be less than initially claimed, or hoped for).
Immunohistochemical stainings bind to a still increasing number of epitopes identified
(e.g. the cluster of differentiation) so its potential is still emerging and includes a large
and broad series of validated diagnostic, predictive and prognostic markers. Proteins
(i.e. their epitopes) recognized by immunohistochemical stainings can be categorized
in different types: structural ECM molecules (e.g. collagens, decorin, vimentin), cell
cycle related proteins (e.g. p53, cyclin D, Ki67), proteins involved in cell maturation/
differentiation (e.g. CD2, CD3, CD4, CD5, CD7, CD8), receptors (e.g. ER, PR,
Her2Neu) and secretory proteins (e.g. gastrin, thyreoglobulin, ACTH, insulin). Hereby,
immunohistochemistry, much more than histochemistry, links protein expression to
tumour biology and bridges a gap between morphology and molecular genetics. Because
of their mesenchymal origin, myxoid tumours of soft tissue nearly always express
vimentin, whereas other markers are helpful for more specific classification and dia-
gnosis, depending on the immunohistochemical expression of epitopes often reflecting
the cell type of differentiation (e.g. desmin and MS actin in smooth muscle cell tumours;
CD31 and CD34 in vascular tumours). In the future, protein screens of (myxoid)
tumours (of soft tissue) without a priori knowledge might lead to the discovery of new
biomarkers useful in their differential diagnosis.
1.3.3. Liquid-based Chromatography Mass Spectrometry
Besides more conventional ways of studying the proteome, there is a tendency to
incorporate more high-tech procedures in the analysis of (soft tissue) tumours during
the last years. With its origins in chemistry, mass spectrometry (MS) has recently
entered the field of tumour biology. Recognition of the identification of many molecules
(including peptides, proteins or lipids) in one single experiment makes MS a promising
technique in cancer research. In contrast to (immuno) histochemistry, it uses masses
(m/z values) and not charge or structure (e.g. epitope) to discriminate between molecules.
Hereby, it allows the identification of many molecules (up to hundreds to thousands)
without a priori knowledge of the targeted molecule. A standard mass spectrometry
experiment consists mainly out of three elements: (a) creation of the ions by an ion
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Figure 3: Simplified methodological overview of the ionisation process by LC-MS/
MS
The ion sources routinely used in mass spectrometry research are matrix assisted laser desorption/
ionization (MALDI) and electrospray ionization (ESI). In MALDI the sample of interest is co-crystallized
with a matrix, overall organic acid.. The idendity depends on the molecules and mass range of interest
(e.g. peptide/proteins, lipids). By irradiating the matrix crystals with a pulsed laser beam, the analytes
are desorbed from the matrix and ionized after which they enter the mass analyzer. In ESI the liquid
sample containing the analytes of interest are passed through a needle hold at high potential. The
electric field between the needle and an other electrode leads to the formation of a Taylor cone at the
needle orifice, from which emerges a jet of charged droplets Sequential cycles of solvent evaporation/
Rayleish instability lead to the generation of very small, highly charged droplets which enter the mass
spectrometer. Evaporation of the remaining solvent leads to gas-phase molecular ions ESI circumvents
the need for matrix application, can be perfectly preceded by a first separation step by liquid
chromatography and allows a continuous introduction of the ions into the mass spectrometer. Adapted
from: Ruedi Aebersold and Matthias Mann (1).
source, (b) the mass analysis and (c) the detection of the masses.  A simplified
methodological overview of the ionisation process by LC-MS/MS is depicted in figure
3. Basically, two types of ion sources are used: matrix-assisted laser desorption/
ionization (MALDI) and electrospray ionization (ESI) (figure 3). Different mass
spectrometers are currently available, such as Time of flight (ToF), quadrupoles (such
as ion trap) and Fourier Transformed (FT) techniques, such as Fourier Transformed
Ion Cyclotron Resonance or Orbitrap). Each of these mass spectrometers has its own
advantages and relative shortcomings so that the specific mass spectrometer of choice
largely depends on the research question(s) imposed to address. A schematic overview
of a routine LC-MS/MS experiment is depicted in figure 4. After data acquisition, the
mass spectra are analyzed by matching the multiple peptide/protein fragments to a
sequence database. Based on the amount of structural overlap of these fragments, a
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probability score (so-called "MASCOT" score) is calculated of the reconstructed peptide/
protein.
1.3.4. Imaging Mass Spectrometry
Recently, imaging mass spectrometry was developed, a technique which combines
conventional mass spectrometry (e.g. MALDI-ToF) with spatial resolution and relates
the obtained spectra to their exact location in the tissue (figure 5). Imaging mass
spectrometry has also entered the field of cancer research. Its particular strengths,
such as the analysis of multiple molecules at the same time, in the same tissue and
related this information to the spatial resolution of these molecules, without a priori
Figure 4: Schematic overview of a routine LC-MS/MS experiment
For the study of tumour tissues or cell lysates, the (often very complex) samples are analyzed with LC-
MS/MS following a 1D or 2D gel electrophoresis. After isolating the spots or bands from the gel ("spot
picking"), these (still complex) samples are digested using a protease (commonly trypsin). Trypsin is
a serine protease, specifically cleaving the carboxyl end of lysine and arginine. The resulting tryptic
peptide samples are typically separated by liquid chromatography (LC) and then ionized using
electrospray ionization (ESI). After mass analysis peptides are automatically selected for tandem mass
spectrometry (MS/MS). This involves the isolation of the selected peptide ion followed by its
fragmentation. Peptide fragmentation follows known rules and so the peptide can be identified by
comparing the experimental MS/MS spectra with a peptide (MS/MS) database. Adapted from koler et
al. (34).
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Figure 5: Schematic overview of a imaging MS experiment
Workflow of a MALDI imaging MS experiment. A) The tissue is prepared for MALDI MS analysis by
depositing a matrix solution onto the tissue. Peptides and proteins dissolved by the matrix solution
become incorporated into the matrix crystals as the solvent evaporates. B) Irradiation of the matrix
crytals with a UV laser leads to efficient production of gas-phase peptide and protein ions, which can
then be mass analyzed in a mass spectrometer. MALDI MS analysis of an array of positions covering
the tissue provides the spatial distribution of many peptides and proteins. C) The data can be analyzed
to reveal the peptide and protein content of defined regions of the tissue or to reveal the distributions
of specific proteins. Adapted from McDoneel LA et al (with permission)(34).
knowing them- makes it a very promising tool, at least in theory (34). A crucial step for
each imaging mass spectrometry experiment, as for all mass spectrometry experiments,
is the quality of the samples ("garbage in = garbage out"), the applied matrix and the
matrix application itself. Depending on the range of spectra one is interested in (e.g.
<1.000 Da, 3.000-20.000 Da, >20 kDa) as well as the nature of the molecules (e.g.
lipids, peptides or proteins), different matrices can be applied. Matrix application can
be done manually but for optimal control and reproducibility is best done in an automated
fashion by computer assistance. The volume of the droplets is a delicate balance bet-
ween resolution and quality of the obtained spectra: a larger droplet volume gives
better extraction and thus a richer spectrum, but it decreases the resolution (and visa
versa).
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1.4 Defining therapeutic targets
The revelation of cell signaling pathways in cancer (cells) does not only provide fund-
amental insight into the mechanisms and biology of cancer. It has also shown to provide
excellent clues for more rational-based molecular targeting of specific signaling
pathways. Many cancers arise form aberrant cell signaling, which is predominantly
regulated by post translational modifications, such as phosphorylation by kinases.
Kinases activate proteins by phosphorylation of the amino acid residues: tyrosine,
serine, or threonine. The possibilities of interfering this aberrant cell signaling by
inhibitors of these kinases, opens a new era of targeted and more cancer cell specific
therapy. The search for pathway discovery, including the activated kinases and their
subsequent inhibitors, is especially relevant in sarcoma patients and has been
underscored in the treatment of GIST. The tyrosine kinase inhibitor imatinib has
quadrupled the median survival of patients with metastatic GIST. However, most patients
inevitably develop resistance, which is mostly conferred by secondary mutations within
the split kinase domain (exon 13 and 17) of KIT (26, 27, 70). Although mutations
within the ATP-binding pocket (exon 13, exon 14) are generally sensitive to secondary
generation direct KIT inhibitors such as sunitinib and nilotinib, mutations within the
activation loop (exon 17) are often cross resistant to these newer generation KIT
inhibitors (7, 53). In sarcoma patients, surgery and irradiation are the mainstay of
curative therapy for local disease. Treatment options for patients with advanced
(metastatic), or inoperable disease is rather poor (28). Conventional chemotherapy is
limited and can have serious side effects, whereas kinase-inhibitors act on more specific
targets and subsequently have less severe side effects (73). Downstream signalling
targets, including activated kinases have been recently elucidated for well and
dedifferentiated liposarcoma (29, 65), low-grade fibromyxoid sarcoma (39),
extraskeletal myxoid chondrosarcoma (19), malignant peripheral nerve sheath tumours
and alveolar soft part sarcoma (2).
1.5 Aims of the thesis
Originating from mesenchymal precursor cells, myxoid tumours of soft tissue are
characterized by their loose myxoid texture of extracellular matrix. In this group,
intramuscular myxoma including its cellular variant (a.k.a. cellular myxoma),
myxofibrosarcoma and myxoid liposarcoma are the most common ones. Though a
hallmark at microscopy, the exact composition of the myxoid ECM is not known.
Interactions between tumour cells and their surrounding ECM play an important role
in tumour biology. The clinical behavior of myxoid tumours of soft tissue ranges form
truly benign to frankly malignant with metastatic potential. On one hand, this might
suggest that the ECM of these tumours is not homogeneous and that ECM constituents
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Ever since Virchow introduced the entity myxoma, abundant myxoid extracellular
matrix (ECM) has been recognized in various reactive and neoplastic lesions. Nowadays,
the term "myxoid" is commonly used in daily pathological practice. But what do today's
pathologists mean by it, and what does the myxoid ECM tell the pathologist? What is
known about the exact composition and function of the myxoid ECM 150 years after
Virchow? Here, we give an overview of the composition and constituents of the myxoid
ECM as known so far and demonstrate the heterogeneity of the myxoid ECM among
different tumors. We discuss the possible role of the predominant constituents of the
myxoid ECM and attempt to relate them to differences in clinical behavior. Finally, we
will speculate on the potential relevance of this knowledge in daily pathological practice.
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Historical perspective
In his 1858 masterpiece Cellularpathologie, Rudolph Virchow introduced the term
"myxoma" to describe a soft tissue tumor, histologically resembling the structure of
the umbilical cord (Figs. 1 and 2) [1]. This description of myxoma was adopted in the
seventh edition of the Medical Lexicon by Robley Dunglison who remarkably added
that "[myxoma] was for the first time described in 1838 by Johannes Müller as
Figure 1: Timetable with key events in studies on myxoid tumors of soft tissue. Though Müller already
mentioned tumors with a macroscopically gelatinous appearance in 1838 [3], it was in 1858 when
Virchow introduced the term myxoma to describe tumors which morphologically resembled the jelly
structure of the umbilical cord [1]. Ever since, the term myxosarcoma, introduced by Bryant in 1802
was reserved for the malignant counterparts [4]. Because of their morphologically overlapping features,
both terms were used interchangeably, which was mentioned by Stout in 1948 as unwise, warranting
for macroscopical and microscopical criteria for the reliable differential diagnosis between the two
entities [5]. The relationship between myxomas and fibrous dysplasia was first described in 1926 by
Henschen [90], though it was Mazabraud who proposed it as a syndrome in 1967 [91]. The association
of cardiac/cutaneous myxomas, hyperpigmentation of the skin, and endocrine overactivity was only
recognized in 1985 by Carney [43]. Progress in the study of the myxoid ECM was made by the invention
of the alcian blue staining in 1950 by Steedman [9], and Scott who developed the CEC method to
distinguish the different GAGs in 1965 [10]. Based upon this technique, Kindblom showed in 1975
that different bone and soft tissue tumors (including myxoid ones) contained different GAGs [11].
From the late 1980s, it became clear that the ECM is a key player in tumor development and tumor
progression, sustained by an exponentially growing number of publications [40]. As myxoid areas
were now being recognized as an intrinsic part of a subset of tumors, Weiss and Angervall simultaneously
described the myxoid variant of malignant fibrous histiocytoma/myxofibrosarcoma as a distinct entity
[92, 93]. Parallel to morphological classification, an increasing number of myxoid tumors showed
specific molecular genetics aberrations, such as (activating) mutations and translocations. The concept
of malignant progression in myxoid tumors of soft tissue (i.e., myxoid liposarcoma) due to chromosomal
instability and subsequent secondary genetic events was described in 1990 by Orndal et al. [94].
Nowadays, classification of myxoid tumors of soft tissues is based upon clinicopathological and
molecular/cytogenetic aberrations as published in the 2002 WHO classification [7].
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Collonema" [2]. Müller used the term collonema (κολλα = glue) for "peculiar gelatinous
tumours, consisting of a remarkably soft gelatiniform tissue, which trembles on being
touched" [3]. Though this description is applicable to most myxoid tumors, it holds
also for many nonmyxoid tumors and it is not particularly clear which tumor type
Müller had in mind. Today, it has been generally accepted that it was indeed Virchow
who introduced myxoma as an entity. The introduction of this new histological concept
of tumors containing myxoid (µυξα = "mucus" and ειδο   = "resemblance") areas
soon led to the recognition of new entities, such as myxadenoma, myxochondroma,
myxofibroma, and myxoneuroma [2]. The term myxosarcoma, introduced in 1802 by
Figure 2:  Characteristic macroscopy and histomorphology of the myxoid ECM. Rudolph Virchow
introduced the term myxoma for those tumors morphologically resembling Wharton's jelly of the
umbilical cord (a), which contains large amounts of GAGs as detected by alcian blue (b). High-power
image of Wharton's jelly showing abundant myxoid ECM containing fibrillary collagens, interspersed
between myofibroblast-like stroma cells (c). Intramuscular myxoma characteristically has a gelatinous
appearance on cut surface (d) and is well circumscribed towards its peripheral tissue (e). On higher
magnification, it shows the same abundant myxoid ECM as the umbilical cord (c) and no significant
atypia of the sparse tumor cells (f). Histological criteria are still a hallmark of diagnosis, showing
characteristic lobulated, hypocellular morphology of grade I myxofibrosarcoma at low magnification
(g).Curvilinear blood vessels are often seen in grade I myxofibrosarcoma (but are not diagnostic),
whereas tumor cells show vesicular, slightly atypical nuclei compared to intramuscular myxoma (h).
Another hallmark of myxofibrosarcoma is areas with abrupt transition of grade (i) which was already
mentioned by Mentzel et al. [95].
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Bryant [4], became reserved for malignant tumors and defined as "a mucous
transformation of round-celled sarcoma, malignant, and of large volume, usually
attacking the omentum and the skin" [2]. Nowadays, myxoid changes/areas are
recognized in both benign and malignant neoplasms (primarily classified as mesenchymal
or epithelial) as well as non-neoplastic (reactive) lesions (Fig. 3).
In his first description, Virchow had already recognized the recurrent nature of some
myxomatous tumors [1] and it became clear that it was difficult to predict the exact
clinical behavior of these different tumors based on their myxoid morphology alone.
Subsequently, the terms myxoma and myxosarcoma were used interchangeably till
Arthur Stout recognized this as unwise [5] because "myxomas do not metastasize and
there is no way to anticipate differences in their growth energy from their histopathology."
Later studies confirmed the distinction between both entities on the basis of
macroscopical and microscopical features (necrosis, nuclear atypia, and mitotic figures;
Fig. 2) [6]. Today, myxoid tumors of soft tissue are classified according to the World
Health Organization (WHO) formulation based on clinicopathological criteria and
specific molecular/cytogenetic aberrations (Table 1) [7, 8]. So what is left of the term
"myxoid" 150 years after Virchow? What do today's pathologists mean by it, and what
Figure 3: Myxoid ECM is a ubiquitously histological feature in physiological and pathological
conditions. Myxoid ECM is a morphological feature in physiological and pathological conditions, such
as in myxedema due to increased production of HA. Myxoid areas/changes are also commonly present
in tumors (both of epithelial and mesenchymal origin). In epithelial tumors, myxoid changes are often
a secondary phenomenon, whereas in mesenchymal tumors, they are more frequently an intrinsic part
of the tumor entity. This group of so-called myxoid tumors of soft tissues contains an increasing number
of entities (e.g., myxofibrosarcoma, formerly called myxoid variant of malignant fibrous histiocytoma),
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does the myxoid extracellular matrix (ECM) tell the pathologist? What is the exact
composition of this myxoid ECM and does it have a function? Here, we give an overview
of the composition and constituents of the myxoid ECM as known so far and demonstrate
the heterogeneity of the myxoid ECM among different tumors. We discuss the possible
role of the predominant constituents of the myxoid ECM and attempt to relate them to
differences in clinical behavior. Finally, we will speculate on the potential relevance of
this knowledge in daily pathological practice.
Composition of the myxoid extracellular matrix
Glycosaminoglycans and proteoglycans
Substantial progress in the study of the myxoid ECM was made after the introduction
of alcian blue staining in 1950 [9]. John Scott was one of the pioneers who used this
Table 1: Myxoid tumors of soft tissue: overview of clinicopathological and genetic features
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histochemical stain to distinguish between the different glycosaminoglycans (GAGs)
in tissue sections [10]. Kindblom et al. showed that the myxoid ECM of various
(non)neoplastic tissues, i.e., Wharton's jelly and myxoid tumors of soft tissue, contained
large amounts of GAGs (Figs. 1 and 2) [11]. GAGs are large macromolecules abundantly
present in pericellular and extracellular matrices and consist of unbranched
polysaccharide chains of disaccharides which are often sulfated. There are six diffe-
rent types of GAGs: hyaluronic acid (HA), keratin sulfate, chondroitin sulfate, dermatan
sulfate, heparan sulfate, and heparin [12]. GAGs form proteoglycans (PGs) once
covalently attached to specific core proteins. Core proteins of PGs are synthesized in
the endoplasmic reticulum and post-translationally modified as they pass through the
Golgi apparatus where hexuronic acid and hexosamine groups are attached. The
exception is HA, which is synthesized directly under the cytoplasmic membrane by the
hyaluronic acid synthetases 1, 2, and 3 [12]. The most common classification of the
different PGs is based upon the properties of the core protein. The three main PG
families present in the ECM are lecticans, small leucine-rich proteoglycans (SLRPs),
and other ECM PG [13]. Lecticans always contain both a hyaluronan-binding domain
and a C-type lectin domain. The lectican family includes: aggrecan, versican, neurocan,
and brevican that can be found at different locations (Table 3) [12]. SLRPs can be
found extracellularly and intracellularly and at the cell surface. They contain nine to
12 tandem repeats of leucine-rich motifs which involve their collagen-binding domains.
The SLRP family includes decorin, biglycan, asporin, ECM protein 2, keratocan,
proline/arginine-rich and leucine-rich repeat proteins, osteoadherin, lumican,
fibromodulin, opticin, epiphycan, osteoglycin, podocan, chondroadherin, and nyctalopin
[14]. ECM PGs do not show significant homology in the content of their core proteins.
Perlecan, agrin, and collagen types XV and XVIII belong in this family [14]. Various
GAGs and PGs have been identified in the myxoid ECM (Table 2): HA is the most
common; none of them are specific for one particular lesion.
Collagens
One of the first papers addressing myxoma and its malignant counterpart
("myxosarcoma") mentioned the presence of fibrillary collagens as a hallmark for
differential diagnosis [6]. Though this criterion did not last long, collagens (κολλα =
glue; γηνε = that which produces) are a main component of the myxoid ECM. They
are characterized by their regular, triple-stranded helix of so-called alpha-chains forming
cord-like strands of 300 nm in length and 1.5 nm in diameter. A separate group of
collagens is formed by the fibril-associated collagens with interrupted triple helices
(FACIT) and includes collagen types XII and XIV. These collagens have several triple
helical domains (collagen type domains [Col]) separated by nontriple helical domains
(NC). All collagens contain large amounts of proline and glycine as well as
hydroxyproline and hydroxylysine which are formed by post-translational modification.
Based on their biochemical differences, more than 30 different types of collagens are
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Table 2: The composition of the myxoid ECM is heterogeneous but not lesion-specific
recognized [15]. The most common types are I, II, III, and IV, which account for 90%
of all collagens in humans. Except for collagen II, which is predominantly present in
cartilage, collagen types I, III, and IV as well as VI, XII, and XIV may be found in the
myxoid ECM (Table 2).
Other ECM molecules
Other structural molecules identified in the myxoid ECM are fibronectin and tenascin
C (Table 2). Fibronectin is a fibril-forming glycoprotein existing in a dimeric or
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multimeric form. Each monomer contains several binding sites for fibrin, heparin,
DNA, and cells. Fibronectin molecules consist of different repeats (types I, II, and III)
and three different sites that can be alternatively spliced (EDA, EDB, and V). The
dimeric, soluble form is produced by hepatocytes and lacks the alternative EDA and
EDB variants. The multimeric form is extensively present in granulation tissue, base-
ment membrane, and on cell surfaces and contains variable proportions of the EDA
and EDB domains [16]. Until now, fibronectin has only been found in myxoid
liposarcoma but might also be present in the ECM of other myxoid lesions (Table 2).
Tenascin C is a highly conserved glycoprotein of the ECM consisting of 300 kDa
monomers, characteristically assembled in 1,800 kDa hexamers [17, 18]. It consists of
several functionally independent domains of which the number is dramatically increased
by alternative splicing. The N-terminal contains the cysteine-rich assembly domain,
followed by EGF-like repeats, eight constant and up to nine alternatively spliced
fibronectin type III repeats and a C-terminal fibrinogen-like globular domain [18]. Till
today, its presence has only been shown in myxoid areas of epithelial but not (yet) in
mesenchymal tumors (Table 2).
Functional role of the different constituents in the myxoid extracellular matrix
Glycosaminoglycans
GAGs have both biophysical and biochemical functions and play important roles in
physiologic and neoplastic processes (Table 3) [19]. Due to their high content of sulfate
and carboxyl groups, complex patterns of sulfation and uronic acid epimerizations,
GAG chains confer upon PGs the diverse capacities to function as ideal physiological
barriers, reservoirs for signaling proteins, and binding partners for structural
macromolecules [13]. We have shown that the myxoid ECM in soft tissue tumors is
heterogeneous in composition and that the relative amount of each GAG is tumor-
type- and tumor-grade-dependent [20]. Because of their negative charge, all GAGs,
especially HA, are able to trap water molecules. Interestingly, HA is the common
denominator in the myxoid ECM (Table 2). This suggests that HA is the major
contributor to the edematous appearance of the myxoid ECM. As a result of the
biophysical properties of GAGs (their high viscosity and low compressibility), they
are ideal for tissue lubrication. On the other hand, their rigidity is responsible for the
structural integrity of tissues facilitating diffusion of metabolites and cell migration
[21]. The biochemical properties of GAGs are mediated by specific binding to other
macromolecules. GAGs can bind to secreted proteases and antiproteases, growth factors,
structural ECM proteins, and proteins expressed on (tumor) cells [22]. Chondroitin
sulfate modulates cell fate as it appears to prevent apoptosis and is involved in cell
proliferation. Since chondroitin sulfate is much more abundant in the ECM of
extraskeletal myxoid chondrosarcoma compared to intramuscular myxoma and
myxofibrosarcoma, it might, therefore, play a role in the more malignant behavior of
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Table 3: GAGs and PGs: their role in physiology and pathologic processes [19]
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this tumor [20]. Large multidomain ECM molecules such as collagen types I, III, V,
and XIV and fibronectin contain at least one GAG binding site. This allows them to
bind to heparan and chondroitin sulfates on cells or in the ECM, contributing to proper
ECM formation.
Proteoglycans
PGs exhibit a wide variety of functions due to their structural diversity (Table 3). As
PGs avidly bind proteins, they are involved in all cellular processes concerning cell-
matrix, cell-cell, and ligand-receptor interactions. PGs are known to have affinity for
a variety of ligands, including growth factors, cell adhesion molecules, ECM
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components, enzymes, and enzyme inhibitors [22]. Lecticans bind other ECM proteins
with its C-type lectin motif, facilitating the formation of networks permissive for cell
growth [23]. For example, aggrecan and versican associate tightly with both HA,
thereby maintaining tissue hydration. Due to the EGF-like repeats, lecticans are directly
involved in growth control. Versican stimulates the proliferation of fibroblasts and is
highly expressed by fast-growing cells and present in myxoid areas of both reactive
and neoplastic (mesenchymal and epithelial) lesions (Table 2) [24].
Small leucine-rich proteoglycans
SLRPs are structurally and functionally related ECM molecules and abundantly
expressed in connective tissues. Decorin and biglycan bind to collagen and influence
collagen fibrillogenesis and ECM assembly in various ways: (a) due to its curved
shape, decorin is able to bind to collagen types I, II, VI, and XIV linking them together
and to fibronectin [25], (b) by decorating collagen fibers, decorin protects them from
degradation by collagenases [25, 26], and (c) by its attached GAG chain, decorin is
capable of modulating the activity of TGF-beta, which plays a central role in fibrogenesis
[13, 25, 27]. Biglycan- and decorin-deficient mice show irregular and defective col-
lagen fibrils, fragile skin, and a phenotype that closely resembles that of patients with
Ehlers-Danlos syndrome [28]. In wound healing, there is a spatial temporal regulation
of the expression of the different SLRPs (decorin, lumican, fibromodulin, and biglycan)
tightly controlling the transformation of the myxoid ECM of granulation tissue towards
fibrotic scar formation [29]. Myxoid areas in pleomorphic adenoma of the salivary
gland and odontogenic myxoma lack expression of biglycan, lumican, and decorin,
whereas these SLRPs are diffusely present in the fibrotic parts of the ECM of these
tumors (Table 2). This suggests that the absence of SLRPs might contribute to impaired
ECM formation resulting in a mere myxoid morphology.
Collagens
As form follows function [30], different collagens have different properties. In the
initial phase of wound healing, collagen type I is quickly produced by fibroblasts and
replaced by collagen type III in the later stage of scar formation [29]. The FACIT
collagen types XII and XIV do not form collagen fibrils themselves but associate with
fibrillary collagens, such as collagen type I, decorin, and GAGs, linking them together
[31-33]. Collagen type XIV interacts with dermatan sulfate sequences on the single
chondroitin sulfate/dermatan sulfate chain attached to decorin, thereby providing a
link between the fibril-forming and the fibril-associated collagens [32]. Collagen type
XIV is expressed significantly higher in grade I myxofibrosarcoma than in intramuscular
myxoma (including its cellular variant) [34]. On one hand, this might have implications
for ECM assembly and tumor development, thereby playing a potential role in the
different biology and clinical behavior of these different entities; on the other hand, the
effect of cell-ECM interaction in these tumors might work the other way around, as
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collagen XIV induces differentiation of fibroblastic cells [35]. Higher expression of
collagen XIV in myxofibrosarcoma is associated with a more mature morphology of
the tumor cells compared to intramuscular myxoma [5].
Other ECM molecules
Fibronectin plays a role in various biological processes, such as wound healing, host
defense, regulation of ECM assembly, adhesion, and proliferation [36]. It is also a key
molecule in cell-ECM signaling, and aberrant activation of fibronectin-ECM signaling
has been described in many tumors [37]. Likewise, tenascin C is an ECM glycoprotein
of which the spatial and temporal expression is tightly regulated during fetal development
[38]. It has been shown that the tenascin C-encoding gene is upregulated in several
pathologic conditions, such as wound healing, inflammation, and malignancies [38].
Elevated tenascin C expression has been found in epithelial and mesenchymal tumors,
both in tumor and stromal cells, and is associated with unfavorable disease outcome
(Table 2) [18]. Tenascin C attaches to cells via integrins, though the effect of this
interaction on cellular signaling and tumor development is largely unknown [39].
Putative relevance for routine pathology practice
In routine general practice, one encounters a group of tumors, mesenchymal as well as
epithelial, which may show variable degrees of myxoid appearance of their ECM.
Myxoid tumors of soft tissue, the focus of this paper, encompass a heterogeneous
group of lesions characterized by a marked abundance of extracellular mucoid/myxoid
matrix (Table 1). This group of tumors exhibits a broad range of biological behavior
varying from those which are entirely benign via locally aggressive (but
nonmetastasizing) behavior to those which are frankly malignant; hence, accurate
histopathological diagnosis is essential for appropriate clinical management. Till today,
there have been no convincing data which demonstrate that the composition of the
myxoid matrix significantly differ between tumors (both of mesenchymal and/or
epithelial origin) and reactive lesions. From a biochemical point of view, the term
"myxoid" is best considered a wastebasket of many different proteins and other
(macro)molecules which might all have a different function (Tables 2 and 3). While
determination of the different GAGs in myxoid tumors is interesting from a research
point of view, Scott's critical electrolyte concentration (CEC) method is no longer a
routinely used technique by pathologists. Most myxoid tumors of soft tissue tumors
contain HA (Table 2), and consequently, its detection is no longer regarded as
discriminatory in differential diagnoses. Outside the academic setting (where recourse
to sophisticated biochemical and molecular genetics techniques is generally not possible),
when confronted with challenging myxoid lesions, the diagnostic process relies primarily
on careful and discriminatory histopathological evaluation in order to reach a correct
diagnosis. Routine histological criteria (e.g., tumor demarcation, growth and vascular
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pattern, and nuclear atypia) remain the hallmarks of diagnosis. (Immuno-)histochemistry
may be useful as a adjunct in the setting of certain differential diagnostic considerations,
but is often not discriminatory and, therefore, not diagnostically useful [8]. Molecular
cytogenetics is of increasing importance for diagnosis in difficult cases, as the genetic
makeup of an increasing number of myxoid tumors of soft tissue is being elucidated
(Table 1). Next to genetic causes (such as driver mutations, translocations, or gene
amplifications), environmental factors have been shown to play an important role in
tumorigenesis of both epithelial and mesenchymal tumors [40]. Virchow already
mentioned the possible relationship between the histological appearance of the myxoid
ECM of tumors and their differences in biological behavior [1]. It is very tempting to
believe that GAGs and PGs play an important role in the biology of myxoid lesions
rather than just being a byproduct of (myo)fibroblastic differentiation. Intramuscular
myxoma expresses significantly less decorin and collagen VI and XIV (both protein
and mRNA level) than grade I myxofibrosarcoma [34]. Next to decorin, liquid
chromatography-mass spectrometry revealed other SLRPs (i.e., lumican, prolargin 4,
biglycan) present in tumor lysates of grade I myxofibrosarcoma but not of intramuscular
myxoma [34]. This suggest that ECM formation in intramuscular myxoma is impaired
compared to grade I myxofibrosarcoma. Increased ECM rigidity activates integrins
and subsequently leads to stimulation of the rho/Rock pathway and cell migration and
invasion [41]. In this respect, the morphological similarity between the process of
wound healing and myxoid changes/areas in (non)neoplastic lesions is rather striking.
In the early phase, granulation tissue shows a loose, edematous/myxoid ECM rich in
GAGs. In the subsequent phase, there is structural organization of the ECM with
deposition of collagens produced by myofibroblasts which locally (de)differentiate
from fibroblast/smooth muscle cells or are derived from the bone marrow. The term
"myxoid" might not only be synonymous with (aberrant turnover and) the presence of
GAGs, but also reflects the absence of proper ECM assembly or incomplete ECM
formation. This might well explain that a myxoid morphology of the ECM is not
specific at all and can be seen in reactive/non-neoplastic processes as well as in benign
and malignant tumors (Fig. 3). As already extensively discussed in this paper, the
ECM is dependent on the interplay of various macromolecules (polysaccharides and
proteins) which determine its texture and consistency. It is becoming increasingly clear
that, within this group of lesions, various tumor types may show differences in the
biological composition of their myxoid matrix, as determined by differences in the
relative proportions of the constituent macromolecules and the presence or absence of
specific stromal constituents. Clearly, this is an important and highly relevant area for
further research in order to identify tumor-specific markers and to consequently develop
economically viable and user-friendly detection methods to facilitate the diagnostic
process and ensure increasingly accurate histopathologic diagnosis.
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Myxofibrosarcoma is one of the most frequent soft tissue tumours in elderly patients,
mostly arising in the extremities. Grade I lesions are only locally aggressive whereas
grade II and grade III lesions have metastatic potential. The differential diagnosis
contains several other (benign) myxoid soft tissue tumours. A number of sarcomas are
characterised by specific cytogenetic aberrations, giving not only insight in their
biological pathways; they also serve as molecular markers in difficult diagnoses.
Cytogenetic data on myxofibrosarcoma are scarce with only few isolated cases described
in the literature. No specific chromosomal aberrations have been detected so far. More-
over, molecular pathways in tumorigenesis and progression of myxofibrosarcoma are
barely understood. We studied the clinicopathologic data and karyotypes of 32
myxofibrosarcomas using conventional banding and multicolour COmbined Binary
RAtio labelling fluorescence in situ hybridisation technique. We included eight grade
I, eight grade II and 16 grade III lesions. In all, 22 were primary tumours, nine were
local recurrences and one a lymph node metastasis. The myxofibrosarcomas showed
equal sex distribution, were mostly located at the extremities with two thirds deep-
seated and had an average age of occurrence of 66 years. We found normal karyotypes
in eight cases and clonal beside nonclonal aberrations in 22 cases. Complex cytogenetic
anomalies were found in all grades. However, no tumour-specific chromosomal
abnormalities could be withdrawn. Local recurrences showed increase in grade compared
to their primary lesions. Interestingly, these recurrences showed more complex
cytogenetic aberrations. Increase in grade seems to parallel increase in cytogenetic
aberrations and malignant potential. Since the chromosomal aberrations found were
not tumour type specific, they seem to be rather the result of secondary events in
tumour progression and tumour genetic instability. Based on these findings, we suggest
that tumorigenesis of myxofibrosarcoma is mainly a multistep genetic process, probably
ruled by genetic instability caused by targeted checkpoint genes.
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Myxofibrosarcoma, formerly also known as the myxoid variant of malignant fibrous
histiocytoma, is one of the most frequent sarcomas in elderly patients with the majority
arising in the extremities, clinically most often presenting as a slowly increasing mass
[1, 2, 3]. Histologically, myxofibrosarcomas show a wide range from hypocellular
grade I tumours with oval to spindle form cells in a myxoid stroma, to hypercellular
grade III lesions of solid sheets with pleomorphic nuclei [4]. According to the French
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading system,
three histological grades are recognised, that is, grade I, II and III [5]. Metastatic
potential is closely related to tumour grade, with a preference for lung, bone and lymph
nodes. Importantly, increasing grade is seen in subsequent recurrences [4]. Cytogenetic
data on myxofibrosarcoma are scarce with 30 isolated cases described in the literature.
Most often, karyotypes are very complex, including ring chromosomes, deletions,
translocations and double minutes. Here, we present the clinicopathologic data and
karyotypes of 32 cases of myxofibrosarcoma and discuss our findings in the light of
tumour grade and clinical behaviour.
Materials and methods
Patient Data
Thirty-two cases of myxofibrosarcoma were identified on which cytogenetic data were
available and collected retrospectively from the files of the Pathology Departments of
the University Hospitals of Leuven and Leiden University Medical Center. Patient and
tumour characteristics were described in Table 1. In each case, 4  m-thick sections of
formalin-fixed, paraffin-embedded material were stained with haematoxylin and eosin
(H&E). Slides were revised and classified according to the 2002 World Health
Organization (WHO) criteria and histological grading was performed according to the
FCNLCC [2, 5].
Cytogenetic Data
Chromosomes were obtained using short-term cultures and harvesting procedures as
described previously [6]. Briefly, nonfixed tissue fragments were disaggregated
mechanically and enzymatically and then cultured on chamber slides in DMEM-F12
medium (Gibco, Invitrogen, Breda, The Netherlands), supplemented with 10% fetal
bovine serum and 0,5% penicillin-streptomycin (Irvine Scientific, Santa Anna, CA,
USA) for 4-9 days. For cases 1-17 and 19-29 the protocol was as follows. At 17 h
before harvest, cells were exposed to Colcemid (0.005  g/ml; Gibco, Invitrogen, Breda,
The Netherlands). After hypotonic treatment (0.8% sodium citrate for 25 min), the
preparations were fixed three times with methanol-glacial acetic acid (3:1). Cytogenetic
analysis was performed on GTG-banded chromosomes and the karyotypes were
classified according to the International System for Human Cytogenetic Nomenclature
[7].
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Table 1: Patient and tumour characteristics
a P=primary lesion; R=local recurrence; M=metastasis.
b M=male; F=female.
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Multicolor Fluorescence In Situ Hybridisation
For cases 18, 30-32, cells were harvested, after which a 48-color fluorescence in situ
hybridisation (FISH) staining was carried out, staining every chromosome-arm in a
different colour combination, after which digital imaging and analysis was performed
as previously described [8, 9, 10]. Hybridisations with individual libraries labeled
with single fluorochromes were used to confirm the detected rearrangements.




The study of myxofibrosarcoma included eight grade I, eight grade II and 16 grade III
cases. The morphological spectrum ranging from low- to high-grade morphology is
depicted in Figure 1. Patient and tumour characteristics are depicted in Table 1, showing
equal sex distribution between males and females with an average age of occurrence of
66 years. In all, 22 cases were primary lesions; nine of these lesions recurred locally
and one was a lymph node metastasis. Of the six cases recurring as grade III lesions,
the primary lesions were either grade III (four cases), grade II (one case) or grade I
(one case). All three grade II recurrences were all primarily grade I. The metastasis
was a grade III lesion. Except for this lymph node metastasis and one lesion occurring
in the thoracic muscles (case 13), all lesions occurred at the extremities (upper ones:
12; lower: 19). In all, 19 were deeply/intramuscular seated (case 13 included), 11
superficially with one not specified regarding the depth of the lesion (case 20).
Cytogenetics
The cytogenetics findings are listed in Table 2 showing normal to very complex
karyotypes. None of them were published in previous publications including these
entities by the authors.11 Eight normal karyotypes were found among these 32
myxofibrosarcoma. Clonal, besides nonclonal, aberrations were found in 22 cases.
These aberrations were present in all grades. Complex cytogenetic anomalies were not
restricted to grade III, but also seen in grade II and grade I cases. There was no difference
in affected chromosomes depending on grade. Although some chromosomes were more
involved than others (Figure 2), there were no consistent chromosomal abnormalities.
In general, grade III lesions showed more complex karyotypes than lower grades.
Remarkably, recurrences (indicated by asterisk) showed more complex karyotypes
than both their grade II and grade III primary lesions. Furthermore, we found the
presence of a ring chromosome, possibly originating from chromosome 3 (case 7).
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Figure 1: Light micrographs displaying the morphological spectrum of myxofibrosarcoma. (a–c) Grade
I myxofibrosarcoma showing a hypocellular lesion with typical elongated curvilinear blood vessels in
a myxoid background with (pseudo)lipoblasts and slight nuclear atypia. (d) Grade II myxofibrosarcoma
showing a more cellular lesions with increased nucleair atypia. (e, f) Grade III myxofibrosarcoma
consisting out of solid sheets of spindled, atypical cells and multinucleated giant cells with abundant
eosinophillic cytoplasm. In the same tumour, there is often a remarkable but characteristic sharp transition
between hypo-and hypercellular areas.
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Table 2: Cytogenetic analysis of the 32 myxofibrosarcoma




Myxofibrosarcoma is one of the most frequent sarcomas in elderly patients, mainly
located on the extremities [2]. Histologically, they compromise a continuous range
from hypocellular tumours, consisting of small spindle cells widely spaced among the
myxoid matrix, to more cellular variants with pleomorphic nuclei and pseudolipoblasts
[1, 2, 3, 4]. A consistent morphologic feature is the presence of curvilinear blood
vessels. Enzinger and Weiss [3] classified the high-grade variant of these tumours as
the myxoid variant of malignant fibrous histiocytoma, besides the storiform-
pleomorphic, giant cell type and inflammatory subtypes. Angervall and Kindblom [1],
almost simultaneously, first used the term myxofibrosarcoma, as they recognised this
tumour as a distinct entity. Nowadays, the recognition as a distinct, separate entity is
generally accepted and included in the 2002 WHO classification of tumours [2].
According to previous studies, grade II and III tumours are true malignant tumours
since they have metastastic potential. This is in contrast to grade I lesions, which are
only locally aggressive [4]. However, since local recurrence goes together with increase
in grade, grade I myxofibrosarcoma may finally gain metastatic potential, warranting
close surveillance.
The differential diagnoses of myxofibrosarcoma include other myxoid tumours
often hard to distinguish from each other, since differences are often very subtle [12].
However, the distinction between all these myxoid subtypes is truly important from a
clinical point of view, both for required therapy as for follow-up. Therefore, the existence
of a specific (cyto) genetic aberration could serve as a welcome diagnostic marker and
a helpful tool to distinguish these subtypes. However, cytogenetic data on
myxofibrosarcoma are scarce, with only a few isolated cases described in literature
showing complex, but nonspecific cytogenetic aberrations (Table 3). These include the
presence of ring chromosomes, deletions and translocations. No specific chromosomal
rearrangement has been identified so far.
Here, we investigated the clinicopathologic and cytogenetic data of 32
myxofibrosarcoma in order to find tumour and/or grade specific cytogenetic aberrations.
Patient and tumour characteristics were in accordance to previous studies (Table 1) [1,
2, 3]. Although some authors suggested that deep-seated lesions were of higher grade,
a large study of grade I myxofibrosarcoma could not confirm this, which is in accordance
to our findings [4, 25, 26]. Interestingly, the grade I tumours progressing to grade II
were located superficially which shows that progression to recurrence is not exclusive
for deep-seated lesions. Normal karyotypes were seen in eight cases (five grade III,
two grade II and one grade I lesion). Aberrations occurred in all chromosomes; no
consistent tumour-specific cytogenetic rearrangement was identified. Those cases with
cytogenetic abnormalities were not restricted to a certain grade with grade I, II and III
lesions showing a wide range from normal till very complex, polyploid karyotypes
(Figures 2, 4). Grade III tumours had, overall, more complex karyotypes than grade I
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Figure 2: Karyotypic aberrations in 32 myxofibrosarcomas. Red=Grade I, Orange=Grade II,
Purple=Grade III. Ideogram showing the distribution of the numerical and structural aberrations of 32
myxofibrosarcoma. Aberrations were found in all grades, including all chromosomes. No tumour or
grade specific cytogenetic aberration could be withdrawn. Gains are shown on the right side of each
chromosome diagram, losses on the left. Arrows indicate inversions.
Figure 3: Karyotypic aberrations in nine myxofibrosarcomas comparing primary lesions to their
recurrences. Green: Primary tumour, Blue: Recurrence. Ideogram showing the distribution of the
numerical and structural aberrations of primary tumours compared to their local recurrences. Recurrences
show more complex cytogenetic aberrations than the primary tumours. Gains are shown on the right
side of each chromosome diagram, losses on the left. Arrows indicate inversions. In general, there is
gain of cytogenetic aberrations with recurrence though no specific pattern is observed for this
phenomenon.
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Table 3: Karyotypes of the 30 Myxofibrosarcoma described in literature
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and grade II lesions. This suggests that these complex karyotypic abnormalities occur
rather randomly as secondary events. We showed that local recurrences occurred in all
grades, with increase in grade upon recurrence, which is in accordance to the literature
[2, 27]. We hypothesised that in the same lesion, increase in grade goes together with
increase in cytogenetic aberrations. Therefore, we compared the karyotypes of primary
lesions to these of the corresponding local recurrences. Recurrences showed increase
in grade and more complex aberrations than the primary tumours (Figure 3). These
complex aberrations suggest additional chromosomal events, corresponding with an
increase in histological grade and, subsequently, increase in malignant potential.
Besides nonclonal and clonal aberrations, we found the presence of a ring chromosome
in one case of low-grade myxofibrosarcoma. The presence of ring chromosomes has
also have been described in one case of myxofibrosarcoma possibly originating from
20q [17]. Ring chromosomes have been described in many tumours, both benign as
well as malignant, including dedifferentiated liposarcoma, a differential diagnosis of
grade III myxofibrosarcoma [11, 28]. However, this is certainly not a consistent feature
and its molecular and biological significance has not been revealed yet. Previous reports
described several translocations in myxofibrosarcoma. Although all of them were dif-
ferent and nonspecific, some of these involve interesting regions. For example, Clawson
et al [13] described a case of grade I myxofibrosarcoma with translocation
t(2;15)(p23;q21.2). The band 2p23 is a site of ALK gene, expressed in normal tissue
and rearrangements have been described in anaplastic large cell lymphomas, and
inflammatory myofibroblastic tumours [29, 30]. Translocations involving 2p23 have
been found in a case of synovial sarcoma as t(2;15)(p23;q26) and also in one case of
Figure 4: COBRA-FISH in a case of a high-grade myxofibrosarcoma.  Example of highly complex
cytogenetic aberrations in a case of high-grade myxofibrosarcoma (case 32). For karyotypic
aberrations see Table 2.
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'malignant fibrous histiocytomas not otherwise specified' as t(2;5)(p23;q13) [31, 32].
Frequent loss of 9p21 (p16) has been reported in malignant fibrous histiocytomas
including also some cases of myxofibrosarcoma [20, 33, 34]. We could not confirm
these aberrations in our study. Some studies showed add2(q37) in myxofibrosarcoma
and in several types of leukaemia [11]. Interestingly, the COL6A1 gene is localised to
2q37, coding for collagen VI alpha-3 polypeptide. At least three other extra cellular
matrix genes are also located on 2q: 2 collagen genes, COL3A1 and COL5A2 and the
fibronectin gene [35]. As described above, myxofibrosarcoma contains areas of abundant
extracellular matrix although only little is known about its constitution. Ultrastructural
studies showed that the majority of cells in myxoid areas of myxofibrosarcoma showed
secretory activity with dilated rough endoplasmatic reticulum. Although further study
is needed, alterations in genes coding for matrix proteins might lead to increased or
impaired matrix production. Interestingly, a myxofibrosarcoma-like appearance appears
to be quite frequent in pleomorphic liposarcoma, thereby including it in the differential
diagnosis [36]. In the light of this differential diagnosis, the cases reported here were
carefully characterised, explicitly excluding contaminations with pleomorphic
liposarcoma karyotypes in this series of myxofibrosarcoma. Finally, a recent study
using comparative genomic hybridisation (CGH) showed very similar chromosome
imbalances between myxoid malignant fibrous histiocytoma and pleomorphic
liposarcoma, suggesting partially common genetics and biology [37]. This study showed
gain of 5p and loss of 4q in myxofibrosarcoma of higher grade compared to tumours
of lower grade. Whether these and other myxoid soft tissue tumours, in parallel to their
morphologic resemblance, also share genetic overlap is a very interesting hypothesis,
which, however, still needs to be confirmed.
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Myxoid tumours of soft tissue are characterized by their so-called 'myxoid' extracellular
matrix. The aim was to investigate the composition and possible function of this ma-
trix which is poorly understood. Using Alcian Blue staining with and without
pretreatment with hyaluronidase and application of the critical electrolyte concentration
method followed by densitometry, the glycosaminoglycan composition of three diffe-
rent myxoid tumours was studied. The composition of glycosaminoglycans varied with
tumour type and grade, despite their general characterization as myxoid tumours.
Intramuscular myxoma contained similar amounts of the various glycosaminoglycans
as grade I myxofibrosarcoma; grade III myxofibrosarcoma contained less hyaluronic
acid and more heparan sulphate, whereas extraskeletal myxoid chondrosarcoma
contained predominantly chondroitin-4 and -6 sulphates. Western blot identified albumin
as a major protein in tumour lysates, and its presence in the extracellular matrix and
cytoplasm of the majority of tumours was demonstrated by immunohistochemistry;
production of albumin by the tumour cells was confirmed by quantitative polymerase
chain reaction. The extracellular matrix of myxoid tumours of soft tissue has a
heterogeneous composition consisting of, amongst others, glycosaminoglycans and
albumin, which appear to play an active role in their morphogenesis.
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Introduction
Myxoid tumours of soft tissue are a heterogeneous group of tumours characterized
histologically by their abundant mucoid/myxoid extracellular matrix (ECM)(1). The
main clinicopathological entities in this group are intramuscular myxoma,
myxofibrosarcoma and extraskeletal myxoid chondrosarcoma and encompass a broad
spectrum of clinical behaviour, ranging from benign to truly malignant. Although these
tumours share a typical ECM, the exact constitution and possible functions of this
myxoid ECM remains poorly understood. Over recent decades, biochemical studies
have emphasized that glycosaminoglycans (GAGs) are important constituents of the
ECM (2) The main GAGs in the ECM of these tumours are hyaluronic acid, heparan
sulphate, chondroitin sulphate and keratan sulphate. Due to the negative charge of the
above-mentioned GAGs, their high viscosity and low compressibility, these molecules
provide structure to the ECM and facilitate the extracellular transport of molecules.
Kindblom and Angervall have demonstrated that the GAGs in the ECM of myxoid
tumours of soft tissue differ from those in the ECM of bone tumours (2). The nature
of, and variation in GAGs among myxoid tumours of soft tissue has not as yet been
studied in any great detail. GAGs are important for signal transduction, sequestration
of growth factors, receptor-ligand recognition during development and interactions
between tumour cells. Together with their surrounding ECM, they play an important
role in tumour progression and invasion (3). We investigated whether the composition
of ECM shows significant variation between myxoid tumours of soft tissue and might
be related to differences in their clinical behaviour. In addition, the aim was to elucidate
how these GAGs, together with other proteins, might play a role in the morphogenesis
of this characteristic myxoid morphology.
Materials and methods
Clinicopathological data and procedures
Nine intramuscular myxomas and seven grade I and eight grade III myxofibrosarcomas
were collected retrospectively from the files of the Pathology Departments of Leiden
and Leuven University Medical Centre. Twelve extraskeletal myxoid chondrosarcomas
were retrospectively collected from the files of the Institute of Pathology, University of
Bern, Switzerland and kindly provided by Dr P. Mainil-Varlet. Patient and tumour
characteristics are described in Table 1. Slides were re-evaluated histologically by two
experienced soft tissue pathologists (R.S., P.C.W.H.), classified according to the 2002
World Health Organization criteria and histologically graded according to the French
Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) when applicable
(4-6). All tissue samples were handled in a coded fashion, according to Dutch national
ethical guidelines (Code for proper secondary use of human tissue, Dutch Federation
of Medical Scientific Societies).
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Table 1: Clinicopathological data of included patients with myxoid tumours
*P, primary; R, recurrence; M, metastasis;  †F, female; M, male; ‡Histological grading was performed
according to the FNCLCC. Accordingly, intramuscular myxoma and extraskeletal myxoid
chondrosarcoma were not graded (NA).
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Determination of glycosaminoglycan composition
For hyaluronidase digestion, slides were incubated for 18 h at 37°C with bovine testes
hyaluronidase (Sigma-Aldrich, Zwijndrecht, the Netherlands) and dissolved in a 0.2
M sodium acetate buffer (pH 5.6). For Alcian blue staining following critical electrolyte
concentration, paraffin slides were incubated for 18 h in 0.1% Alcian Blue 8GX solution
(Sigma-Aldrich) dissolved in 0.2 M sodium acetate buffer (pH 5.6) together with mag-
nesium chloride in variable concentrations (0, 0.3, 0.6 and 1.2 M). With this technique,
each biochemically determined GAG possesses its own specific critical electrolyte
concentration (Table 2). Chondrosarcoma served as an external positive control.
Densitometry was performed with a Leica DM-RXA microscope (Leica, Chicago, IL,
USA) with an HQ tetrarhodamine isothiocyanate red filter connected to a digital ca-
mera. For computerized analysis of the absorption the program ColourProc 2003c
was used. Average absorption was calculated after measuring six separate fields, using
a threshold set at 2600 and 3800 to distinguish the nuclei from ECM absorption.
Protein analysis of tumour lysates
To identify other major ECM proteins, we analysed tumour lysates of three intramuscular
myxomas (cases 2, 7 and 8), three extraskeletal myxoid chondrosarcomas (cases 14,
15 and 16), three grade I, and three grade III myxofibrosarcomas (cases 24, 25, 26 and
32, 33 and 36. respectively). Forty slides of 20 µm were cut from each tumour. After
adding 2 ml of Aurum serum protein binding buffer (Bio-Rad, Hercules, CA, USA),
samples were mixed for 15 s using a homogenizer (Ultra-Turrax T8; Rose Scientific,
Edmonton, Canada). Reduced samples were separated by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gel and stained with
Coomassie Brilliant Blue (Merck, Amsterdam, the Netherlands). Tumour tissue lysates
were separated by SDS-PAGE on 10% gel and transferred to polyvinylidene fluoride
membrane filters. Transferred membranes were blocked with phosphate-buffered saline
(PBS)-Tween (0.05%) for IgG staining and skimmed milk in PBS-Tween for albumin
staining. Polyvinylidene fluoride filters were washed and incubated for 30 min with
polyclonal α-rabbit albumin and polyclonal α-rabbit IgG antibodies (both 1:20 000;
DakoCytomation, Glostrup, Denmark) in PBS-Tween. After incubating the filters,
enhanced chemiluminescence (Amersham, Diegem, Belgium) was used as a detection
method. To evaluate the relative contribution of albumin and IgG to the total protein
content of the ECM, samples were depleted of albumin and IgG using the Aurum
Serum Protein kit (Bio-Rad). Protein concentrations were measured with a detergent
Table 2: Identification of GAGs by applying differences in CEC
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compatible protein assay (Bio-Rad). Relative amounts of albumin and IgG were
calculated as the differences in protein concentrations before and after depletion.
Tissue microarray construction
To validate the specificity of albumin staining in myxoid soft tissue tumours, a soft
tissue tumour microarray was constructed. Seventy-nine soft tissue tumours (28 diffe-
rent entities) with well-documented clinicopathological data and follow-up were selected
from the files of the Pathology Department of Leiden University Medical Centre. The
slides were reviewed by an experienced pathologist (P.C.W.H.), classified according
to the 2002 World Health Organization criteria (7) and histologically graded according
to the FNCLCC (5, 6). Representative tumour areas were selected and four tissue
cores from each specimen were obtained using a manual tissue arrayer (Beecher
Instruments, Silver Springs, MD, USA). The punches with a diameter of 0.6 mm were
arrayed on a recipient paraffin block, using standard procedures (8, 9).
Immunohistochemistry and criteria for scoring
Sections (4 µm thick) were mounted on 3-aminopropylethoxysilane (Sigma, St Louis,
MO, USA) and glutaraldehyde-coated slides and dried overnight at 37°C.
Immunohistochemistry was performed as previously described with rabbit polyclonal
anti-albumin antibody (1:20 000; DakoCytomation), using antigen retrieval (citrate
10 min, microwave)(10). Normal liver was used as a positive control. ECM and
cytoplasm of slides and punches were scored by three different observers (S.M.W.,
J.V.M.G.B. and P.C.W.H.) separately. ECM of whole sections and punches were scored
as either positive (+) or negative (-). Cytoplasmic expression of whole sections was
scored as previously described (11). Cytoplasmic expression of tissue microarray
punches was scored as either positive (>10% of cells positive) or negative (<10% of
cells positive).
Real-time polymerase chain reaction for albumin
RNA was isolated from formalin-fixed paraffin-embedded material as described
previously (12). Real-time polymerase chain reaction (PCR) was performed as described
previously (13). The following primers were used: forward, 5'-AGA GGT TTA AAT
TCA TCG AAC ACT TTG-3' and reverse, 5'-CGT GCT GCT GCT GCT GAG ACT
TG-3'. After real-time PCR, the products were purified using Qiagen QIAquick PCR
Purification Kit (Qiagen, GmbH, Hilden, Germany) prior to sequencing. For sequence
confirmation of the products the ABI PRISM® Big Dye Terminators v. 2.0 Cycle
Sequencing Kit was used (Applied Biosystems, Foster City, CA, USA). Samples were
run on an ABI 3700 Genetic Analyser (Applied Biosystems). TATA box binding protein
(TBP) was used as a housekeeping gene to check for the quality of the mRNA using
the following primers: forward, 5'-CAC GAA CCA CGG CAC TGA T-3'and reverse,
5'-TTT TCT TGC TGC CAG TCT GGA C-3'.
chapter 4.p65 12/28/2010, 11:11 AM68
69
Heterogeneous composition of the myxoid matrix
RNA in situ hybridization
A 450-bp product coding for albumin RNA probe was generated using the following
primers: forward, 5'-CTT TCA AAG CAT GGG CAG TAG C-3' and reverse, 5'-GCA
GCG GCA CAG CAC TTC-3' on DNA from liver Hep-G2 cells. This fragment was
cloned into a pGEM easy (t) vector (Promega, Madison, WI, USA). After transfection
in Escherichia coli HB101, plasmids were isolated using the QIAfilter Maxi KITS
protocol (Qiagen GmbH).14 RNA in situ hybridization was performed as previously
described (14).
Confocal microscopy for albumin-Golgi double staining
One each of extraskeletal myxoid chondrosarcoma, intramuscular myxoma and grade
I myxofibrosarcoma with cytoplasmic albumin expression were selected. For
immunofluorescence double staining polyclonal rabbit albumin (1:20 000;
DakoCytomation) and polyclonal rabbit 58 Golgi protein antibodies (1:100; Abcam
Ltd, Cambridge, UK) were used both with antigen retrieval (citrate, 10 min microwave).
Immunoreactivity was detected using Alexa Fluor 488, or 647 secondary antibodies
(Molecular Probes, Invitrogen, Breda, the Netherlands). Scanning was done as
previously described, using a Laser Scanning Microscope (LSM) 510 confocal
fluorescence microscope (Zeiss, Jena, Germany)(15).
Statistical analysis
Differences in intensity of immunoreactivity following critical electrolyte concentration
were calculated with the one-way ANOVA test and post hoc comparisons. Differences
in the outcome of the hyaluronidase experiment were calculated with a two-tailed t-




Patient and tumour characteristics are depicted in Table 1. Intramuscular myxoma
occurred in the extremities only, showed equal sex distribution and a median age of
occurrence of 54 years. All myxofibrosarcomas, regardless of grade, occurred in the
extremities, except for case 28 (lung). They showed a male predominance and a median
age of occurrence at 62 (grade I) and 59 years (grade III) of age. Extraskeletal myxoid
chondrosarcomas occurred predominantly in the extremities and occasionally in the
thoracic and neck region. The median age of occurrence was 56 years. All tumours,
except for case 10 (vertebral metastasis), were primary lesions, not treated by any
form of preoperative radiotherapy or chemotherapy. Examples of the histology are
shown in Figure 1.
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Figure 1: Characteristic morphology, immunohistochemistry and in situ hybridization for albumin
in myxoid tumours of soft tissue. Intramuscular myxoma shows a hypocellular lesion with myxoid
background and sparsely distributed tumour cells without atypia (A). Grade I myxofibrosarcoma is
usually more cellular than intramuscular myxoma, shows more nuclear atypia and is hypervascular
with typical curvilinear vessels (B). Grade III myxofibrosarcoma shows increased cellularity, more
nuclear atypia and more collagenous extracellular matrix (ECM) than grade I myxofibrosarcoma
(C). Extracellular myxoid chondrosarcoma has a rather chondro-myxoid ECM with tumour cells
forming strands and cords (D). E-H, Immunohistochemistry for albumin shows diffuse reactivity of
the ECM in intramuscular myxoma (E), grade I and grade III myxofibrosarcoma (F and G,
respectively) and extraskeletal myxoid chondrosarcoma (H). Interestingly, tumour cells show
cytoplasmic reactivity for albumin, as in this case of grade I myxofibrosarcoma (I) and extraskeletal
myxoid chondrosarcoma (J). RNA in situ hybridization with antisense probes for albumin show
diffuse cytoplasmic reactivity of tumour cells in the case of extraskeletal myxoid chondrosarcoma
(K), whereas the sense probes are negative (L). Immunohistochemistry of the tissue microarray for
albumin shows cytoplasmic expression in desmoid-type fibromatosis (M), whereas schwannoma is
completely negative (N). Interestingly, grade III myxofibrosarcoma and solitary fibrous tumour show
perivascular accentuation (O and P).
Determination of glycosaminoglycans
The ECM of intramuscular myxoma, extraskeletal myxoid chondrosarcoma, grade I
and grade III myxofibrosarcoma showed a statistically significant decrease in absorption
after treatment with hyaluronidase (results not shown). The decline in absorption did
not differ significantly between tumours and was almost equal between intramuscular
myxoma and grade I myxofibrosarcoma. Applying the method of critical electrolyte
concentration, the ECM of intramuscular myxoma, extraskeletal myxoid
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Figure 2: Extracellular matrix of myxoid soft tissue tumours contain different amounts of glycosa-
minoglycans (GAGs). Pie charts showing relative amounts of GAGs. Intramuscular myxoma (IM)
contains the same amounts of various GAGs as grade I myxofibrosarcoma (MFS Gr I). Grade III
myxofibrosarcoma (MFS Gr III) contains less hyaluronic acid and more heparan sulphate. Extra-skeletal
myxoid chondrosarcoma (MCS) contains chondroitin-4 and -6 sulphates.
chondrosarcoma, grade I and grade III myxofibrosarcoma showed heterogeneity in the
various GAGs present in the ECM within this group of tumours (Figure 2).
Protein analysis of tumour lysates
Coomassie brilliant blue staining of undepleted tumour lysates showed clear, domi-
nant bands at 66, 75 and 200 kDa (Figure 3). Western blot analysis confirmed that the
66-kDa band corresponded to albumin and the 200-kDa band to IgG (results not shown).
Contribution of albumin and IgG to the total ECM protein content is depicted in Figure
3. The results of the immunohistochemistry for albumin on sections and tissue
microarray are shown in Figure 1.
Immunohistochemistry for albumin
Results of the immunohistochemistry with antibodies directed against albumin are
shown in Figure 1. All tumours showed diffuse reactivity for albumin in the ECM and
cytoplasm. Interestingly, perivascular staining for albumin was present in the majority
of cases. Neither extracellular nor cytoplasmic reactivity for albumin were tumour-
type specific, and both were also present in the majority of the non-myxoid tumours in
the tissue microarray, although schwannoma and synovial chondromatosis were
completely negative.
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Figure 3:  Albumin is a major extracellular matrix (ECM) protein of myxoid tumours of soft tissue and
is produced by the tumour cells.  A, Intramuscular myxoma (IM) and grade I myxofibrosarcoma (MFS),
showing an intense band at 66 kDa and a smaller band at 200 kDa (A, lanes 2 and 4). Western blot
analysis confirmed that these bands correspond to albumin (66 kDa) and IgG (200 kDa, not shown).
There is a marked decrease in intensity of both 66-kDa and 200-kDa bands after depletion for albumin
and IgG (A, lanes 3 and 5).B, Histogram showing that albumin is a major protein in the ECM of
extraskeletal myxoid chondrosarcoma (EMC), IM and grade I and III MFS (Gr I and Gr III). Note that
there is a significant decrease in albumin content in the ECM of myxofibrosarcoma with increased
grade (*P = 0.004). C and D, Tumour cells of myxoid soft tissue tumours produce albumin, as in this
case of extraskeletal myxoid chondrosarcoma. Two-colour immunofluorescence staining of 58K Golgi
protein (green) and albumin (red) in extraskeletal myxoid chondrosarcoma. Note the overlap of the
green and the red signal in the cytoplasm of the cells, indicative of co-localization (1, Golgi-
immunofluorescence staining; 2, albumin-immunofluorescence staining; 3, Golgi-albumin
immunofluorescence double staining; 4, Nomarski). Colocalization is shown as an intensity profile for
one cell (C).
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RNA in situ hybridization, real-time PCR and sequencing
Real-time PCR showed mRNA expression for albumin by the tumour cells in all cases,
except for case 33. This was not due to the quality of the cDNA, as there was normal
TBP expression. Sequencing of the samples confirmed that the reaction product was
albumin. In situ hybridization with probes against albumin showed mRNA in the
cytoplasm of the tumour cells, but not in the endothelial, perivascular cells or
lymphocytic infiltrate (Figure 1).
Confocal microscopy for albumin-Golgi double staining
Colocalization of immunoreactivity for Golgi and albumin was found in the cytoplasm
of tumour cells, as depicted in Figure 3.
Discussion
The term 'myxoid' was first used by Rudolf Virchow in 1871 to describe tumours that
shared morphological features with the jelly-like structure of the umbilical cord (16).
Nowadays, more than 60 reactive and neoplastic entities have been described as being
predominantly myxoid or containing myxoid areas.1 Although GAGs undoubtedly
contribute at least to some extent to the myxoid nature of the ECM, the exact composition
and function of this so-called myxoid ECM are unknown. Interactions between tumour
cells and their ECM are important in tumour progression and tumour invasion (17).
Interestingly, we found that the distribution of the different GAGs in the ECM of
intramuscular myxoma was identical to that of grade I myxofibrosarcoma. This
corresponds to the comparable morphology of these tumours (Figure 1), but not to
their clinical behaviour, as the former is truly benign (18) and the latter shows an
increase in histological grade (19) and cytogenetic aberrations (20) on recurrence,
probably responsible for the increase in metastatic potential. We have shown that for
myxofibrosarcoma there is a significant increase in the amount of heparan sulphate
with an increase in grade. Heparan sulphate facilitates metastasis by sequestering
chemokines and/or growth factors, establishing a haptotactic gradient that drives tumour
cells to specific stimuli. Furthermore, heparan sulphates are thought to aid in protection
and localization of proteases and hinder the interactions between tumour cells and
other adhesion molecules (21) The core protein of heparan sulphate interacts as a co-
receptor with growth factors. This might explain how an increase in heparan sulphate
in the ECM of myxofibrosarcoma is related to tumour progression. We have shown
that the ECM of extracellular myxoid chondrosarcoma contains significantly more
chondroitin-4 and -6 sulphates than intramuscular myxoma and myxofibrosarcoma.
In this respect, our results correspond to previous cDNA microarray studies of
extraskeletal myxoid chondrosarcoma showing overexpression of chondroitin sulphate
proteoglycan 2 (versican)(22). Chondroitin sulphate interacts with several different
ECM molecules and plays a crucial role in ECM assembly. Perhaps the best known
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Figure 4:  Proposed model for the role of glycosaminoglycans (GAGs) and albumin in extracellular
matrix (ECM) formation in myxoid tumours of soft tissue. Interplay between GAGs and albumin in
ECM formation and morphogenesis of myxoid tumours of soft tissue. Tumour cells produce GAGs and
albumin, which attract water from adjacent blood vessels (interrupted arrows), which in turn is
subsequently trapped in the interstitial space by GAGs.
interaction is between the amino-terminal domain of chondroitin sulphate and hyaluronic
acid, which we have shown to be the second most abundant GAG in these tumours.23
Both GAGs are therefore crucial for ECM assembly and stability in extraskeletal
myxoid chondrosarcoma. Chondroitin sulphate is involved in cell proliferation and
migration, and appears to prevent apoptosis. Its abundant presence in the ECM of
extraskeletal myxoid chondrosarcoma might play a role in the malignant behaviour of
these tumours (Figure 2), although the exact underlying mechanisms are not yet fully
understood.We have demonstrated that albumin is a major protein in the myxoid ECM,
which we have confirmed by immunohistochemistry in a larger series (Figures 1 and
3). Albumin is the most abundant plasma protein, is important for transporting fatty
acids, thyroid hormones and steroid hormones and is produced mainly by the liver. As
a result of leakage of tumour vessels, at least part of the albumin in the ECM might be
blood-borne, which is supported by the finding of other plasma proteins in the ECM.
Interestingly, tumour cells of intramuscular myxoma, myxofibrosarcoma and
extraskeletal myxoid chondrosarcoma also showed cytoplasmic staining for albumin,
suggesting that it might be produced by the tumour cells. However, this pattern of
immunoreactivity is not specific for myxoid tumours of soft tissue, since it is also
found in many other tumours, including those without a myxoid morphology. Thus,
the presence of albumin in itself cannot explain the myxoid ECM. Nevertheless, we
hypothesize that albumin plays an important role in the morphogenesis of the ECM of
myxoid tumours of soft tissue. Tumour cells produce collagens, GAGs and albumin,
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as illustrated in Figure 4. Albumin and GAGs attract water from adjacent blood vessels
by osmosis. This extracellular water percolates the tissue, delivering nutrients and
oxygen and carrying away metabolites. Albumin is freely mobile in the ECM. Therefore,
its presence does not depend heavily on production by (tumour) cells, but relies on
stereometric and charge exclusion by trapped (macro)molecules such as collagens and
hyaluronic acid (24) Following an increase in histological grade, the ECM of
myxofibrosarcoma shows an increase in collagen, but no significant difference in
hyaluronic acid (Figure 3). Thus, exclusion of albumin from the ECM in
myxofibrosarcoma appears to be primarily regulated by collagen, but not by hyaluronic
acid. This corresponds to our findings showing an inverse correlation between col-
lagen and albumin (and IgG) content upon increase in histological grade.
Morphologically, this is reflected in the transition from the more jelly-like ECM of
grade I myxofibrosarcoma to the more collagenous ECM in grade III myxofibrosarcoma
(Figure 1). Based on these results, we propose a model illustrating the interplay bet-
ween albumin, GAGs and collagens in ECM formation as depicted in Figure 4. Albumin
mRNA has been detected in several tissues such as the gastrointestinal tract, kidney,
striated muscle, pancreas, placenta, spleen and uterus (http://cgap.nci.nih.gov). This
suggests that albumin has important functions other than merely serving as a plasma
protein. Perivascular albumin is essential for the integrity of the endothelial-ECM
barrier (25). Interestingly, we observed that albumin present in the ECM has a
perivascular accentuation (Figure 1). As the percentage of myxoid ECM inversely
correlates with the vessel density in myxofibrosarcoma (19) albumin might act as an
important transport molecule for diffusion of metabolic substrates in these tumours.
This corresponds to our finding that the ECM of grade I myxofibrosarcoma (and
intramuscular myxoma) contains significantly more albumin (and IgG) than grade III
myxofibrosarcoma (Figure 3).
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Cellular myxoma and grade I myxofibrosarcoma are mesenchymal tumours that are
characterized by their abundant myxoid extracellular matrix (ECM). Despite their
histological overlap, they differ clinically. Diagnosis is therefore difficult though im-
portant. We investigated their (cyto) genetics and ECM. GNAS1-activating mutations
have been described in intramuscular myxoma, and lead to down-stream activation of
cFos. KRAS and TP53 mutations are commonly involved in sarcomagenesis whereby
KRAS subsequently activates cFos. A well documented series of intramuscular myxoma
(three typical cases and seven cases of the more challenging cellular variant) and grade
I myxofibrosarcoma (n 10) cases were karyotyped, analyzed for GNAS1, KRAS and
TP53 mutations and downstream activation of cFos mRNA and protein expression.
ECM was studied by liquid chromatography mass spectrometry and expression of
proteins identified was validated by immunohistochemistry and qPCR. Grade I
myxofibrosarcoma showed variable, non-specific cytogenetic aberrations in 83,5% of
cases (n 6) whereas karyotypes of intramuscular myxoma were all normal (n 7). GNAS1-
activat-ing mutations were exclusively found in 50% of intramuscular myxoma. Both
tumour types showed over-expression of cFos mRNA and protein. No mutations in
KRAS codon 12/13 or in TP53 were detected. Liquid chromatography mass spectrometry
revealed structural proteins (collagen types I, VI, XII, XIV and decorin) in grade I
myxofibrosarcoma lacking in intramuscular myxoma. This was confirmed by
immunohistochemistry and qPCR. Intramuscular/cellular myxoma and grade I
myxofibrosarcoma show different molecular genetic aberrations and different
composition of their ECM that probably contribute to their diverse clinical behaviour.
GNAS1 mutation analysis can be helpful to distinguish intramuscular myxoma from
grade I myxofibrosarcoma in selected cases.
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Introduction
Myxoid tumours of soft tissue comprise a heterogeneous group of mesenchymal tumours
characterized by abundant extracellular matrix (ECM). In this group, intramuscular
myxoma and myxofibrosarcoma are most frequent, usually occurring in the extremities
and at older age [1]. Histologically, intramuscular myxoma, and in particular its cellular
variant (i.e. cellular myxoma), and grade I myxofibrosarcoma show considerable
overlapping fea-tures [2]. Clinically, they differ as intramuscular myxoma shows no
recurrence except for the cellular variant and never metastasizes. This is in contrast to
myxofibrosarcoma that has a tendency to recur and, importantly, shows increase in
tumour grade upon recurrence, thereby gaining metastatic potential [3]. Thus, the
differential diagnosis between these two entities is important though can be challenging
especially when presenting as an intramuscular tumour. Myxofibrosarcoma is usually
characterized by complex, non-specific karyotypic aberrations. (Cyto) genetic data on
intramuscular myxoma are sparse with only two cases described in the literature showing
normal karyotypes [4, 5]. Recently, activating mutations in codon 201 of the GNAS1
gene have been described in intramuscular myxoma [6]. This gene encodes, among
others, for the alpha-sub-unit of the heterotrimeric G-protein. This protein is involved
in cell signalling and leads to the transcription of the protein cFos and subsequently
activation of the cell cycle. Activating GNAS1 mutations and the subsequent activation
of cFos are involved in the pathogenesis of fibrous dysplasia, which is a benign bone
tumour associated with intramuscular myxoma in Mazabraud syndrome [7]. Activating
mutations in codon 12/13 of KRAS also lead to downstream activation of cFos. KRAS-
activating mutations have been described in both mouse and human sarcomas. Kirsch
et al. showed that KRAS and TP53 mutations were sufficient to initiate high-grade
sarcomas with myofibroblastic features in mice [8]. TP53 mutations are relatively
common in sarcomas with nonspecific genetic aberrations compared with sarcomas
with reciprocal specific translocations [9]. Previous studies showed
immunohistochemical p53 expression in 33% of myxofibrosarcoma, mainly occurring
in grade II and grade III tumours [10]. We studied the genetic make-up of these tumours
at levels of karyotype, GNAS1, TP53 and KRAS mutations and down-stream expression
of cFos in order to find a potential tool for differential diagnosis and to get more
insight into the biology of these tumours. The constitution and function of their so-
called myxoid ECM are poorly understood. Previously, we demonstrated that
intramuscular myxoma and grade I myxofibrosarcoma showed no significant differences
in the glycosaminoglycans present in their ECM [11]. To study the differences in ECM
organization and association with clinical behaviour, we screened ECM lysates of
intra-muscular myxoma and grade I myxofibrosarcoma in a broad liquid
chromatography mass spectrometry (LC-MS)-based survey.





The study included 10 intramuscular myxoma cases and 10 grade I myxofibrosarcoma
cases that were collected retrospectively from the files of the Pathology Departments
of the University Hospitals of Leuven and Leiden University Medical Center. In each
case, 4-mm-thick sections of formalinfixed, paraffin-embedded material were stained
with haematoxylin and eosin (H&E). The histological diagnoses were revised (CDMF,
PCWH, RS) and classified according to the 2002 WHO criteria. In case of
myxofibrosarcoma, histological grading was performed according to the FNCLCC
[12, 13]. Patient and tumour characteristics are shown in Table 1. Characteristic
morphology of intramuscular myxoma, cellular myxoma and grade I myxofibrosarcoma
is depicted in Fig. 1.
Karyotyping
Cells were harvested and 48-colour fluorescence in situ hybridization (FISH) staining
was carried out, which stains every chromosome arm in a different colour combination.
This was followed by digital imaging and analysis as previously described [5, 14].
Hybridizations with individual libraries labelled with single fluorochromes were used
to confirm the detected re-arrangements. Break-points were assigned by using inverted
DAPI counterstained images of the chromosomes.
GNAS1 direct sequencing
GNAS1 mutation analysis was performed for codon 201 (exon 8) and codon 227 (exon
9) using oligonucleotide primers extended with an M13-forward or reverse sequence
(see supplementary Table 1). Tumour tissue was isolated from formalin-fixed, paraffin-
embedded material (FFPE) by microdissection to enrich for tumour cells and avoid
'contamination' of non-neoplastic cells, that is, lymphocytes, endothelial cells/pericytes
or muscular tissue at the periphery of the tumour. Genomic DNA was isolated from 10
consecutive 10-mm sections using a Chelex extraction method, as described earlier
[15]. Polymerase chain reaction (PCR) was carried out to amplify the GNAS1 gene
with the primers for exon 8 and exon 9, as previously reported [16]. PCR products
were visualized and sequenced as previously described [17, 18].
GNAS1 multiplex ligation-dependent probe amplification (MLPA)
To detect mutations that are missed by direct sequencing due to contamination with
normal cells, we set up GNAS1 MLPA for the mutations already detected by direct
sequencing. MLPA was performed using the following oligonucleotide probes attached
to M13-tail, depicted in supplementary Table 3. For the R201C mutant, probes with
additional stuffer sequence were added: forward: 5-CAGAC-3 and reverse 5-
GATGTGCT-3. MLPA was performed as previously described [19]. In short, adjacently
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Table 1: Patient and tumour characteristics
*These were all cellular myxomas.
Abbreviations: IM, intramuscular myxoma; MFS, myxofibrosarcoma; P, primary lesion; R, local
recurrence; M, metastasis, NSR, no sign of recurrence; LR, local recurrence. Intramuscular myxoma
showed a female predominance and myxofibrosarcoma a slight male predominance. The median age of
occurrence was 56 years for intramuscular myxoma and 66 years for myxofibrosarcoma. All cases were
primaries except for case 15, which was a local recurrence. Except for case 2 and 20, all lesions
occurred at the extremities. Out of the intramuscular myxomas, eight were truly intramuscular, whereas
single cases were identified at other sites (case 2 and 4). None of the lesions were situated near
articular surfaces. Clinical, radiological and histological follow-up (17–94 months) showed no local
recurrence for intramuscular myxoma but did in half of the cases of myxofibrosarcoma. No patients
had any clinical evidence for endocrinopathy or café-au-lait spots. One patient (case 1) suffered
monostotic fibrous dysplasia of the distal femoral bone, diagnosed by conventional radiological
examination and MRI, and was therefore suspected for Mazabraud or a partial form of McCune–
Albright syndrome.
annealing oligonucleotide probes were hybridized and ligated. After ligation, the common
ends of the probes served as a template for PCR amplification using the primer pairs
that are depicted in supplementary Table 3, with one of each pair fluorescently labelled.
Products were separated on the ABI 3700 genetic analyser (Applied Biosystems, Foster
City, CA) and analyzed.
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Figure 1: Overlapping histology of intramuscular myxoma, cellular myxoma and grade myxo-
fibrosarcoma and their immunohistochemical expression for cFos, decorin, collagen I, collagen VI
and CD44. (A) Low-power view of intramuscular myxoma showing a hypocellular and hypovascular
tumour. Its cellular variant is both more cellular and more vascular (B) but lacks the cytonuclear
atypia and characteristic curvilinear vascular pattern of grade I myxofibrosarcoma (C). Low-power
view of intramuscular myxoma (D) showing moderate cytoplasmic and nuclear expression for cFos
in the majority (75%) of tumour cells. (E) Low-power view of intramuscular myxoma was complete-
ly negative for decorin, whereas grade I myxofibrosarcoma showed diffuse fibrillary staining for
decorin in the ECM (F). Lack of collagen I expression in the ECM of intramuscular myxoma (G)
and moderate stain-ing for collagen VI in the ECM of grade I myxofibrosarcoma (H). A majority of
tumour cells of grade I myxofibrosarcoma showed strong membranous staining for CD44 in the
majority of tumour cells (I ).
KRAS mutation analysis
KRAS mutation analysis was performed on microdissected FFPE tumour tissue using
two primer sets in a nested PCR which specifically amplifies a 114 bp fragment of
KRAS exon 2, including codons 12 and 13 (supplementary Table 1). All primer sequences
and amplification protocols have been previously described [20]. PCR products were
purified with the QIAquick PCR Purification Kit (Qiagen, Germantown, MD) and
sequenced with the fluorescent Big-Dyes Terminators Sequencing Kit (Applied
Biosystems).
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Table 2 Cytogenetic findings and GNAS1, KRAS and TP53 mutation analysis in
intramuscular myxoma and grade I myxofibrosarcoma
aTP53 analysis was performed for exons 4a, 4b, 5c, 6, 7 and 8.
bKaryotypes were previously published [5].
Abbreviation: NA, not available.
TP53 mutation analysis
TP53 hotspot mutation analysis was performed on microdissected FFPE tumour tissue
using primer sets for exons 4a, 4b, 5c, 6, 7 and 8 in a nested PCR (supplementary
Table 2). Samples were used in high-resolution melting curve analysis as previously
described [46]. PCR products were purified with the QIAquick PCR Purification Kit
(Qiagen) and sequenced with the fluorescent Big-Dyes Terminators Sequencing Kit
(Applied Biosystems).
SDS-PAGE, in-gel tryptic digestion and mass spectrometry
Tumour lysates of intramuscular myxoma and grade I myxofibrosarcoma were prepared
and depleted of albumin and IgG as previously described [11]. From each sample, 150
g was separated by SDS-PAGE and stained with Colloidal Coomassie (Invitrogen,
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Extracellular protein extracts from MFS and IM were depleted for albumin and IgG, separated by
SDS-PAGE, in-gel digested with trypsin and analyzed by LC-MS. Shown are the top 30 proteins
identified in MFS. Proteins that were also identified in IM are indicated with a sign. Many forms of
keratins and IgGs were also identified within the initial top 30 protein list, but for the sake of
clarity, they have been removed.
Leek, The Netherlands). The complete lanes from both intramuscular myxoma and
grade I myxofibrosarcoma were cut into approximately 30 protein bands, and these
samples were subsequently reduced, alkylated and in-gel digested using trypsin as
described previously [21]. Peptides were subsequently collected using two rounds of
extraction with 20 l of 0.1% trifluoroacetic acid and were stored at -20-C prior to
analysis by mass spectrometry. Samples were injected onto a nano-LC system (Ultimate,
Dionex, Amsterdam, the Netherlands) equipped with a peptide trap column (Pepmap
100, 0.3 i.d. 1 mm) and an analytical column (Pepmap 100, 0.075 i.d. 150 mm, Dionex).
The mobile phases consisted of (A) 0.04% formic acid/0.4% acetonitrile and (B) 0.04%
Table 3: Proteins identified in MFS and IM
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formic acid/90% acetonitrile. A 45-min. linear gradient from 0% to 60% B was applied
at a flow rate of 0.2 ml/min. The outlet of the LC system was coupled to an HCT Ultra
ion-trap mass spectrometer (Bruker Daltonics, Bremen, Germany) using a nano-
electrospray ionization source. The spray voltage was set at 1.2 kV, and the temperature
of the heated capillary was set to 165-C. Eluting peptides were analyzed in the data-
dependent MS/MS mode over a 400-1600 m/z range. The five most abundant fragments
in each MS spectrum were selected for MS/MS analysis by collision induced
dissociation. Mass spectra were evaluated using the DataAnalysis 3.1 software package
(Bruker Daltonics) and exported as a Mascot Generic File (MGF). MGF files were
merged using the OMSSA Browser version 2.1.0. and searched against the human
International Protein Index (IPI) database using the Mascot search algorithm (version
2.2, Matrixscience, London, UK), allowing mass tolerances of 0.5 Da for MS (# 13 C
1) and 0.75 Da for MS/MS. One missed cleavage site was allowed for tryptic peptides.
Carbamidomethylcysteine was taken as a fixed modification and oxidation of methionine
as a variable modification.
qPCR for mRNA expression
Following microdissection, RNA isolation and purification, qPCR was performed for
c-Fos, decorin, collagen I alpha 1, collagen VI alpha 1, collagen XII alpha 1 and
collagen XIV alpha 1, as described previously [11, 22, 23]. Primers (including those
of the housekeeping genes) and controls are summarized in supplementary Table 1. A
reference control panel, including a variety of neoplastic and non-neoplastic tissue was
used as described previously [24]. After qPCR, the products were purified using
QIAquick PCR Purification Kit (Qiagen). For sequence confirmation of the products,
we used the Big Dyes Terminators Sequencing Kit (Applied Biosystems).
Immunohistochemistry
Immunohistochemistry was performed for c-Fos, decorin, collagen I-A1, collagen VI-
A1 and CD44. Sections (4-m-thick) were mounted on 3-aminopropylethoxysilane
(Sigma, St. Louis, MO) and glutaraldehyde-coated slides and dried overnight at 37-C.
Immunohistochemistry was per-formed as previously described, using the antibodies,
conditions and controls described in supplementary Table 4 [11, 25]. For c-Fos and
CD44, only nuclear and membranous staining were assessed, respectively, and scored
as previously described [26]. For decorin, collagen I-A1 and collagen VI-A1, the ECM
of whole sections were assessed. Scores of 0 (absent) and 1 (weak) were considered
negative; scores of 2 (moderate) and 3 (strong) were considered positive.
Statistical analysis
Wilcoxon-Mann-Whitney test was used to calculate the differences for both the
immunohistochemical and qPCR results.





Karyotypes were available for seven intramuscular myxomas (five cases were of the
cellular variant) and six grade I myxofibrosarcomas. The karyotypes of the
intramuscular myxomas (both typical and cellular cases) were all normal. Out of the
grade I myxofibrosarcoma cases, only one case showed a normal karyotype, whereas
five out of six cases showed variable, non-specific cyto-genetic aberrations (Table 2).
GNAS1, KRAS and TP53 mutation analysis
By direct sequencing, we found codon 201 activating GNAS1 mutations in 50% of
intramuscular myxoma cases (including its cellular variant), but none in grade I
myxofibrosarcoma cases. All GNAS1 mutations occurred in exon 8 with the base pair
substitutions as shown in Table 2. GNAS1 MLPA confirmed the mutations detected by
direct sequencing. In theory, MLPA should be able to detect mutant alleles in a
background of wild-type alleles. Here, we show that this technique picks up mutations
if only 10% of the alleles is mutated, which is superior to direct sequencing (requiring
at least 25% mutated alleles). GNAS1 MLPA could not detect additional mutations.
We did not observe any mutations in codon 12 or 13 of the KRAS gene in neither the
intramuscular myxoma nor the grade I myxofibrosarcoma cases. Hotspot mutation
analysis for TP53 showed wild-type sequences in all samples (Table 2).
LC-MS
The top 30 proteins identified in a proteomic screen of tumour lysates of grade I
myxofibrosarcoma and intramuscular myxoma are shown in Table 3. Even after
depletion, albumin was still the most prominent protein, and also other 'classical' se-
rum proteins were among the most significant hits. We found five collagens (VI-A1, 2
and 3, XII-A1, XIV-A1) and five proteoglycans (lumican, PRG4, prolargin, decorin
Abbreviations: FOS, FBJ murine osteosarcoma viral oncogene homolog; DCN, decorin; COL1A1,
collagen, type I, α1; COL6A1, collagen VI, α1; COL12A1, collagen, type XII, α1; COL14A1, col-
lagen, type XIV, α1.
Table 4: Log2-transformed relative expression data in qPCR
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and biglycan) among the top 30 proteins in MFS. Only the collagen VI isoforms and
lumican were identified in IM. Besides collagen VI isoforms and lumican, the other
four collagens and four proteoglycans were not shown to be present in IM using mass
spectrometry. qPCR for mRNA expression Results of relative mRNA expression are
shown in Table 4 and boxplots in Fig. 2. qPCR showed that cFos RNA was over-
expressed in all tumours compared with control tissue, but not significantly differently
expressed between intramuscular myxoma and grade I myxofibrosarcoma. No signifi-
cant differences were seen between typical intramuscular myxoma and cellular myxoma.
Grade I myxofibrosarcoma showed significant expression of decorin mRNA, whereas
decorin mRNA was barely detectable in intramuscular myxoma. Grade I
myxofibrosarcoma clearly showed significant over-expression of mRNA expression
for collagens I-A1, VI-A1 and XIV-A1 compared with intramuscular myxoma (including
cellular myxoma).
Immunohistochemistry
The majority of intramuscular myxomas and grade I myxofibrosarcomas showed dif-
fuse cytoplasmic and nuclear staining for cFos (Table 5). Both cytoplasmic and nuclear
staining for c-Fos have been obtained in FFPE materials from other tumours [27].
However, the biological role of cytoplasmic cFos expression is not fully understood.
And because c-Fos is a transcription factor that is active in the nucleus, we assessed
only nuclear staining in scoring. Intramuscular myxoma and grade I myxofibrosarcoma
did not show significantly different cFos expression (P 0.648; Table 5). Decorin, col-
lagen I-A1 and collagen VI-A1 were only present in the ECM. Strong positive staining
for decorin was detected in all grade I myxofibrosarcomas but not in intramuscular
myxoma, including its cellular variant (P 0.0000). Collagen I-A1 expression was found
to be equally present in the ECM of grade I myxofibrosarcoma and intramuscular
Figure 2: Box-plots showing qPCR results of structural ECM proteins. Abbreviations: IM, intramuscular
myxoma; MFS, grade I myxofibrosarcoma. Intramuscular myxoma showed significantly lower mRNA
expression for decorin (P 0.000), collagen I-A1 (P 0.003), collagen VIA1 (P 0.023) and collagen XIV-
A1 (P 0.001).




myxoma (P 1.000). Collagen VI-A1 expression was present in 40% of the ECM of
intramuscular myxoma and all grade I myxofibrosarcoma (P 0.004). Illustrations of
collagen I-A1 and VI-A1 protein expression are shown in Fig. 1. Both grade I
myxofibrosarcoma and intramuscular myxoma showed membranous and cytoplasmic
staining for CD44 in the majority of cases, the latter most probably due to its production
in the rough endoplasmic reticulum. As we were interested in the role of CD44 as a cell
surface receptor for ECM molecules, only membranous staining was assessed in
statistical analysis. Tumour cells of intramuscular myxoma and grade I
myxofibrosarcoma showed no significantly different expression for CD44 (P 0.0542;
Table 5). Illustrations are shown in Fig. 1.
Discussion
The cellular variant of intramuscular myxoma, also known as cellular myxoma, is the
morphological intermediate between intramuscular myxoma and grade I
myxofibrosarcoma. Compared with typical intramuscular myxoma, cellular myxoma
is hypercellular, usually more vascular and shows increase in collagenous stroma.
However, it lacks clear cytonuclear atypia and classical curvilinear blood vessels [2].
The risk of recurrence is rather low, which is sustained by the present data showing
local recurrence in 50% of grade I myxofibrosarcoma but not in intramuscular myxoma.
This includes the cases of the cellular variant, even after long-term follow-up, which is
in accordance with the literature [2, 28]. It should be noted that not all cellular myxomas
are truly intramuscular (see Table 1), which was already demonstrated by Van Roggen
et al. [2]. In a previous study, we showed that myxofibrosarcoma is characterized by
complex, non-specific cytogenetic aberrations probably reflecting genomic instability
[5]. Chromosomal instability is often an early event in tumourigenesis, and there is a
significant correlation between chromosomal instability phenotype and poor biological
behaviour [29]. This is sustained by our data showing karyotypic aberrations only in
myxofibrosarcoma but not in intramuscular myxoma. TP53 is an important mitotic
check-point regulator, and p53 deficiency plays an important role in chromosomal
instability and ploidy control [29]. Mutations in TP53 resulting in dysfunctional p53
Table 5: Results for immunohistochemical staining in intramuscular myxoma and grade I
myxofibrosarcoma
Abbreviations: IM, intramuscular myxoma; MFS, myxofibrosarcoma; dcn, decorin; pos*, number of
positive tumours/total number of tumours that could be evaluated; pos#, percentage of cases that
were positive.
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occur mostly (93%) in exons 4-8, which are therefore called hotspot mutations [30].
We did not detect any TP53 hotspot mutations in intramuscular myxoma or in grade I
myxofibrosarcoma. This means that TP53 mutations might not be involved in the
tumourigenesis of either tumour. Otherwise, it might support the notion that structural
loss of p53 is not always the cause of aneuploidy and that loss of p53 might represent
a late event in tumourigenesis of myxofibrosarcoma, whereas aneu-ploidy occurs early
[31]. This was sustained by previous data that p53 immunohistochemical staining was
predominantly found in myxofibrosarcoma of grade II and III [10]. Cytogenetic data
on intramuscular myxoma are sparse in the literature, with only two isolated cases
described showing normal karyotypes [4, 32]. The present study confirms in a larger
series that intramuscular myxoma has a normal karyotype. Cytogenetics might therefore
be helpful in the differential diagnosis but are not always easily available in routine
laboratories. Okamoto et al. showed GNAS1-activating mutations in a small series of
intramuscular myxoma [6]. We showed that GNAS1 codon 201 mutations were pre-
sent in 50% of intramuscular myxoma and not in grade I myxofibrosarcoma. All
mutations were heterozygous. Direct sequencing of codon 201 GNAS1 mutations is
therefore a highly specific, not very sensitive but easy to perform method to distinguish
intramuscular myxoma from grade I myxofibrosarcoma. Interestingly, here we report
for the first time the R201S mutation in intramuscular myxoma. We could not detect
any mutation in codon 227 (exon 9) of the GNAS1 gene, previously detected in fibrous
dysplasia [33]. The GNAS1 gene encodes for the alpha sub-unit of the G-protein.
Somatic-activating mutations in codon 201 and 227 of the GNAS1 gene have been
described in fibrous dysplasia and the related Mazabraud and McCune Albright
syndromes, leading to increased levels of cAMP and activation of protein kinase A and
the MAPK pathway [7, 33-35]. This leads to increased transcription of the cFos protein,
which is involved in growth and the inhibition of apoptosis [36]. We showed both RNA
and protein over-expression for cFos in each of the tumour samples of intramuscular
myxoma and grade I myxofibrosarcoma, suggesting that the MAPK signalling pathway
is activated in these tumours. We did not detect GNAS1-activating mutations in
myxofibrosarcoma nor did we detect codon 201 or 227 activating mutations in the
other 50% of the intramuscular myxoma cases. As both are hypocellular tumours, we
hypothesized that wild-type DNA of blood vessels and lymphocytes might interfere
with the detection of this heterozygous mutation. Neither enrichment for mutated DNA
by microdissection nor the use of more sensitive method to detect the mutations (MLPA)
with a detection threshold of only 10% could increase the number of mutations found.
Therefore, we believe that activation of the MAPK pathway in the tumours with no
detectable mutations is caused by a different mechanism than GNAS1-activating
mutations, possibly downstream of the G-protein. In vivo studies on mice showed that
KRAS-activating mutations play an important role in sarcomagenesis [8]. In general,
about 30% of solid tumours show activating mutations in codon 12 and 13 of the
KRAS gene causing activation of the MAPK pathway and increased transcription of c-
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Fos [37, 38]. Moreover, KRAS mutations have been associated with chromosomal
instability suggesting a potential role of KRAS in the tumourigenesis of grade I
myxofibrosarcoma [39]. However, we could not detect any activating mutations in
codon 12 and 13 of the KRAS gene in intramuscular myxoma nor grade I
myxofibrosarcoma. Intramuscular myxoma (including its cellular variant) and grade I
myxofibrosarcoma are both characterized by their abundant so-called myxoid ECM.
We have shown recently that glycosaminoglycans (e.g. hyaluronic acid) are major
polysaccharides in the myxoid ECM of intramuscular myxoma and myxofibrosar-
coma [11]. Based on the present, more detailed LC-MS-based survey, we showed that
decorin, collagen VI-A1 and XIV-A1 were significantly overexpressed in the ECM of
grade I myxofibrosarcoma compared with that of intramuscular myxoma. Decorin is a
small leucine-rich proteoglycan (SLRP) in the ECM that 'decorates' collagens by
interaction with their 'd' and 'e' bands. Decorin links these collagens (especially collagens
I, VI and XIV) and plays an important role in fibrillogenesis and ECM formation.
Decreased and impaired expression of decorin leads to abnormal ECM formation as in
Ehlers-Danlos syndrome [40, 41]. Next to decorin, LC-MS revealed other SLRPs (i.e.
lumican, PRG4, prolargin, biglycan) present in tumour lysates of grade I
myxofibrosarcoma but not of intramuscular myxoma. Collagens XII and XIV are
fibril-associated collagens with triple helices (FACIT) and modify the interactions
between collagen I fibrils and the surrounding ECM [42]. Increased ECM rigidity
activates integrins to promote focal adhesion families, leading to stimulation of the
rho/Rock pathway and increased cell contractility, cell migration and invasion [43].
Intramuscular myxoma was found to express significantly less decorin and collagen
VI and XIV (both protein and mRNA level) than grade I myxofibrosarcoma, suggesting
that ECM formation in intramuscular myxoma is impaired compared with grade I
myxofibrosarcoma. Validation of these immunohistochemical results in an independent
series of both entities would be interesting though is hampered by the availability of
well-characterized frozen material. Cell surface receptors facilitate the assembly and
retention of the ECM and link changes in the ECM to activation of signal transduction
pathways [44]. CD44 glycoprotein is a well-characterized cell adhesion molecule that
is ubiquitously expressed on tumour cells of intramuscular myxoma and grade I
myxofibrosarcoma. Its principal ligand is hyaluronic acid which was, however, not
expressed significantly differently in intramuscular myxoma compared with grade I
myxofibrosarcoma [11]. CD44 is also an important cell surface receptor for collagen
I and XIV, suggesting that ECM-cell signalling via CD44 might play a role in these
myxoid tumours of soft tissue [45]. Although grade I myxofibrosarcoma showed
significantly higher mRNA expression for collagen I and XIV, this was not obvious at
the protein level for collagen I. Whether differences in (the assembly of) the ECM of
myxoid tumours of soft tissue effectively affect cell signalling and subsequent tumour
growth and progression is still unknown. The evidence in our studies to support this
theory is indirect and our results cannot exclude that the content and organization of
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the myxoid ECM might be just an epiphenomenon, driven by the initiating genetic
event(s) or by the precise lineage or subtype of the cell that is transformed. Based on
our results, we suggest that molecular and cytogenetic aberrations as well as proper
ECM organization might explain the different biology of these tumours.
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Imaging mass spectrometry of myxoid sarcomas
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Myxofibrosarcoma and myxoid liposarcomas are relatively common soft tissue tumours
that are characterized by their so-called myxoid extracellular matrix and have to some
extent overlap in histology. The exact composition and potential role of their myxoid
extracellular matrix are insufficiently understood. To gain more insight into the
biomolecular content of these tumours we have studied 40 well-documented
myxofibrosarcoma and myxoid liposarcoma cases using imaging mass spectrometry.
This technique provides a multiplex biomolecular imaging analysis of the tissue, span-
ning multiple molecular domains and without a priori knowledge of the tissue's
biomolecular content. We have developed experimental protocols for analyzing the
peptide, protein and lipid content of myxofibrosarcoma and myxoid liposarcomas, and
have detected proteins and lipids that are tumour-type and tumour-grade specific. In
particular lipid changes observed in myxoid liposarcomas could be related to pathways
known to be affected during tumour progression. Unsupervised clustering of the
biomolecular signatures was able to classify myxofibrosarcoma and myxoid
liposarcomas according to tumour type and tumour grade. Closer examination of
histologically similar regions in the tissues revealed intratumour heterogeneity, which
was a consistent feature in each of the myxofibrosarcoma studied. In intermediate
grade myxofibrosarcoma it was found that single tissue sections could contain regions
with biomolecular profiles similar to high-grade and low-grade tumours, and that these
regions were associated with the tumour's nodular structure, thus supporting a concept
of tumour progression through clonal selection.
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Introduction
Myxoid tumours of soft tissue are a heterogeneous group of mesenchymal origin and
characterized by their so-called myxoid extracellular matrix (ECM)[1,2]. In this group,
myxofibrosarcoma and myxoid liposarcoma are relatively common, mostly occurring
in the extremities. Although their histology overlaps to some extent, these tumours
have different clinical behaviour[3]. Recently, we demonstrated that the composition
of the myxoid ECM is tumour type and tumour grade dependent by conventional
histochemical techniques as well as by mass spectrometry-based proteomics[3,4]. We
illustrated that these differences in ECM composition paralleled the different biological
and clinical behaviour of these tumours[4]. Myxofibrosarcoma is characterized by
non-specific cytogenetic aberrations that increase with grade, suggesting a multistep
tumour progression model due to acquired genetic instability[5]. Low-grade
myxofibrosarcoma is microscopically characterized by a multinodular growth
pattern[6]. Most human malignancies originate from a single cell but display intratumour
heterogeneity by the time of diagnosis. This heterogeneity might be due to metabolic
and epigenetic differences in the tumour though strong evidence showed that intratumour
heterogeneity also arises from genetically distinct clones within the tumour[7-13]. This
suggests that these tumours progress through multiple nodules, one of which becomes
more dominant and will progress towards high-grade myxofibrosarcoma, as has been
shown in other neoplasms[14-16]. How this clonal selection is reflected at the level of
protein expression is still unclear. Furthermore, methods for the combined analysis of
phenotypic and protein diversity at microscopical level in-situ in tissue sections are
also lacking. In contrast to myxofibrosarcoma, myxoid liposarcoma is characterized
by its predominant tumour specific translocation t(12;16) (q13;p11) involving the FUS
and DDIT3 genes, whose transcribed fusion protein acts as a transcription factor[17-
20]. This transcription factor plays a pivotal role in its tumourigenesis by regulating
the expression of genes involved in cell proliferation[20-22]. It also controls the
transcription of C/EBP which affects the expression of peroxisome proliferator-activated
receptor gamma, a key player in adipocytic differentiation[19,23,24]. This links the
FUS/DDIT3 fusion protein to its histological phenotype. To get more insight into (chan-
ges in) the expression of peptides, proteins and lipids during tumour progression we
studied a well documented series of myxoid liposarcoma and myxofibrosarcoma tissues
using MALDI imaging mass spectrometry. This rapidly developing technique uses
spatially resolved proteomic and metabolomic methods to simultaneously trace the
distributions of hundreds of peptides, proteins, or metabolites in a tissue section[25].
The technique uses the masses of the biomolecules to distinguish between different
species and thus does not require any form of labelling. The biomolecular profiles can
be used to obtain biomolecular signatures associated with specific histological features,
to distinguish different regions within a tissue or to differentiate and classify tissues
and is beginning to have in impact in cancer research[26-31]. In the present study we
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investigated the ECM of myxofibrosarcoma and myxoid liposarcoma by using MALDI
imaging mass spectrometry to analyze the peptide, protein and lipid content of low-
and high-grade myxofibrosarcoma and low- and high-grade myxoid liposarcoma. This
allowed a detailed examination of the myxoid ECM of these tumours, especially in
relation to their grade specific phenotype and indicated that the technique may also




Slides were re-evaluated histologically and classified according to the 2002 World
Health Organization criteria[32,33]. Myxofibrosarcoma cases were histologically
graded according to the French Fédération Nationale des Centres de Lutte Contre le
Cancer[34]. Myxoid liposarcoma cases were graded on the basis of percentage of their
round cell component[32,33]. All tissue samples were handled in a coded fashion,
according to Dutch national ethical guidelines (Code for proper secondary use of human
tissue, Dutch Federation of Medical Scientific Societies).
Sample preparation
Tumour tissue samples obtained form surgical resection specimens were snap frozen
in liquid isopentane and then stored at -80 °C until sectioning. 5 µm thick tissue sections
were cut at -20 °C using a cryomicrotome and stained with hematoxylin & eosin (H&E)
to check diagnosis and viability of the tissue. For the MALDI imaging mass spectrometry
experiments 12 µm thick tissue sections were cut at -20 °C and thaw mounted onto
conductive glass slides (Delta Technologies, Stillwater, USA). The tissues were then
slowly brought to room temperature in a desiccator and prepared for MALDI analysis
of the tissue's peptides, proteins, or lipids.
Protein and peptide imaging: The tissues were washed in ice-cold 70% ethanol (2x30
seconds), dried under a stream of nitrogen and a uniform coating of the MALDI ma-
trix deposited onto the tissue using an ImagePrep device (Bruker, Bremen, Germany)
and a 20 mg/ml solution of sinapinic acid in 6:4 AcN:0.5% TFA(aq.).
Peptide and protein profiling: The tissues were washed in ice-cold 70% ethanol (2x30
seconds), dried under a stream of nitrogen and 1  l droplets of the sinapinic acid matrix
solution deposited onto the tissue.Lipid imaging: A uniform coating of 2,5-
dihydroxybenzoic acid was added using an ImagePrep device and a 10 mg/ml solution
in 7:3 MeOH:H2O.
Immediately prior to loading the sample in the mass spectrometer, a 1200 dpi scan was
recorded using a flatbed scanner.
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Mass Spectrometry
Peptides and proteins
All peptide and protein mass spectrometry experiments were performed on an Autoflex
III mass spectrometer (Bruker Daltonics, Bremen, Germany) and were acquired in
fully automated mode using the Flex software suite (FlexControl 3.0, FlexImaging
2.1, FlexAnalysis 3.0, Bruker). Imaging mass spectrometry experiments were performed
using 100 µm pixel size, 600 laser shots per pixel (50 laser shots per position of a
random walk within each pixel). During definition of the imaging mass spectrometry
experiment the dataset is manually aligned with an optical image of the tissue, and
were then subsequently aligned with an optical image of the H&E stained tissue (tissue
stained after the imaging mass spectrometry experiment[35]. Profiling mass
spectrometry experiments were performed by accumulating the signals from 1200 la-
ser shots (50 laser shots per position of a random walk within each matrix spot).
Lipids
Lipid imaging mass spectrometry experiments were performed using an UltrafleXtreme
mass spectrometer (Bruker Daltonics, Bremen, Germany) and were acquired in fully
automated mode using the Flex software suite (FlexControl 3.3, FlexImaging 2.1,
FlexAnalysis 3.3) and used 100 ?m pixel size with 500 laser shots per pixel (100 laser
shots per position of a random walk within each pixel). Lipid peak assignments were
made by first comparing each peak's accurate mass measurement with the LIPID MAPS
database (http://lipidmaps.org, mass accuracy  0.005 Da) and then confirming the
assignments by MS/MS of selected peaks.
Data Analysis
Each pixel's spectrum was first processed using a smoothing and baseline subtraction
routine using FlexAnalysis. A Gaussian smoothing algorithm was used for mass spectral
smoothing (proteins: width 2 m/z and 4 cycles; lipids: width 0.05 m/z and 3 cycles)
and a ConvexHullV3 algorithm was used for baseline subtraction. Each pixel's or each
profile's mass spectrum was then normalized to its total ion count. These mass spectral
processing steps have been previously shown to result in superior quantitative
capabilities[36,37]. Statistical analysis was performed using ClinProtTools 2.2 and
the results visualized in FlexImaging 2.1 (Bruker Daltonics, Bremen, Germany). An
automated peak selection algorithm then reduced the dimensionality of the dataset to
the 300 most intense peptide and protein peaks.
Unsupervised analysis:Principal component analysis was performed using mean-cent-
ring and auto-scaling. Hierarchical clustering was performed by first reducing non-
correlated signals in the data by applying a principal component analysis data reduction
step[38]. All data that constituted 90% of the variance was retained, the 10% omitted
from the analysis was found to contain mostly uncorrelated signals. Hierarchical
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clustering was performed using the Euclidian distance between each pixel's mass spec-
trum and an average linkage. All results of hierarchical clustering or principal compo-
nent analysis were then presented as false colour images on the tissue sections to
examine the spatial variation of the pixels found to have correlated mass spectra, and
to compare these results with each tissue's histology.
Supervised analysis: all tissues were first annotated based on a histological analysis of
the H&E stained tissues. Mass spectra from multiple patients with low grade MFS,
defined as class 1, and spectra from multiple patients with high grade MFS, defined as
class 2, were used to build a support vector machine classification algorithm, which
was then used to reveal the regions with a low/high grade biomolecular signature in
intermediate grade MFS.
 To compare and contrast intratumour heterogeneity across multiple patient samples
six localized regions within one intermediate grade MFS were selected, based on a
histological analysis of the tissue, and used to create a support vector machine model.
This SVM classifier was then applied to additional patient samples of intermediate




Clinicopathological data are summarized in table 1. Myxofibrosarcomas and myxoid
liposarcomas both showed a slight male predominance. The median age of occurrence
was 67,9 years for myxofibrosarcomas (low-grade: 66,4 and 69,4 for high-grade) and
44,9 for myxoid liposarcomas (low-grade: 42,2 and high-grade: 47,6). All tumours
occurred in the extremities, except for one low-grade myxofibrosarcoma (case 10:
occiput) and 1 high-grade myxoid liposarcoma (case 37: pelvic region). Most cases
were primary tumours including a higher number of (non-related) local recurrences
and metastasis in both groups of high-grade tumours. All myxofibrosarcomas exhibited
increased numerical and structural non-specific cytogenetic aberrations upon increase
in grade[4,5]. All myxoid liposarcomas contained the tumour specific t(12;16)
translocation as confirmed by FISH and/or RT-PCR (data not shown).
Tissue profiling
Aged tissue samples or tissues that have been in contact with Tissue-Tek optimal cutting
temperature polymer can lead to poor MALDI mass spectrometry results[39]. A quality-
control experiment was first performed to ensure that tissues included in the subsequent
imaging mass spectrometry analysis generated rich peptide and protein profiles.
Immediately after mass spectrometry analysis the matrix was removed and the tumours
H&E stained[35]. Each tissue was then examined to make sure the tissues did not
contain necrotic areas. Tissue sections from ten low-grade myxofibrosarcoma, ten
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Table 1: Clinicopathological data of included myxoid soft tissue tumours
Abbreviations: MFS: myxofibrosarcoma; MLS: myxoid liposarcomas: P: primary
tumour; R: local recurrence; M: metastasis: M: male; F: female.
Cases with asterisk (*) were included in imaging mass spectrometry experiments.
high-grade myxofibrosarcoma, ten low grade-myxoid liposarcoma, and ten high-grade
myxoid liposarcoma patients were analyzed using MALDI-ToF protein profiling.
Tissues free of necrosis, which did not exhibit Tissue-Tek contamination and which
generated rich peptide and protein profiles were retained. Five tissues from each tumour
group were then randomly selected for MALDI imaging mass spectrometry.
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Unsupervised clustering distinguishes myxofibrosarcoma and myxoid liposarcoma
according to tumour type and tumour grade
For the profiling experiments approximately 2000 spectra were recorded from each
tissue. Random selections of 200 spectra from each tissue were then imported into the
statistical analysis software ClinProtTools. Figure 1 shows examples of mass spectra
obtained from the different individual tissue sections, and clearly demonstrates that
low-grade myxofibrosarcoma, high-grade myxofibrosarcoma, low-grade myxoid
liposarcoma and high-grade myxoid liposarcoma generate different peptide and protein
profiles, and that each tumour's profile is highly reproducible. An automated feature
recognition system was then used to reduce these spectra to the 300 most abundant
peaks (each peak corresponds to the mass of a peptide or protein), and principal com-
ponent analysis performed. This is a multivariate analysis technique frequently used to
distinguish underlying trends in highly complex datasets[30]. The results are a series
of principal components which describe the largest variance (spread) in the dataset
(principal component 1), the next largest variance (principal component 2), and so on.
The first three principal components of the myxoid tumour profiling data reveal four
specific groupings which differentiate between high-grade myxofibrosarcoma, low-
grade myxofibrosarcoma, high-grade myxoid liposarcoma and low-grade myxoid
liposarcomas (figure 1). Principal components 1 and 2, which describe the largest
variance in the data, discriminate between low-grade myxofibrosarcoma, low-grade
myxoid liposarcomas and the high-grade tumours. High-grade myxofibrosarcoma and
high-grade myxoid liposarcoma showed considerable overlap in principle component
1 and principal component 2 but were clearly separated in principal component 3.
Principal component analysis also provides the contribution of each protein to each
principal component and thus revealed which protein peaks discriminate between the
different myxoid tumours and grades. This included peaks consistent with proteins
previously shown to discriminate between high-grade and low-grade soft-tissue sarcomas
including calgizzarin, calcyclin, calgranulin, histone H2A, histone H2B, histone H3
and histone H4 [40].
MALDI imaging mass spectrometry of peptide and proteins in myxoid soft tissue
tumours
Tissues sections from the five selected patient samples of high-grade myxofibrosarcoma,
low-grade myxofibrosarcoma, high-grade myxoid liposarcoma and low-grade myxoid
liposarcoma were prepared for peptide and protein MALDI imaging mass spectrometry
and analyzed with a pixel size of 100  m using an Autoflex III MALDI-ToF. Each
tissue generated rich datasets describing the distributions of a large number of peptide
and protein ions, and included several proteins that were upregulated in specific tumour
types and grades. Figure 2 shows examples of tumour specific proteins detected by
imaging mass spectrometry and also includes a table listing the masses of multiple
tumour and grade specific protein peaks, several of which are consistent with identified
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Figure 1: Initial screening of spectra obtained form the tissues of 10 high-grade and 10 low-grade
myxofibrosarcoma (A and C) and 10 high-grade and 10 low-grade myxoid liposarcomas (B and D) was
used to select tissues that generate rich high quality peptide/protein spectra (E). F: 3D plotting graph
of principal component analysis of these samples separate low-grade tumours in principal component
1 (PC1) and principal component 2 (PC2) and high-grade tumours in principal component 3 (PC3).
Corresponding 2D plots of the same analysis were visualized in figure panels G-I. Orange: high-grade
myxofibrosarcoma; red: high-grade myxoid liposarcoma; blue: low-grade myxofibrosarcoma; green:
low-grade myxoid liposarcoma.
proteins previously revealed found to discriminate between high-grade and low-grade
soft-tissue sarcomas (calcylin, m/z 10090; Histone H2A, m/z 14007)[40].
Lipid profiling of myxoid liposarcoma separates low-grade from high-grade tumours
MALDI imaging mass spectrometry of myxoid liposarcoma revealed differential lipid
profiles according to tumour grade that could be used to classify the tissues and that
are consistent with the known molecular pathology of the tumour. A comparison of the
lipid signatures obtained from low- and high-grade liposarcomas is shown in figure 3.
Low- and high-grade tumours each contain specifically expressed lipids and whose
images clearly reveal their localization to one grade. These lipids were then identified
using MS/MS and the lipidmaps database. Phospholipids, particularly phosphocholines,
were detected in both low and high-grade tumours but were detected at higher levels in
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Figure 2: Discriminating power of imaging mass spectrometry illustrated by tumour and grade specific
m/z values. The images illustrate the distribution of intensities of tumour type and grade specific m/z
values (left panel). Table shows tumour-and grade specific m/z values. Abbreviations: MFS:
myxofibrosarcoma; MLS: myxoid liposarcomas: low: low-grade; high: high-grade.
the high-grade tumours. Low-grade myxoid liposarcoma contained additional peaks
due to triacylglycerols.
Myxofibrosarcoma shows intratumour heterogeneity
MALDI imaging mass spectrometry enables the variation of biomolecular content
within single tissues to be examined and compared with its histology. Macroscopically
and microscopically, myxofibrosarcoma is characterized by a multinodular growth
pattern[6]. Close examination of low- and intermediate-grade myxofibrosarcoma data-
sets revealed that different locations within the same tumour generated different peptide/
protein spectra and that these differences appear to be related to the nodular structure
of the tissue.
Mass spectra from the peptide and protein datasets of high grade, low grade and
intermediate grade myxofibrosarcoma samples were analyzed using a hierarchical
clustering algorithm. Figure 4A shows that a significant number of the spectra (329)
from the intermediate-grade tumour clustered with the high grade myxofibrosarcoma
patient samples, and the remaining spectra (706) clustered with the low grade
myxofibrosarcoma patient samples. In both instances the intermediate-grade spectra
were separated from the high-/low- grade spectra at the next level of hierarchical tree,
indicating that the intermediate spectra were high-/low-grade-like but were also quite
distinct from the real high-/low-grade tumours.
To investigate this intratumour heterogeneity further the mass spectra from multiple
high grade myxofibrosarcoma patient samples and multiple low grade
myxofibrosarcoma patient samples were used to build a support vector machine
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Figure 3: Lipid imaging mass spectrometry of high- and low-grade myxoid liposarcoma reveals
differential lipid profiles and the spatial distributions show the localization of specific lipids in one
tumour grade. The lipids were identified using tandem mass spectrometry. The experimental mass, the
assignment and the mass accuracy of the assignments are provided alongside the image. * matrix
clusters.
classification algorithm. Application of this high-grade/low-grade classifier to
intermediate grade myxofibrosarcoma samples revealed that different regions of the
intermediate grade tissue samples generated biomolecular MS signatures consistent
with high-grade or low-grade tumours, and which resembled the characteristic
multinodular morphology of myxofibrosarcoma tumours (figure 4B).
Figures 4A and 4B indicate that the intermediate grade myxofibrosarcoma tissue
possessed nodules with high-grade- and low-grade-like character, but did not address
if the nodules can be further subdivided on the basis of their biochemical signatures
nor if the same intratumour heterogeneity is present in multiple tissues. To address
these questions six different regions-of-interest were selected in a tissue sample (indicated
in figure 4C left panel), based on a histological analysis of the tissue, and a new
support vector machine classification model generated. This model was then applied to
multiple intermediate grade myxofibrosarcoma patient samples. The results of this
analysis demonstrate that many intermediate grade tissues exhibit significant biochemical
intratumour heterogeneity, figure 4C. Within the two areas highlighted at low-grade-
like and high-grade-like in figure 4B, figure 4C indicates that both areas consist of
multiple nodules with different protein signatures.
Discussion
Myxofibrosarcoma and myxoid liposarcoma are, as their names imply, characterized
by their abundant so-called myxoid ECM. To study the molecular composition of the
ECM of these tumours in relation to tumour progression, we performed imaging mass
spectrometry in a well-documented series representing their low-grade and high-grade
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Figure 4: A) Hierarchical clustering analysis of mass spectra from low-(dark blue), intermediate-
(light blue) and high-grade (orange) myxofibrosarcoma reveals differential clustering of the intermediate
grade spectra into low-grade-like and high-grade-like spectra. B) Application of classification algorithm
to an intermediate-grade myxofibrosarcoma tissue, which was developed to distinguish between high-
grade and low-grade myxofibrosarcoma tissues using five patient samples of each class, indicates the
nodular structure of the low-grade-like and high-grade-like regions of the tissue. C) Six localized
regions were selected on the basis of a histological examination of an H&E stained tissue section
(indicated) and a classification algorithm developed to distinguish between the different regions.
Application of the classification algorithm to multiple intermediate-grade myxofibrosarcoma tissues
reveals a nodular like structure in each tissue.
variants. The imaging mass spectrometry experiments were performed using matrix
assisted laser desorption/ionization (MALDI), an ionization technique that enables
highly sensitive mass analysis of biomolecules[41]. MALDI imaging mass spectrometry
combines the advantages of biomolecular mass spectrometry, unbiased and simultaneous
analysis of multiple biomolecules (peptides, proteins and lipids), with an analysis of
their spatial distribution[25,42-44]. Principle component analysis of total m/z spectra
showed that myxofibrosarcoma and myxoid liposarcoma clustered separately according
to tumour type and tumour grade (figure 1). Based on the principle component analysis
and corresponding loading plots, m/z values that contributed most to the separation of
each group could be identified. From principal component 1 and principal component
2 it is clear that high-grade myxofibrosarcoma and high grade myxoid liposarcoma
show considerable overlap. Low-grade myxofibrosarcoma and low-grade myxoid
liposarcoma clustered most separately. In other words, most variance is seen between
the two different groups of low-grade tumours compared to the two different groups of
high-grade tumours. This means that although both low-grade tumours show some
degree of histological overlap (i.e. their abundant myxoid ECM), the biochemical
composition of their ECM differed significantly. Imaging mass spectrometry identified
tumour type and tumour grade specific peptides, proteins and lipids in the tissue section
(figures 2 and 3).
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Myxofibrosarcoma is characterized by multinodular growth[6]. These nodules,
especially in low-grade tumours, can be histologically identical. The results reported
here, and intimated previously[31,38,45], indicate that imaging mass spectrometry
may be used to study intratumour biomolecular heterogeneity of primary human
tumours, directly on tissue slides. Despite their histological resemblance imaging mass
spectrometry revealed that intratumour heterogeneity was a consistent feature in each
of the myxofibrosarcomas studied,   and revealed that different nodules exhibited high-
grade-/low-grade-like biomolecular signatures (figure 4). Intratumour heterogeneity
has been described in many neoplasms, as well in soft tissue sarcomas[13,46]. Orndal
et al. have already shown intratumoural cytogenetic variability by identifying
karyotypically different though cytogenetically related clones in different parts of the
same tumour. Hence, cytogenetic heterogeneity and clonal evolution seem to be common
in soft tissue sarcoma and have been detected most often in malignant fibrous
histiocytoma and leiomyosarcoma[47]. Similar intratumour heterogeneity was detected
in a number of patient tissues. From a conceptual point of view, this might suggest that
one of the nodules in low-grade myxofibrosarcoma becomes more dominant over time
and turns into a dominant tumour nodule with a more histologically homogeneous
growth pattern, though as other possibilities cannot be ruled out as only part of the
tumour in selected cases was studied. Indeed, an attractive alternative hypothesis is a
multifocal clonal evolution in myxofibrosarcoma and has already been shown in other
neoplasms [48,49].
Lipid analysis of myxoid liposarcomas by imaging mass spectrometry revealed
differences between low- and high-grade tumours (figure 3). The spectra from high-
grade tumours revealed higher levels of phosphocholines. Phosphocholines are
commonly detected by MALDI [48] and are thought to derive from (cell) membranes.
The higher levels of these lipids in high grade tumours is consistent with the higher
cellularity of higher grade tumours[50] (figure 3). These results are consistent with
previous studies of Singer and coworkers which already demonstrated increased
phosphocholines in high-grade myxoid liposarcoma using high resolution ex vivo NMR
spectroscopy. These studies already demonstrated a correlation of lipid content and
composition with the histology and grade in liposarcoma and how NMR-derived para-
meters can be used to classify liposarcoma subtypes [51,52]. These findings were
underscored by our study using a different method (i.e. imaging mass spectrometry) in
a different group of myxoid liposarcoma patient samples. Moreover, relative
phosphocholine contents detected with high-resolution NMR spectroscopy predicted
histological response of myxoid liposarcoma after treatment with troglitazone (a PPARγ
agonist) [53]. Identification of lipids by imaging mass spectroscopy showed a
predominant expression of PPARγ induced fatty acids in low-grade tumours such as
triacylglycerols. PPARγ plays a key role in fatty acid synthesis[54]. Active PPARγ
signalling promotes adipocytic differentiation in pre-adipocyts and is active in myxoid
liposarcoma cells[24,55]. Our data suggest decreased PPARγ regulated fatty acid
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synthesis in myxoid liposarcoma upon increase in grade, histologically reflected in a
diminished adipocytic phenotype, and consistent with recent work that established that
PPARγ inactivation by the FUS/DDIT3 liposarcoma specific fusion protein is required
for liposarcoma development[56].
Activation of PPARγ signalling also stimulated cell cycle withdrawal and PPARγ
agonists have been shown to be promising in cancer treatment[57]. This is an attractive
drug target as treatment options for myxoid liposarcoma patients with advanced disease
are poor. However, phase II trials with rosiglitazone (a PPARγ agonist) in myxoid
liposarcoma patients with advanced disease showed no effect on tumour size[58].
In conclusion, we have demonstrated that imaging mass spectrometry can distinguish
between different types and different grades of myxoid tumours based solely on their
biomolecular signatures, and can be used to identify proteins lipids specific to each
type. Close examination of the data revealed previously unreported biomolecular changes
consistent with the known tumour biology of myxofibrosarcoma and myxoid
liposarcoma. Substantial intratumour heterogeneity was detected in the biomolecular
profiles of myxofibrosarcoma tissues, consistent across multiple patient samples, that
is consistent with the clonal selection model of myxofibrosarcoma tumour development.
For myxoid liposarcoma tumour development is associated with inactivation of PPARγ
by the FUS/DDIT3 fusion protein; PPARγ plays a crucial role in adipocytic
differentiation and so led to the observed reduction in triacylglycerols with increasing
tumour grade.
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Myxoid liposarcoma is a relatively common malignant soft tissue tumor, characterized
by a (12;16) translocation resulting in a FUS-DDIT3 fusion gene playing a pivotal
role in its tumorigenesis. Treatment options in patients with inoperable or metastatic
myxoid liposarcoma are relatively poor though being developed and new hope is
growing. Using kinome profiling and subsequent pathway analysis in two cell lines
and four primary cultures of myxoid liposarcomas, all of which demonstrated a FUS-
DDIT3 fusion gene including one new fusion type, we aimed at identifying new molecular
targets for systemic treatment. Protein phosphorylation by activated kinases was verified
by Western Blot and cell viability was measured before and after treatment of the
myxoid liposarcoma cells with kinase inhibitors. We found kinases associated with the
atypical nuclear factor-kappaB and Src pathways to be the most active in myxoid
liposarcoma. Inhibition of Src by the small molecule tyrosine kinase inhibitor dasatinib
showed only a mild effect on cell viability of myxoid liposarcoma cells. In contrast,
inhibition of the nuclear factor-kappaB pathway, which is regulated by the FUS-DDIT3
fusion product, in myxoid liposarcoma cells using casein kinase 2 inhibitor 4,5,6,7-
tetrabromobenzotriazole (TBB) showed a significant decrease in cell viability, decreased
phosphorylation of nuclear factor-kappaB pathway proteins, and caspase 3 mediated
apoptosis. Combination of dasatinib and TBB showed an enhanced effect. Kinases
associated with activation of the atypical nuclear factor-kappaB and the Src pathways
are the most active in myxoid liposarcoma in vitro and inhibition of nuclear factor-
kappaB pathway activation by inhibiting casein kinase 2 using TBB, of which the
effect is enhanced by Src inhibition using dasatinib, offers new potential therapeutic
strategies for myxoid liposarcoma patients with advanced disease.
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Background
Myxoid liposarcoma accounts for 40% of all liposarcomas and occurs most commonly
in the extremities [1]. In about 95% of cases, myxoid liposarcoma is cytogenetically
characterized by t(12;16)(q13;p11), creating a chimerical FUS/DDIT3 gene which
has been thought to play a pivotal role in its tumourigenesis [2-4]. The cornerstone of
curative treatment for myxoid liposarcoma is surgery with an overall 10 years survival
of 80%. Prognosis is mainly determined by the percentage of round cell component of
the tumor. Myxoid liposarcoma with more than 5% round cell component are defined
as high-grade and prone to metastasis[5]. Treatment options for patients with inoperable
or metastatic disease are relatively poor, though trials with new drugs reveal good
perspectives for the future[6, 7]. Therefore, clinical trials to test and validate new
treatment options for liposarcoma subtypes (such as myxoid liposarcoma) are
necessary[6]. Nowadays, (neo) adjuvant chemotherapy of liposarcoma patients is limited
with only ifosfamide and anthracyclins showing 20-40% response rates in untreated
patients[8]. Trabectedin (Yondelis, ET 743) is a novel chemotherapeutic agent derived
from the marine tunicate Ecteinascidia turbinate. By binding to the DNA minor groove,
ET-743 forms covalent adducts with the N2-position of guanine through its
carbinolamine moiety. As a result, the minor groove bends toward the major groove.
The cytotoxic activity of ET-743 is largely based on its interaction with nucleoside
excision repair machinery, as well as through the induction of double strand breaks[9-
11]. Phase I and II studies showed promising results in myxoid liposarcoma patients
with advanced disease though recent studies reported an increasing number of side
effects[12, 13]. During the last years, tumor specific targeted therapy has shown to be
effective in many cancers, including sarcomas. Especially kinase inhibitors are an
emerging class of small molecule inhibitors that target unique kinase conformational
forms and binding sites[14]. Notable advantages are higher specificity and generally
more manageable and reversible side effects [15]. This necessitates the study of separate
soft tissue tumour entities[7]. In the present study, we explored the activated pathways
in myxoid liposarcoma cells using kinome profiling to find new treatment possibilities.
Kinases phosphorylate tyrosine, threonine or serine residues on proteins, thereby ser-
ving as a switch to (in) activate pathways involved in cell cycle, cell survival and
differentiation. Moreover, kinases are promising targets for anti-cancer therapy as
they do not require new protein synthesis, therefore act rapidly and are also promising
in slow-cycling tumors [16, 17]. Data on activated pathways in myxoid liposarcoma
are sparse[18, 19]. By using a kinase substrate specific protein array chip combining
1024 different kinase substrates, we identified kinases associated with Src and NF-
kappaB pathways to be active in myxoid liposarcoma. NF-kappaB is an inducible
cellular transcription factor that regulates a variety of cellular genes, including those
involved in immune regulation, inflammation, cell survival and cell proliferation. Hereby,
active NF-kappaB plays a pivotal role in tumorigenesis and increased expression of
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the phosphorylated NF-kappaB protein is found in many tumors[20, 21]. We showed
that in myxoid liposarcoma cells, inhibition of kinases associated with the NF-kappaB
pathway (by TBB) resulted in decreased viability and that this effect was enhanced by
Src-inhibitor dasatinib. These results show that targeting NF-kappaB pathway might
be a potential treatment option in myxoid liposarcoma patients with advanced disease.
Results
Molecular and cytogenetic analysis
FISH of the primary myxoid liposaromas showed the tumor specific t(12;16) in three
out of four cases (table 1).
All four primary cultures showed the FUS/DDIT3 fusion transcripts[22]. Case
Table 1: clinicopathological and genetic data of myxoid liposarcoma samples
Primary cultures of samples L1187, L1357, L1434 and L2187 were obtained from fresh tumors.
Tumors L1187 and L1357 were high grade (>5% round cell component), whereas L1434 and L2187
were low-grade (<5 % round cell component). These differences in grade however were not
reflected in growth rate of the primary cultures (doubling times of primary cultures were all ~ 4
days; doubling times of cell lines ~ 2 days).
L1187 showed a 1033 bp long fusion transcript involving exon 11 of the FUS and
exon 2 of the DDIT3 gene, which has not been reported previously (figure 1). This
chimera includes the RNA-binding domain (exon 8-11) of the FUS gene as in fusion
type 8, which is absent in the other fusion types. This new  FUS/DDIT3 fusion type
was deposited in GenBank (GenBank accession number GU933437). COBRA-
FISH of both myxoid liposarcoma cell lines showed the myxoid liposarcoma
specific t(12;16) translocation. The precise karyotype of 402-91 was: 46, X,
der(Y)t(Y;19)(q11;p11), t(1;7)(p12;p12), der(8)t(8;21)(p11;p11)[7],
der(8)t(8;9)(p11;p11)[7], del(8)(p11)[4], del(10)(p11), t(12;16)(q13;p11),
del(18)(p11), -19,+20, -21[7][cp20], several additional, non-clonal rearrangements
involving chromosomes 4, 5, 6 and 8 with various partner chromosomes.
The precise karyotype of 1765-92 was 90-99, XX,
der(1)inv(1)(p32q31)t(1;10)(p33;p12), der(1)inv(1)(p32q31)t(1;10) (p33;p12), -
1,del(2)(p11), -3, +5, der(6)t(4;6)(4q,6q), der(6)t(6;10)(p;q), +der(6)t(6;10) (p;q),
der(8)t(3;8), i(8)(q10), +i(8)(q10), +9, der(10)t(1;10)(1p32,p12), der(10)t(1;10)
(1p32,p12), -10, +11, t(12;16)(q13;p11), t(12;16)(q13;p11), -13,der(13)t(6;13)(q;q),
+14, +15, +18, +20, +20 [cp20].
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Identification of active kinases and pathways
A list of phosphorylated targets and their corresponding active kinases was created by
kinome profiling of two cell lines and four primary cultures of myxoid liposarcoma.
Average spot intensity and target frequency of the top 100 phosphorylated substrates
revealed the most activated kinases in myxoid liposarcoma (table 2). Both in myxoid
liposarcoma cell lines as well as in primary cultures, casein kinase 2, alpha 1 (ck2a1),
lymphocyte-specific protein tyrosine kinase (lck), fyn oncogene related to SRC (fyn),
Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog (fgr), v-yes-1
Yamaguchi sarcoma viral oncogene homolog (yes), calcium/calmodulin-dependent
protein kinase II beta (camk2b) and protein kinase, cAMP-dependent, catalytic, alpha
(prkaca) were most activated (table 2). There were no clear differences between the
cell lines and the primary cultures. The specificity of the list of substrates for myxoid
liposarcomas was verified by comparing the intensity of the signals with those for
Figure 1: Exon 11 of the FUS gene is fused to exon 2 of the DDIT3 gene. The corresponding
chimeric protein retains the RNA binding domain of the FUS protein.
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Table 2: Top 100 activated kinases and targeted drugs in myxoid liposarcoma cell lines and
primary cultures.
Top list of kinases was based on the intensity of incorporated radioactively labeled phosphorus,
corresponding with kinase activity. The number of hits corresponds to the number of substrates to be
phosphorylated by a specific kinase, not necessarily associated with kinase activity as substrates
were not equally covered by the different kinases.
normal MSCs which served as a normal control for this tumor type, using Limma
(additional file 1). Specificity of the activated kinases in this type of cancer (i.e. myxoid
liposarcoma) was additionally verified by comparison with the same analysis in four
colorectal carcinoma cell lines and thirteen chondrosarcoma cell lines and cultures
using Limma, which revealed a different list of substrates and kinases[16]. Pathway
analysis based on the most active kinases (table 3) identified kinases associated with
NF-kappaB pathway (ck2a1, fgr, inhibitor of kappa light polypeptide gene enhancer
in B-cells, kinase (ikk), protein kinase RNA-activated (pkr), v-akt murine thymoma
viral oncogene homolog (akt), NF-kappa-beta-inducing kinase (nik), mitogen-activated
protein kinase kinase kinase 3 (mekk3) and focal adhesion kinase 1 (fak1) to be most
activated. Also kinases associated with Src-pathway (lck, fyn) were highly active. In
addition, retinoic acid receptor pathway (RAR) and peroxisome proliferator-activated
receptor (PPAR) activation pathway were found. The top 5 of activated pathways was
identical in cell lines and primary cultures. Results of the analysis leaving out all cell
cycle related kinases (27% of all kinases detectable), which might be artificially
upregulated due to cell culturing, and results of analysis after starvation of the cell
lines are shown in table 3.
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Additional file 1:  Top 100 of activated kinases in MSCs obtained by kinome analysis.
Table shows list of kinases found to be activated in mesenchymal stem cells, in decreasing order.
The intensity correlates with the radioactivity of 33P incorporated in the substrates by their active
kinases. The number of hits are the number of substrates related to the respective kinase.
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Verification of kinome profiling
Western blotting showed that all myxoid liposarcoma samples (both cell lines and
primary cultures) expressed comparable amounts of total Src and NF-kappaB p65.
Phosphorylation of Src (Y419) was present in all samples (figure 2) confirming
activation of Src pathway. Likewise, western blotting showed the presence of ck2a1
and phosphorylated NF-kappaB p65 (S468) in all samples, confirming the results of
the IPA analysis that kinases associated with NF-kappaB pathway are active in myxoid
liposarcoma cells.
Table 3: Top lists of activated kinases and pathways in different conditions.
Figure 2: Immunoblotting was used for verification of the results obtained by Pepchip analysis.
Band heights were all corresponding to the manufacturer’s datasheets (P-Src: 2 bands between 56-
61 kDa, Src: 60 kDa, Casein Kinase 2: 42 kDa, P-p65: 65 kDa and p65: 65 kDa). Both cell lines and
primary cultures showed phosphorylation of Src and slight variation in amounts of total Src. Casein
Kinase 2 and p65 protein were present in all samples in comparable amounts, as is phosphorylated
p65, indicating active NF-kappaB signaling.
Whereas activated kinases differed between cells grown in normal medium (RMPI supplemented
with 10% inactivated calf serum), top five of activated signaling pathways were identical. Results
were identical for cell lines and primary cultures. Cell lines cultured in starved medium conditions
revealed a different top list of both kinases and activated signaling pathways. However, in all three
different conditions, NF-kappaB was the most activated signaling pathway identified.
prkcd: protein kinase C, delta; mapk14: mitogen-activated protein kinase 14; egfr:
epidermal growth factor receptor; erbb2: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2
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In vitro targeting of kinases associated with Src and NF-kappaB pathways by dasatinib
and TBB
WST-1 analysis of GIST882 showed a profound decrease in cell viability of up to ~
80% relative to the DMSO control at even low dosages of Src-inhibitor dasatinib
(figure 3). The decrease in cell viability of myxoid liposarcoma cells treated with
dasatinib was rather mild as WST-1 analysis of all four cell cultures and 1 out of 2 cell
lines showed a maximum decrease in cell viability of 40% at higher doses (figure 3).
Cell line 1765-92 did not respond to dasatinib. In contrast, myxoid liposarcoma cells
showed a decline of more than 50% in viability after treatment with casein kinase 2-
inhibitor TBB in two out of four cultures and in both cell lines. This effect was also
observed in Jurkat cells as described (positive control)[23]. There was no relation
between the response rate and type of fusion gene. For combination experiments, the
two cell lines (402-91 and 1765-92) and the two most sensitive myxoid liposarcoma
primary cultures (L1357 and L2187) were treated with both dasatinib and TBB.
Figure 3: Effect of dasatinib and TBB treatment on cell viability of myxoid liposarcoma cells.”
3A) Treatment of myxoid liposarcoma cell cultures with dasatinib leads to maximum 20% decrease
in viability at the concentrations higher than 200 nM, though this effect is limited as compared to
GIST882. 3B) Treatment with TBB shows a 20% decrease at lower concentrations (20 µM) and a
maximum decrease of 75% at 200 M (cell line 402-92) in the majority of cases. Cell viability with
IC50s as depicted in 3C. 3D) Combined treatment with TBB (at IC50 concentration) and dasatinib
(concentrations as in 3A).Jurkat cells where susceptible to TBB, but not to dasatinib. Interestingly,
the effect of dasatinib when preceded by TBB was significantly more pronounced than dasatinib in
monodrug treatment which means that dasatinib and TBB have an enhanced effect. Graphs show
data from four representative experiments. Error bars indicate the standard error of the mean.
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Combined administration of both drugs led to a dramatic decrease in cell viability and
showed an enhanced effect (figure 3D), for instance: L1357 cells show 80% viability
at maximum dasatinib dose (5000 nM), whereas viability was only 5% at lower
concentration of dasatinib (500 nM) at IC 50 for TBB (figure 3D).
Dasatinib inhibits phosphorylation of Src but does not cause apoptosis
To investigate the effect of dasatinib on Src signalling, a good responsive (60 % cell
viability at 500 nM; figure 3A) myxoid liposarcoma cell culture (L1357) was treated
with 50, 200 and 500 nM of dasatinib for 6 hours. Whereas levels of total Src did not
visibly decrease upon dasatinib treatment, a decrease in phosphorylated Src (p-Src)
(Y419) was found (figure 4). At a dose of 200 nM dasatinib p-Src staining the lower
band faded and at 500 nM both bands disappeared. Interestingly, a similar decrease in
p-Src was also observed at 200 nM dasatinib when post-treated with TBB. There was
no effect of dasatinib treatment on total NF-kappaB p65 or phosphorylated NF-kappaB
p65 and there was no caspase-3 mediated apoptosis, since the level of caspase-3 did
not increase upon dasatinib treatment (figure 4).
Figure 4: Effect of dasatinib and TBB treatment on phosphorylation of Src and NF-kappaB related
proteins. Experiments were run in duplicate and showed similar results in two cell lines (402-91
and 1765-92) and primary cultures (L1357 and L2187). Treatment of L1357 with dasatinib did not
affect total levels of Src, but gradually decreased P-Src levels at 200 nM to almost absence at 500
nM. There was no effect of dasatinib on total p65 and phosphorylated-p65 levels. Treatment of
L1357 with TBB did not affect total levels of p65, but gradually decreased P-p65 levels at 200 ìM.
TBB treatment had no effect on the levels of total Src and phosphorylated Src. Interestingly, TBB
and dasatinib showed enhancement to decrease levels of phosphorylated Src and p65. Strikingly,
there was a gradual increase in caspase-3 levels upon treatment with TBB, which was enhanced by
combination with dasatinib, suggesting caspase-3 mediated apoptosis underlying the observed
decrease in cell viability. Abbreviations: DAS50 = dastinib 50 nM, etc. DAS and TBB = 200 ìM
dasatinib and IC50 concentration for TBB.
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TBB inhibits NF-kappaB p65-phosphorylation resulting in caspase-3 mediated
apoptosis
To investigate the effect of TBB on kinases associated with NF-kappaB signalling,
L1357 was treated with increasing doses for 6 hours. Whereas levels of total NF-
kappaB p65 did not decrease upon treatment, a decrease in phosphorylated p65 (p-
p65) was found (figure 4).
At a dose of 20 µM TBB p-p65 staining slightly started to fade and obviously decreased
at 200 µM TBB. Casein Kinase 2 levels of TBB treated samples were  lower than the
DMSO control, but remained unchanged compared to samples treated with various
concentrations TBB or dasatinib, suggesting that TBB does not alter the overall
expression of casein Kinase 2, which is in accordance with the literature[24]. TBB
treatment had no effect on the levels of total Src and phosphorylated Src. Strikingly,
the effect of TBB was increased by pretreatment with dasatinib (figure 4), which was
also visible in the viability assay (figure 3D). Moreover, there was a gradual increase
in caspase-3 levels upon treatment with TBB, suggesting caspase-3 mediated apoptosis.
Discussion
Treatment options for myxoid liposarcoma patients with advanced disease are poor.
Recently, the chemotherapeutic drug Trabectedin showed promising results in phase I
and II trials in advanced disease though adverse effects have also been reported[13,
25]. Small molecule targeting, especially with kinase inhibitors, has shown to be effective
and more specific in many tumors with less severe side effects than conventional
chemotherapeutic agents. To identify new potential treatment options for myxoid
liposarcoma patients with advanced disease, we explored the kinome of myxoid
liposarcoma cells in vitro and performed subsequent pathway analysis. We previously
established the reliability of kinome profiling using Pepchip in untreated versus imatinib
treated GIST882 cell line which correctly identified the pathways known to be involved
in GIST[16]. Moreover, we previously demonstrated the reliability of our analysis
which is based on averaging results of a number of samples to get an impression of the
most activated kinases in a series of tumors[16]. By additionally performing the Pep-
chip experiments in the myxoid liposarcomas cell lines after serum starvation as well
as by excluding cell cycle related kinases from the analysis we determined that the
detected kinases in the present analysis are indeed tumor specific and not related to the
high proliferation rate of the myxoid liposarcoma cell lines. Moreover, by comparing
with previously analyzed series of colorectal cancer and chondrosarcoma, as well as
by comparing with mesenchymal stem cells we could confirm that the list of kinases
was specific for myxoid liposarcomas. We could demonstrate activation of the
peroxisome proliferator-activated receptor gamma pathway, which could be expected
since it has been shown to play a pivotal role in adipocytic differentiation and is regulated
by the FUS-DDIT3 fusion product[26-28](Figure 5). The DDIT3 gene encodes a DNA-
damage inducible member of the C/EBP family of transcription factors and inhibits
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adipocytic conversion of preadipocytes[29, 30]. Transfection of primary mesenchymal
progenitor and human fibrosarcoma cells with the FUS/DDIT3 fusion protein induces
a myxoid liposarcoma phenotype[31, 32]. Treatment of myxoid liposarcoma cells in
vitro and in vivo with peroxisome proliferator-activated receptors gamma agonists
induced terminal differentiation[33], although phase II studies with the peroxisome
proliferator-activated receptors gamma agonist Rosiglitasone did not show the anti-
tumor effect in advanced myxoid liposarcoma patients[34]. Until today, nine different
types of FUS/DDIT3 fusion genes have been described, involving predominantly the
central and C-terminal parts of the FUS-gene and nearly always the whole DDIT3
gene[22]. We describe here for the first time a new fusion type (Figure 1) including the
RNA binding domain of the FUS gene, which is not found in the other fusion types
except for type 8. Whether this new rare fusion gene will be translated to a protein or
will have any promoting effect on tumor development is not clear and is hard to study
due to the rarity of these variants. We found no differences between the type of FUS/
DDIT3 fusion gene and kinases activated. Till now, the molecular variability of fusion
types has not shown to have any effect on transforming capacities, adipogenesis nor
prognosis in myxoid liposarcoma[5, 35].  We showed that kinases associated with NF-
kappaB pathway were highly active in myxoid liposarcoma. In the atypical (IKK
independent) NF-kappaB pathway, phosphorylation of inhibitors of NF-kappaB (IkB),
and subsequent activation of NF-kappaB (p65) is controlled by casein kinase 2 and
tyrosine kinase-dependent pathways (figure 5)[36, 37]. We did not measure NF-kappaB
pathway activation by analysis of downstream products or electrophoretic mobility
shift assays. Göransson et al. has recently shown that NF-kappaB is a major factor
controlling IL8 transcription in FUS-DDIT3 expressing cells. This could be explained
by direct binding of FUS/DDIT3 to the C/EBP-NF-kappaB composite site of the
immediate promoter region of IL8. Moreover, FUS/DDIT3-GFP expressing cell lines
showed upregulation of the NF-kappaB controlled genes LCN2 and MMP1 whereas
DDIT3 had little effect. These findings were also quantitatively confirmed by RT-
PCR[17]. Active (phosphorylated) p65 was present in cell lysates of myxoid liposarcoma
cell cultures and cell lines. We did not explicitly show that the phosphorylated p65
protein was located in the nucleus/nuclear fraction. Phosphorylation of p65 could be
counteracted by TBB, an inhibitor of the casein kinase 2 and resulted in decreased cell
viability as shown in figure 3 and 4. This suggests that NF-kappaB signaling is active
in myxoid liposarcoma and that its activation is, at least in part, regulated via the
atypical pathway. This is an important finding which suggests that NF-kappaB pathway
inhibition might be beneficial in myxoid liposarcoma patients with advanced disease.
The exact driving force behind NF-kappaB activation in myxoid liposarcoma is unclear.
Gene expression studies revealed that p50 was significantly upregulated in FUS/DDIT3
transfected fibroblastic cell lines[38]. This suggests that NF-kappaB (p50) transcription
in myxoid liposarcoma might be regulated by the FUS/DDIT3 fusion gene. After
translocation to the nucleus, transcriptional activation of NF-kappaB requires multi-
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ple co-activating proteins[39]. The C-terminus of FUS co-activates p65 and plays a
pivotal role in NF-kappaB mediated transcription though this C-terminus is lost in the
FUS/DDIT3 fusion protein. Recent studies showed that the FUS/DDIT3 fusion protein
facilitates NF-kappaB binding to its target genes, probably in an indirect manner[19,
39-41]. The FUS-DDIT3 fusion protein deregulates NF-kappaB controlled genes by
interaction with nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor zeta (NFKBIZ)[19]. This synergistic role between a fusion protein and
activation of NF-kappaB signaling might also be important in other translocation based
sarcomas and has already been shown in Bcr-Abl mediated leukemias[42].
In all myxoid liposarcoma samples we showed overexpression of casein kinase 2,
which has been shown in many other neoplasms[43]. We showed inhibition of casein
kinase 2 and subsequent decreased levels of active p65 to be associated with decreased
Figure 5: In myxoid liposarcoma, the FUS/DDIT3 protein has been shown to upregulate the expression
of CCAAT/enhancer binding protein (C/EBP) which leads to the transcription of peroxisome proliferator-
activated receptors gamma and other genes involved in adipocytic differentiation. We showed that in
myxoid liposarcoma, the atypical NFkappaB pathway is active. Hereby casein kinase 2 phosphorylates
the nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IkB), which releases
from the NF-kappaB p50/p65 complex and gets degraded. The NF-kappaB p50/p65 complex then
shuttles into the nucleus were it promotes the transcription of genes involved in cell proliferation.
Recent studies showed that the FUS/DDIT3 protein facilitates DNA binding of the NF-kappaB p50/
p65 complex in a non-direct manner, probably by interfering with IkB. Also Src pathway is activated in
myxoid liposarcoma, which leads through different signaling pathways (AKT, MEK, ERK) to tumor
growth and cell survival. This pathway can be inhibited n vitro by Src-inhibitor dasatinib.
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viability and increase in caspase 3 protein expression in myxoid liposarcoma cells.
Caspase 3 is released by cleavage of its inactive precursor procaspase 3, and mediates
apoptosis[44, 45]. Decreased cell viability with increased levels of the effector caspase
3 therefore suggests caspase 3 mediated apoptosis. Recently, phase I trials have been
started to test the effect of casein kinase 2 inhibitors in vivo which seems to be
promising[46]. In addition to kinases associated with NF-kappaB, Fyn, Lck and Yes
were most active as indicated by specific sequences on the chip. They are members of
the Src family of kinases. Src plays an important role in embryonic development, cell
growth and cell survival and activating mutations in Src have been reported in colorectal
carcinoma[47, 48]. Src signaling can lead to downstream activation of ERK/MAPK
and PI3K/AKT signaling. Activation of both pathways in myxoid liposarcoma is
associated with more aggressive behavior[49]. The Src pathway can be inhibited by
the small molecule tyrosine kinase inhibitor dasatinib limiting cell growth in various
cancers in vitro, thereby having promising therapeutic potential[16, 50, 51].
Immunoblotting confirmed the expression of Src and phosphorylation of Src at Y419
in myxoid liposarcoma cell cultures and cell lines. Dasatinib treatment showed a
reduction in phosphorylated (active) Src and a decrease in cell viability. However, this
latter effect was only very mild with maximum decrease in viability of only 40%
maximally, and no IC50 levels could be calculated. This might be explained by Src
pathway activation occurring upstream, close to its receptor (figure 5) and that the
effect of the inhibition of Src phosphorylation might be (partly) circumvented by cross-
talk activation downstream. Our data suggest that the active Src pathway is not crucial
for myxoid liposarcoma survival and that monotherapy with dasatinib is no suitable
option for treatment, although the additional effect of dasatinib in vivo through inhibition
of angiogenesis is not encountered here. Combinations of different drugs (including
dasatinib) have been shown to act synergistically in many tumors and combination
drug therapy is commonly used in cancer treatment[50]. Recently, a synergistic effect
of dasatinib when combined with other drugs (i.e. oxaliplatin) has been described in
colorectal carcinoma[50].  Since we showed NF-kappaB and Src to be the two most
active pathways we studied the effect of combination of dasatinib and TBB and we
found a enhanced effect on cell viability of myxoid liposarcoma cells in vitro. To be
more specific: L1357 cells show 80% viability at maximum dasatinib dose (5000 nM),
whereas viability was only 5% at lower concentration of dasatinib (500 nM) at IC50
for TBB (figure 3). However, it was not possible to calculate if this enhancement was
also a true synergistic effect as IC50 values for dasatinib could not be calculated
(figure 3)[52]. IC50 values for TBB (but not for dasatinib) could be calculated for
most primary cultures and cell lines, but not for L1187 and L1434. Though cell line
1765-92 responded well to TBB treatment, no enhancement could be observed upon
addition of dasatinib, which might be related to a relative resistance of 1765-92 cells to
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dasatinib as also visible from figure 3A.  Future experiments, for instance studying the
changes at the kinome level upon dasatinib treatment may reveal (1) why dasatinib is
not effective as a monotherapy but is effective in combination with TBB, and (2) what
might be the exact underlying mechanism why 1765-92 myxoid liposarcoma cells
showed resistance for dasatinib treatment and thereby the absence of enhancement in
combination treatment as was observed for the other cell line and primary cultures.
Conclusion
In conclusion our results indicate that the NF-kappaB and Src pathway include the
most active kinases in myxoid liposarcoma, and inhibition of casein kinase 2 and
thereby interference with kinases associated with the NF-kappaB pathway decreases




Dasatinib (Sprycel, BMS- 354825) was obtained from Bristol-Myers Squibb (New
York, USA) and TBB from Calbiochem (San Diego, CA). Both drugs were dissolved
in Dimethylsulfoxide (DMSO).
Cell cultures and cell lines
The two myxoid liposarcoma cell lines 402-91 and 1765-92, and gastro-intestinal
stroma cell tumor cell line (GIST882) were kindly provided by Prof. Dr. P. Aman
(Lundberg Laboratory for Cancer Research, Department of Pathology, Göteborg
University, Goteburg, Sweden) and Prof. Dr. J. Fletcher (Brigham and Women's
Hospital, Boston, USA) respectively[53, 54]. Jurkat and HeLa cell lines (American
Type Culture Collection, Rockville, MD) were used as positive controls for Western
blotting. Myxoid liposarcoma cell lines, primary cultures of four myxoid liposarcomas
(L1187, L1357, L1434 and L2187) and two cell cultures of normal bone marrow
derived mesenchymal stem cells (L2361 and L2370) were cultured in RPMI 1640
(Gibco, Invitrogen Life-Technologies, Scotland, UK), supplemented with 10% heat-
inactivated fetal calf serum (Gibco). Cells were grown in a humidified incubator at
37ºC with 5% CO2. In addition, two samples (402-19 and L1357) were analyzed after
also culturing in starved RPMI 1640, containing 0,5% fetal calf serum.
RT-PCR and karyotyping
Diagnosis of the primary tumors from which the cultures were obtained was performed
on histology. Primary tumors were analyzed for their tumor specific translocation with
double-fusion fluorescence in situ hybridization (FISH) and cell lines were karyotyped
with Combined Binary Ratio Labeling (COBRA) as previously described [55-57]. In
primary cultures, tumor cells were genotyped for the presence of the fusion gene by
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RT-PCR. Total RNA was isolated using TRIzol (Invitrogen, Breda, The Netherlands).
Complementary DNA was synthesized from 1 µg of total RNA using oligo dT primers
and Superscript II MMLV reverse transcriptase (Life Technologies, Carlsbad, CA).
Reverse-transcription polymerase chain reaction (RT-PCR), sample purification and
DNA sequence analysis were performed as described previously [58]. The following
primers were used: FUS-forward, CAG AGC TCC CAA TCG TCT TAC GG and
DDIT3-reverse, GAG AAA GGC AAT GAC TCA GCT GCC.
Kinome array analysis
Kinase substrate peptide arrays (Pepchip Kinomics, Pepscan Presto, Lelystad, the
Netherlands) containing 1024 different kinase substrates spotted in triplicate together
with 16 negative, and 16 positive controls were used and successfully used in prior
studies [16, 59]. The distribution of the target sequences in terms of kinase recognition
is described in detail on the website (http://www.pepscanpresto.com/index.php?id=30).
Cells were harvested during their exponential growth phase and lysated as previously
described. Concentration of the protein lysates was measured using the DC Protein
Assay (Biorad, Hercules, CA, USA). Analysis was performed as described earlier,
including the two serum-starved samples[16]. Autoradiographic signals were sensed
by phosphoimage screen and scanned by Typhoon 9400 phosphoimager (GE Healthcare,
Piscataway, NJ). At least 1x106 hits were collected.
Data analysis
The scanned images were analyzed and quantified using ImageQuant software
(Molecular Dynamics, Sunnyvale, CA). For further data mining R-packages Affyio
and Limma were used (http://www.bioconductor.org). Quality of the triplicates and
distribution of the data was assessed and quartile normalization (Affyio) was performed
as previously described[16]. Median intensities of the triplicates were calculated and
the top 100 spots were imported for core analysis in Ingenuity Pathway Analysis (IPA,
Ingenuity Systems, http://www.ingenuity.com). IPA is a literature based program that
calculates the probability of involvement of identifiers, in this case combinations of
kinases, in 74 different pathways. Data of the myxoid liposarcoma cell lines and cultu-
res were averaged to find the common denominators that are active in all cultures[16].
To ensure that artificially induced kinase activity due to cell culturing interfered with
tumor specific kinase activity, the same analysis was run excluding cell cycle related
kinases as well as after starvation. Specificity of activated kinases and activated
pathways in myxoid liposarcoma was verified by comparison the same analysis of
four colorectal carcinoma cell lines and thirteen chondrosarcoma cell lines and cultu-
res using Limma[16].
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Immunoblotting
Western blotting was performed as previously described[58]. Rabbit polyclonal anti-
body to phosphorylated Src (Y419) was obtained from R&D Systems (1/2000;
Minneapolis, MN USA). Monoclonal antibody to total Src and alpha-tubulin were
obtained from Upstate Biotechnology (clone GD11, 1/2000, Lake Placid, NY, USA)
and Sigma Aldrich (St. Louise, MO, USA), respectively. Rabbit polyclonal antibodies
against casein kinase 2alpha; NF-kappaB p65, phospho- NF-kappaB p65 (S468) and
caspase 3 were obtained from Cell Signaling Technology (Beverly, MA). HeLa cell
lines, untreated and treated with TNFalpha (20 ng/ml) were used as a positive control
for casein kinase 2alpha and NF-kappaB p65/phospho- NF-kappaB p65, respectively,
according to the manufacturer's protocol.
In vitro viability assays
Measurement of metabolic activity by a WST-1 colorimetric assay (Roche Diagnostics
GmbH, Penzberg, Germany) was used as a read-out system for cell viability in res-
ponse to kinase inhibitors. Dasatinib was used to inhibit Src-pathway; TBB was used
to inhibit casein kinase 2, which is an important kinase in atypical NF-kappaB signalling.
After harvesting, 2000 cells/well of every cell line and primary culture were seeded
into 96-well flat-bottom plates. After 24 hours, increasing concentrations of the drugs
(50, 100, 200, 500, 1000 and 5000 nM for dasatinib and 10, 20, 50, 100, 200 and 500
µM for TBB respectively) were added or 0,1% DMSO as vehicle control, each condition
in quadruplicate. Ten percent serum supplementation was used for all experiments.
After 3 days of treatment, absorbance was measured on a Victor Multilabel Counter
1420-042 (Perkin Elmer, Groningen, The Netherlands) at 450 nm, and was corrected
for background and averaged. GIST882 and Jurkat cell lines were used as positive
controls for dasatinib and TBB experiments, respectively[16]. In combination
experiments, 2000 cells were plated overnight followed by treatment with dasatinib
which was added 30 minutes after TBB administration. In these experiments, increasing
concentrations of dasatinib at IC50 concentrations of TBB were used.
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8.1 Molecular genetics and cytogenetics to classify myxoid tumours of soft tissue
An increasing number of (cyto-) genetic aberrations have been identified in (myxoid)
soft tissue tumours during the last decade. This gives a. insight in their underlying
biology, b. often provides tools for differential diagnosis, prediction of clinical outcome
and potential clues for more targeted therapy (1-3). Chapter 2 gives an overview of the
myxoid tumours of soft tissue recognized and their characteristic molecular/cytogenetic
aberrations. Roughly, sarcomas can be divided in two major groups: (a) sarcomas with
relatively "simple" karyotypes showing specific genetic alterations, such as balanced
translocations in about 15% in general, and reaching up till 95% of myxoid liposarcoma
with t(12;16) leading to the formation of the FUS/DDIT3 fusion gene or point mutations
in a single gene like KIT/PDGFR in GIST (4) and (b) sarcomas with non-specific gene
alterations and very complex karyotypes with structural and numerical aberrations,
e.g. myxofibrosarcoma (5). Cytogenetic data on myxofibrosarcoma were scarce until
now with only isolated cases described in the literature. In chapter 3 we describe a
large serie of karyotyped myxofibrosarcoma showing that upon recurrence, there is an
increase in tumour-grade (5); as well as, upon increase in grade, myxofibrosarcomas
show an increase in non-tumourtype-specific cytogenetic aberrations. Our data suggests
that myxofibrosarcoma arises and progresses by genetic instability via a multistep
tumour progression model, which is estimated to be the case in about 50% of soft
tissue sarcomas (6). The differential diagnosis of myxoid tumours of soft tissue can be
difficult especially in biopsies and when presenting as an intramuscular tumour. An
example of this is the differential diagnosis between low-grade myxofibrosarcoma and
intramuscular myxoma (especially its cellular variant, a.k.a. cellular myxoma) (7, 8).
In chapter 5 we show that karyotyping can be helpful to distinguish both entities as
intramuscular myxoma (including cellular myxoma) often show no cytogenetic
aberrations, whereas low-grade myxofibrosarcoma does (9). However, (molecular)
karyotyping is a technique which is not routinely available in most pathology labs, is
laborious and has a limited success rate. Therefore, we investigated the potential role
of direct mutational analysis of GNAS1 activating mutations which is a more accessible
technique and more easily to incorporate in pathology laboratory practice. GNAS1
activating mutations (codon 201 and 227) have previously been described in fibrous
dysplasia, a benign bone tumour that can be associated with intramuscular myxoma in
the Mazabraud-,  and McCune-Albright syndromes (10). Scarse cases of intramuscular
myxoma in both syndromatic as well as non-syndromatic context showed activating
mutations in GNAS1 (11). We confirmed the presence of these mutations in 50% of
intramuscular myxoma cases, in a larger series including its cellular variant, which
has been confirmed in a similar study (12). We could not detect these mutations in low-
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grade myxofibrosarcoma. GNAS1 codon 201/227 mutation analysis is thus a helpful
and specific (though not very sensitive) method to distinguish intramuscular myxoma
from low-grade myxofibrosarcoma. Activating mutations in GNAS1 lead to consecutive
activation of cAMP, increased expression of c-Fos and subsequent transcription of
genes involved in cell cycle regulation (13). We confirmed high expression of c-Fos on
both the protein and the mRNA level in intramuscular myxoma as well as in low-grade
myxofibrosarcoma. Thus immunohistochemistry for c-Fos is not a discriminatory
diagnostical adjunct to differentiate between both entities. KRAS codon 12/13 and
TP53 mutations were previously shown to be involved in sarcomatogenesis (14). We
could not detect mutations in these genes in low-grade myxofibrosarcoma, nor in
intramuscular myxoma.
Interestingly, previous immunohistochemical studies showed p53 overexpression in
myxofibrosarcoma upon increase in grade, suggesting that TP53 mutations are a
relatively late event in the tumourigenesis of myxofibrosarcoma (15). Because of its
role in guarding cell cycle regulation, TP53 mutations probably contribute to genomic
instability in myxofibrosarcoma, reflected in the increase in non-specific cytogenetic
aberrations in higher grades (grade 2 and 3) whereas low-grade (grade 1)
myxofibrosarcoma usually has a normal karyotype or only slight cytogenetic aberrations
(5).
8.2 Constitution of myxoid extracellular matrix depends on type and grade of tumours
Myxoid tumours of soft tissue are, per definition, characterized by their myxoid ("jelly")
extracellular matrix. In chapter 2, we describe how the concept of "myxoid" evolved
over the years and still its exact constitution has not been elucidated, 150 years after
Virchow introduced the term "myxoid" (16). In this chapter we give an overview of the
literature of the high- and low-abundant constituents which have been reported to be
present in the myxoid extracellular matrix in both reactive lesions and in tumours (17).
We discuss their potential role and conclude that myxoid changes are not tumour specific
at all since they can be found in tumours of both mesenchymal and epithelial origin
(both benign as well as malignant). In chapter 4 we showed that next to
glycosaminoglycans, serum proteins (IgGs and albumin) are major components of the
myxoid extracellular matrix. With classical Alcian Blue staining using the CEC (critical
electrolyte concentration) method, we demonstrated that the relative amount of these
glycosaminoglycans in the myxoid extracellular matrix depends on histological type
and grade of the tumour and how this might relate to their different clinical behavior
(18). In chapter 5 we studied the myxoid extracellular matrix by liquid chromatography
mass spectrometry, a more sophisticated technique not applied before in these tumours.
We confirmed the abundant presence of serum proteins and collagens in the myxoid
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extracellular matrix. Above that, we showed that low-grade myxofibrosarcoma contains
certain small leucine rich proteins, such as biglycan, decorin, lumican, which we could
not detect in intramuscular myxoma (9). We confirmed that decorin, collagen I, VI,
XII and XIV were significantly overexpressed in low-grade myxofibrosarcoma (both
on the protein and at the mRNA level) compared to intramuscular myxoma. Based on
these results we argue that immunohistochemistry for decorin might be a helpful tool
in the differential diagnosis between these two entities. Our findings are also interesting
from a conceptional point of view, on one hand showing that the myxoid extracellular
matrix is characterized by the presence of certain molecules and peptides (such as
serum proteins, glycosaminoglycans, collagens etc.). On the other hand, the myxoid
extracellular matrix (such as in intramuscular myxoma) is characterized by low
expression of decorin and collagens which are important for the well-structured
formation of the extracellular matrix (19). This paucity of structural proteins/molecules
suggests that a myxoid histology reflects a merely improper organization of the
extracellular matrix. In chapter 6 we show that direct profiling of tissue slides by
imaging mass spectrometry, is an elegant and robust method to classify myxoid tumours
of soft tissue (myxofibrosarcoma and myxoid liposarcoma) according to tumour-type
and tumour-grade. Low-grade myxofibrosarcoma is characterized by a multinodular
growth pattern on both the macroscopical and microscopical level. Using imaging
mass spectrometry, we demonstrate that these histologically identical nodules express
different peptides/proteins and thus display intratumour heterogeneity on the biochemical
level. We hypothesize that this might be the reflection of clonal selection upon tumour
progression in myxofibrosarcoma. With the same technique, we demonstrate that myxoid
liposarcoma shows a transition in lipid profiles with decreased fatty acid content upon
increase in grade, whereas phosphocholines were predominantly detected in the higher
grades. Interestingly, these findings were reported in a different independent group of
myxoid liposarcoma by ex vivo NMR spectroscopy (20-22). We speculate that these
differences reflect the genetic changes occurring upon tumour progression especially
in relation to the role of peroxisome proliferator-activated receptor γ (PPARγ), a key
player in adipocytic differentiation. Hereby we illustrate how imaging mass spectrometry
can form a bridge between the molecular genetics and the morphological features
characteristic of myxoid liposarcoma.
8.3 New therapeutic strategies for myxoid liposarcoma patients with advanced disease
In chapter 5 we describe that activating mutations in exon 201 and 227 of the GNAS1
gene were present in intramuscular myxoma but not in low-grade myxofibrosarcoma.
These mutations subsequently lead to consecutive activation of c-AMP and downstream
transcription of c-Fos. From a theoretical point of view, targeting this pathway would
be an option for targeted therapy, as these upstream activating mutations are highly
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specific (despite its low sensitivity of 50%). However, intramuscular myxoma is a
benign tumour and curative surgery suffices with no need for (neo) adjuvant therapy
(23). In contrast to intramuscular myxoma, myxoid liposarcoma is a malignant soft
tissue tumour metastasizing in about 30-80% of cases (24). In this respect, identification
of new targets in treatment of liposarcomas makes especially sense because therapeutic
options for patients with advanced/inoperable disease are rather limited.
Chemotherapeutical options are restricted to ifosfamide and anthracyclins, which have
only response rates of 20-40% although trabectidin (ET-743, Yondelis®) has recently
shown activity in phase I and II trials and retrospective series (25-28). In chapter 6 we
illustrate by imaging mass spectrometry that upon increase in grade, myxoid
liposarcomas shows a decrease in the content of fatty acids, which is probably the
effect of deceased signaling of PPARγ. Active signaling of the transcriptional activator
PPARγ does not only play a key role in adipogenesis but also leads to cell cycle arrest
(29, 30). In this perspective, PPARγ signaling might offer a promising target in the
treatment of (myxoid) liposarcoma although activation of this pathway by PPARγ
agonists (rosiglitazone) in patients with advanced disease was not conclusive (31, 32).
During the last decade, with the unraveling of (aberrant) cell signaling pathways in
many cancers, small molecule targeting has been shown to be a promising therapeutic
approach (33). This more "rationale" based targeting of cancer cells by (more or less)
specifically inhibiting pathways involved in tumourigenesis has been shown to be
effective, such as in translocation driven sarcomas and hematological malignancies as
well tumours driven by activating mutations, such as in lung cancer and GIST (34). In
chapter 7, we showed by in vitro kinome profiling and pathway analysis that Src and
NF-kB pathway are active in myxoid liposarcoma cells. We were able to block these
pathways by their respective inhibitors dasatinib® and 4,5,6,7-tetrabromobenzotriazole.
This led in the case of 4,5,6,7-tetrabromobenzotriazole to a significant decrease in cell
growth probably by induction of apoptosis.  Interestingly, administration of both drugs
had an addidative effect. Our results open perspectives to the development of new
therapeutic strategies in the treatment of metastatic, or irresectable myxoid liposarcomas.
For myxofibrosarcoma, no direct clues for targeted therapy were obtained, mainly
hampered by the lack of myxofibrosarcoma cell lines for performing functional
experiments.
8.4 Future view
The results as described in this thesis have provided a more profound understanding of
the biology of myxoid tumours of soft tissue. With a wide array of techniques ranging
from classical Alcian Blue to kinome analysis and imaging and liquid chromatography
mass spectrometry of tissue samples, we analyzed myxoid tumours of soft tissue in
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more depth. We showed that the myxoid extracellular matrix differs in composition
according to tumour-type and tumour-grade, and how these differences might affect
the biology/development of various myxoid tumours of soft tissue. We showed that for
the study of the proteome of these tumours, mass spectrometry contributes to a more
profound knowledge of high-and low abundant constituents of the myxoid extracellular
matrix. An advantage of mass spectrometry is the simultaneous analysis of numerous
proteins at the same time without a priori knowledge of these proteins (35). Imaging
mass spectrometry adds spatial information of the identified molecules, which is
especially interesting as the importance of spatial (next to temporal) protein expression
is essential in many (inter) cellular processes both in physiological and pathological
conditions (such as cancer) (35). Imaging mass spectrometry allows direct mass
spectrometric analysis of tissue sections, which makes trypsinization -essential for
subsequent tandem MS/MS experiments- rather challenging and hampers direct
identification of m/z values of interest. Future challenge is to overcome this problem,
as well as increasing the spatial resolution (yet up to 50 micrometer) to the level of the
individual cell, without losing the quality of the spectra. The possibility to use not only
frozen tissue samples but also (molecular cross-linked) formalin fixed paraffin embedded
tissue would substantially expand its application and possibility. Another future
challenge will be the analysis and integration of the huge amounts of datasets generated
by (imaging) mass spectrometry. Especially in this respect, the field of mass spectrometry
can learn a lot from the hurdles which had to be (and have been taken) in the field of
genomics. Reserving substantial time, money and effort for data analysis in any mass
spectrometry experiment is crucial and should be well considered beforehand.
Aberrant cell signaling has been shown to play a pivotal role in many cancers (33, 36).
As cell signaling is predominantly regulated at the posttranslational level (thus at the
level of the protein), proteomic analysis is not only complementary but even crucial for
proper understanding the biology of cancer (37). Understanding the exact molecular
pathways activated in intramuscular myxoma offer specific targets for molecular
diagnostics. This has resulted in the incorporation of direct GNAS1 mutation analysis
in the molecular diagnostic amendatory section of the department of pathology. So
albeit without implications for targeted therapy with small inhibitory molecules, cor-
rect (molecular) classification by GNAS1 mutation analysis has a direct clinical
application as it is helpful in differentiating intramuscular myxoma from low-grade
myxofibrosarcoma (and thus whether free resection margins are required). In
myxofibrosarcoma we could not detect any tumour specific karyotypic aberrations
which might however be unrevealed by more detailed genomic screens in the future.
Functional studies to validate potential molecular targets in myxofibrosarcoma are
hampered by the lack of myxofibrosarcoma cell lines which are available for many
other sarcomas. By such experiments, such as in vitro kinome analysis, we were able
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to identify new treatment options for myxoid liposarcoma patients with advanced disease.
This is especially relevant as conventional chemotherapeutic options in these patients
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achieved excellently, and sometimes more specifically with RNA interference. Given
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9.1 Moleculaire genetica en cytogenetica ter classificatie van myxoide wekedelen
tumoren
De laatste jaren is een toenemend aantal (cyto-) genetische afwijkingen geïdentificeerd
in (myxoide) wekedelen tumoren. Deze geven a. inzicht in hun onderliggende biologie,
en b. bieden handvatten voor differentiaaldiagnostiek, voorspelling van klinische prog-
nose en mogelijke aanknopingspunten voor gerichtere ("targeted") therapie (1-3). Hoofd-
stuk 2 geeft een overzicht van de tot nu toe bekende myxoide wekedelen tumoren met
hun karakteristieke moleculaire/cytogenetische afwijkingen. Ruwweg kunnen sarcomen
worden in twee grote groepen ingedeeld: (a) sarcomen met relatief "eenvoudige"
karyotypes met veelal specifieke genetische afwijkingen zoals gebalanceerde
translocaties in 15 % van de gevallen in het algemeen, en oplopend tot 95% (zoals
t(12;16) in het myxoid liposarcoom, resulterend in de vorming van het FUS/DDIT3
fusie gen, of punt mutaties in één enkel gen zoals KIT/PDGFR in GIST (4) en (b)
sarcomen met niet specifieke genetische veranderingen en erg ingewikkelde karyotypes
met structurele en numerieke afwijkingen, zoals bijvoorbeeld in het myxofibrosarcoom
(5). Cytogenetische gegevens over het myxofibrosarcoom zijn tot op heden zeldzaam
met slechts enkele geïsoleerde gevallen beschreven in de litteratuur. In hoofdstuk 3
beschrijven we een grote serie gekaryotypeerde myxofibrosarcomen en laten zien dat
er bij het lokaal recidief van deze tumor een toename is van graad van de tumor (5).
Tevens toont het myxofibrosarcoom bij toename in graad een  toename van
cytogenetische afwijkingen die overigens niet specifiek zijn voor de tumor. Onze gege-
vens suggereren dus dat het myxofibrosarcoom ontstaat en zich verder ontwikkelt via
genetische instabiliteit volgens een meerstaps-tumorprogresssiemodel, wat het geval is
in ongeveer 50% van de wekedelen tumoren (6). De differentiaaldiagnostiek van myxoide
wekedelen tumoren kan moeilijk zijn, m.n. op biopsien en als de tumor zich
intramusculair presenteert. Een voorbeeld hiervan is de differentaaldiagnose tussen
het laaggradig myxofibrosarcoom en het intramusculair myxoom (m.n. de celrijke
variant, ookwel celrijk myxoom genaamd) (7, 8). In hoofdstuk 5 laten we zien dat
karyotypering behulpzaam kan zijn in het onderscheiden van beide entiteiten gezien
het intramusculair myxoom (inclusief het celrijk myxoom) vaak geen cytogenetische
afwijkingen heeft, in tegenstelling tot het laaggradig myxofibrosarcoom (9). Echter,
(moleculaire) karyotypering is een techniek die niet routinematig beschikbaar is in de
meeste pathologielaboratoria, arbeidsintensief is en slechts een beperkte mate van suc-
ces kent. Daarom onderzochten we de mogelijke rol van directe mutatie-analyse van
GNAS1 activerende mutaties, wat een veel toegankelijker methode is en bovendien
makkelijker te incorporeren binnen de dagelijkse pathologiepraktijk. GNAS1 active-
rende mutaties (codon 201 and 227) zijn reeds eerder beschreven in fibreuze dysplasie,
een goedaardige bottumor die geassocieerd kan zijn met het intramusculair myxoom in
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het kader van het syndroom van Mazabraud of McCune-Albright (10). GNAS1 acti-
verende mutaties werden eerder beschreven in een kleine serie gevallen van
intramusculair myxoom zowel syndromatisch als niet-syndromatisch (11). Wij hebben
in 50% van gevallen van intramusculair myxoom de aanwezigheid van deze mutaties
bevestigd, in een grotere serie en inclusief de celrijke variant, wat ook bevestigd werd
door een andere studie (12). We konden deze mutaties niet detecteren in het laaggradig
myxofibrosarcoom. Mutatieanalyse van GNAS1 codon 201/227 is dus een behulp-
zame en specifieke (hoewel niet erg sensitieve) methode om het intramusculair myxoom
van het laaggradig myxofibrosarcoom te onderscheiden.
Activerende mutaties in GNAS1 leiden tot activatie van cAMP, toegenomen expressie
van c-Fos en zetten vervolgens aan tot transcriptie van genen die betrokken zijn in de
regulatie van de celcyclus (13). We toonden de verhoogde expressie van c-Fos aan
zowel op eiwit als mRNA niveau in het intramusculair myxoom alsook in het laaggradig
myxofibrosarcoom. Immuunhistochemische kleuring voor c-Fos bleek dus niet een
diagnostisch hulpmiddel om deze beide entiteiten beter te onderscheiden. Van KRAS
codon 12/13 en TP53 mutaties is aangetoond dat ze een rol spelen in sarcomatogenese
(14). Wij konden zowel in het laaggradig myxofibrosarcoom als in het intramusculair
myxoom geen mutaties in deze genen aantonen Interessant genoeg hebben eerdere
immuunhistcohemische studies aangetoond dat het myxofibrosaroom overexpressie
toont van p53 en wel in toenemende mate in hogere graad van de tumor, wat suggereert
dat mutaties in TP53 een relatieve late stap zijn in de tumorgenese van het
myxofibrosarcoom (15). Gezien de rol van p53 in het bewaken van de regulatie van de
celcyclus, dragen deze mutaties waarschijnlijk bij aan de genomische instabiliteit in
het myxofibrosarcoom, wat tot uiting komt in de toename van aspecifieke cytogenetische
afwijkingen in de hogere tumorgraden (graad 2 en 3) terwijl het laaggradig
myxofibrosarcoom (graad 1) meestal een normaal karyotype heeft of slechts geringe
afwijkingen hierin toont  (5).
9.2 Samenstelling van de myxoide extracellulaire matrix is afhankelijk van het
type en de graad van de tumor
Myxoïde wekedelen tumoren worden, per definitie, gekenmerkt door hun myxoide ("slij-
merige") extracellulaire matrix. In hoofdstuk 2 beschrijven we hoe het concept "myxoid"
vorm gekregen heeft door de jaren heen, en dat de precieze samenstelling van de myxoide
extracellulaire matrix nog steeds niet is opgehelderd, zelfs niet 150 jaar nadat Virchow
de term "myxoid" introduceerde (16). In dit hoofdstuk geven we een overzicht van de
litteratuur van de veel- en weinigvoorkomende bestanddelen waarvan gerapporteerd is
dat ze aanwezig zijn in de myxoide extracellulaire matrix van zowel reactieve laesies
als tumoren(17). We bediscussiëren hun mogelijke rol en concluderen dat myxoide
veranderdingen helemaal niet tumorspecifiek zijn en kunnen voorkomen in tumoren
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van zowel epitheliale als mesenchymale oorsprong (goedaardig en kwaadaardig). In
hoofdstuk 4 laten we zien dat naast glycosaminoglycanen, serum eiwitten (IgGs en
albumine) de belangrijkste componenten zijn in de myxoide extracellulaire matrix.
Met behulp van klassieke Alcian Blue kleuringen volgens de CEC methode (CEC =
"critical electrolyte concentration"), hebben we aangetoond dat de relatieve hoeveel-
heid van deze glycosaminoglycanene in de myxoide extracellulaire matrix afhangt van
het histoloische type en de graad van de tumor en hoe dit gerelateerd zou kunnen
worden aan het verschillend klinisch gedrag van deze tumoren (18). In hoofdstuk 5
hebben we de myxoide extracellulaire matrix met behulp van LC-MS (LC-MS = "liquid
chromatography mass spectrometry") bestudeerd, wat een meer gesofisticeerde tech-
niek is en die nog niet eerder in deze tumoren werd toegepast. We bevestigden de veel
voorkomendheid van serumeiwitten en collagenen in de myxoide extracellulaire ma-
trix. Daarenboven toonden we aan dat de extracellulaire matrix van het laaggradig
myxofibrosarcoom bepaalde SLRPs (SLRP = "small leucine rich proteins") bevat zo-
als biglycan, decorine, lumican, die we niet konden aantonen in het intramuscular
myxoom (9). We verifieerden dat decorine en collageen I, VI, XII en XIV significant
tot overexpressie kwamen in het laaggradig myxofibrosarcoom (zowel op eiwit niveau
als op RNA niveau) in vergelijking met het intramusculair myxoom. Op basis van deze
resultaten stellen wij dat immuunhistochemie voor decorine behulpzaam kan zijn in de
differentaaldiganotiek van deze twee entiteiten. Onze bevindingen zijn daarnaast ook
interessant vanuit conceptioneel oogpunt, waarbij we aan de ene kant laten zien dat de
myxoide extracellulaire matrix gekenmerkt wordt door de aanwezigheid van bepaalde
moleculen (zoals serumeiwitten, glycosaminoglycanen, collagenen, etc.). Aan de an-
dere kant, wordt de myxoide extracellulaire matrix (zoals in het intramusculair myxoom)
gekenmerkt door een lage expressie van decorine en collagenen die belangrijk zijn voor
een goede structurele opbouw van de extracellulaire matrix (19). Deze spaarzaamheid
van structurele eiwitten/moleculen doet vermoeden dat de myxoide extracellulaire matrix
in essentie de afspiegeling is van een onvoldoende en slecht georganiseerde extracellulaire
matrix. In hoofdstuk 6 laten we zien direct profilen van weefselcoupes met behulp van
imaging massa spectrometrie een elegante en robuuste methode is om myxoide weke-
delen tumoren (zoals het myxofibrosaroom en het myxoid liposarcoom) te classifice-
ren naar type en graad van de tumor. Het laaggradig myxofibrosarcoom wordt zowel
macroscopisch als microscopisch gekenmerkt door een multinodulair groeipatroon.
Met behulp van imaging massa spectrometrie hebben we aangetoond dat deze
histologisch identieke nodulen verschillende eiwitten tot expressie brengen en dus intra-
tumoraal heterogeniteit tonen op biochemisch niveau. Onze hypothese is dat dit de
weerspiegeling is van klonale selectie gedurende tumorprogressie in het
myxofibrosarcoom. Met dezelfde techniek hebben we laten zien dat het myxoid
liposarcooom een verandering in lipideprofiel met minder vetzuren naarmate de graad
van de tumor toeneemt, terwijl phosphocholines domineren in de hogere graden. Inte-
ressant is daarbij dat dezelfde bevindingen gerapporteerd werden in een andere, onaf-
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hankelijke groep myxoid liposarcomen met behulp van ex vivo NMR spectroscopie
(20-22). We speculeren dat deze verschillen een weerspiegeling zijn van de genetische
veranderingen die optreden tijdens tumorprogressie, met name in relatie tot de rol van
PPARγ (PPARγ = " peroxisome proliferator-activated receptor γ"), dat een belangrijke
rol speelt in de vetceldifferentiatie. Hiermee hebben we laten zien hoe imaging mass
spectrometrie een brug kan slaan tussen moleculaire genetica en de morfologische
eigenschappen van het myxoid liposarcoom.
9.3 Niewe therapeutische strategieën voor de behandeling van patiënten met myxoid
liposarcoom in een gevorderd stadium
In hoofdstuk 5 beschrijven we dat actieverende mutaties in exon 201 and 227 van het
GNAS1 gen aanwezig zijn in het intramusculaire myxoom, maar niet in het laaggradig
myxofibrosarcoom. Deze mutaties leiden vervolgens tot de activatie van cAMP  en
hierna tot transcriptie van c-Fos. Vanuit theoretisch oogpunt zou het ingrijpen op deze
signaleringsroute een behandelingsoptie kunnen zijn, omdat deze activerende mutatie
zeer specifiek zijn (ondanks de lage sensitiviteit van 50%). Het intramusculair myxoom
is echter een goedaardige tumor waarbij curatieve chirurgie volstaat, en er geen nood-
zaak bestaat voor (neo) adjuvante therapie (23). In tegenstelling tot het intramusculaire
myxoom, is het myxoid liposarcoom wel een kwaadaardige tumor die metastaseert in
ongeveer 30-80% van de gevallen (24). In dit opzicht is het vinden van nieuwe molecu-
laire aangrijpingspunten voor behandeling voor het myxoid liposarcoom wel relevant,
zeker gezien de behandelingsmogelijkheden voor patiënten met vergevorderde/
gemetastaseerde ziekte beperkt zijn. Chemotherapeutische mogelijkheden zijn hierbij
beperkt tot ifosfamide and anthracyclines, met respectievelijke "response rates" van
20-40% hoewel er hoop gloort aan de horizon sinds de introductie van trabectidin (ET-
743, Yondelis®) dat veelbelovend bleek in fase I en fase II studies en retrospectieve
series en vooral bij het myxoid liposarcoom (25-28). In hoofdstuk 6 laten we door
middel van imaging massa spectrometrie zien dat er in het myxoid liposarcoom, bij
toename in graad, een afname is van de inhoud van vetzuren, wat meest waarschijnlijk
het effect is van verminderde celsignalering van PPARγ. ctieve celsignalering van de
transcriptie-activator PPARγ speelt niet alleen een belangrijke rol in de vetcel-
differentiatie, maar leidt ook tot stilzetting van de celcyclus (29, 30). In dit opzicht zou
de celsignaleringsroute van PPARγ een veelbelovend aangrijpingspunt kunnen zijn in
de behandeling van het (myxoid) liposarcoom hoewel activering van deze
signaleringsroute door middel van PPARγ agonisten (rosiglitazone) in patiënten met
vergevorderde ziekte niet conclusief bleek (31, 32).
Bij het ontrafelen van de (afwijkende) celsignaleringsroutes in talrijke kankers gedu-
rende de laatste jaren, is gebleken dat doelgerichte behandeling met kleinmoleuclaire
kinase remmers ("small molecule targeting") een veelbelovende behandelings-
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mogelijkheid is (33). Deze rationelere wijze om kanker cellen aan te pakken door het
(min of meer) specifiek remmen van celsignaleringsroutes betrokken in tumorgenese,
is een erg effectieve methode gebleken bij de behandeling van bv. sarcomen en
hematologische maligniteiten die gedreven worden door translocaties, alsook in de
behandeling van longkanker en GIST (34). In hoofdstuk 7 hebben we laten zien dat
met behulp van het in vitro profilen van het kinoom en analyseren van
celsignaleringsroutes, de Src en NF-kB signaleringsroutes geactiveerd zijn het myxoid
liposarcoom. We waren in staat deze celsignaleringsroutes te blokkeren met hun res-
pectievelijke inhibitoren dasatinib® and 4,5,6,7-tetrabromobenzotriazole. Dit leidde
in het geval van 4,5,6,7-tetrabromobenzotriazole tot een significante daling van cel-
groei waarschijnlijk door de inductie van apoptose. Interessant was dat toevoeging van
beide inhibitoren een additief effect had. Onze resultaten bieden een veelbelovende
mogelijkheid op de ontwikkeling van nieuwe behandelingsopties voor gemetastaseerd
of irresectabel myxoid liposarcoom. Voor het myxofibrosarcoom werden geen directe
aanwijzingen voor dergelijke behandelingsopties gevonden, wat vooral bemoeilijkt werd
door het ontbreken van cellijnen van het myxofibrosarcoom voor het uitvoeren van
functionele experimenten.
9.4 Toekomstperspectief
De resultaten beschreven in dit proefschrift hebben tot een dieper inzicht geleid in de
onderliggende biologie van myxoide wekedelen tumoren. Met behulp van een breed
pallet aan technieken, variërend van ouderwetse Alcian Blue kleuringen tot kinoom
analyse en "imaging" en "liquid chromatography" massa spectrometrie, hebben we de
myxoide wekedelen tumoren in detail geanalyseerd. Wij hebben laten zien dat samen-
stelling van de myxoide extracellulaire matrix verschilt naar het type en de graad van
de tumor, en hoe deze verschillende biologie/genese van de verscheidene myxoide weke-
delen tumoren zouden kunnen beïnvloeden. We hebben laten zien dat bestudering van
het proteoom van deze tumoren met massa spectrometrie leidt tot een dieper inzicht
van de veelvoorkomende maar ook weinig abundante componenten van de myxoide
extracellulaire matrix. Een voordeel van massa spectrometrie is de gelijktijdige ana-
lyse van talrijke eiwitten zonder a priori kennis hiervan (35). Imaging massa
spectrometrie voegt daarenboven spatiële informatie toe aan de geïdentificeerde mole-
culen, wat bijzonder interessant is omdat spatieel (naast temporele) gereguleerde eiwit-
expressie wezenlijk is voor veel (inter) cellulaire processen zowel in fysiologische als
pathologische omstandigheden (zoals in kanker) (35). Imaging massa spectrometrie
maakt het mogelijk om direct massa spectrometrie te verrichten op weefselcoupes, wat
trypsinisering - essentieel voor de hieraan gekoppelde MS/MS experimenten- tot een
uitdaging maakt en de directe identificatie van interessante m/z waarden bemoeilijkt.
Het wordt een uitdaging om dit probleem in de toekomst te overwinnen, alsook om de
spatiële resolutie (nu tot circa 50 micrometer) terug te brengen tot het niveau van de
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individuele cel, zonder dat de kwaliteit van de gemeten spectra minder wordt. De mo-
gelijkheid om naast vers ingevroren weefsel, ook (moleculair gecross-linked) in formaline
gefixeerd materiaal te gebruiken, zal haar toepassingsbereik en mogelijkheden aan-
zienlijk vergroten. Een andere uitdaging voor de toekomst is de analyse en integratie
van de enorme datasets verkregen met (imaging) massa spectrometrie. Met name zou
de massa spectrometrie hierbij kunnen leren van de hordes die genomen moe(s)ten
worden in het genomicsveld. Het reserveren van voldoende tijd, geld en energie voor de
data-analyse is cruciaal en moet op voorhand goed overwogen worden.
Afwijkingen in celsignalering spelen een voorname rol in vele soorten kankers (33,
36). Gezien celsignalering voornamelijk op posttranslationeel (dus op eiwit-niveau)
wordt gereguleerd, is analyse van het proteoom niet alleen complementair maar zelfs
cruciaal om de biologie van kanker goed te begrijpen (37). Begrip van de precieze
onderliggende moleculaire signaleringsroutes in het intramusculaire myxoom biedt
specifieke aanknopingspunten voor moleculaire diagnostiek. Dit heeft reeds geresul-
teerd in de incorporatie van directe GNAS1 mutatieanalyse in het moleculair diagnos-
tische repertoire op de pathologie-afdeling. Hoewel er dus geen implicaties zijn voor
gerichte therapie, heeft (correcte) moleculaire classificatie met behulp van GNAS1
mutatieanalyse wel een directe klinische toepasbaarheid omdat deze techniek behulp-
zaam is in het differentiëren van het intramusculair myxoom van het laaggradig
myxofibrosarcoom op biopsies (en dus of vrije resectiemarges noodzakelijk zijn). In
het myxofibrosarcoom konden we geen tumorspecifieke karyotypische afwijkingen
ontdekken, die echter misschien in de toekomst wel zouden kunnen worden aangetoond
met meer gedetailleerde genomische screening. Functionele studies om mogelijke mo-
leculaire aangrijpingspunten in het myxofibrosarcoom te valideren, worden bemoei-
lijkt door het gebrek aan cellijnen. Met behulp van dergelijke experimenten, zoals bij-
voorbeeld in vitro kinoomanalyse, bleken we in staat om aanknopingspunten voor
gerichtere therapie te identificeren voor patiënten met het myxoid liposarcoom in een
vergevorderd stadium. Dit is juist interessant omdat de conventionele
chemotherapeutische mogelijkheden in deze patiëntengroep beperkt zijn. Analyse van
celsignaleringsroutes legt de mechanismen bloot achter de onderliggende biologie van
tumoren en biedt mogelijke aangrijpingspunten voor behandeling. Het in vitro blokke-
ren van kinasen kan ook uitstekend worden bereikt met RNA interference. Gelet de
wijze waarop kinase-inhibitoren en RNAi het basaal-wetenschappelijke onderzoek
beïnvloed hebben, alsook de ongekende snelheid waarmee dit de kliniek heeft bereikt,
beloven de komende jaren opwindend te worden (38).
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